WO2002060877A1 - Imidazole derivatives - Google Patents

Imidazole derivatives Download PDF

Info

Publication number
WO2002060877A1
WO2002060877A1 PCT/EP2002/000552 EP0200552W WO02060877A1 WO 2002060877 A1 WO2002060877 A1 WO 2002060877A1 EP 0200552 W EP0200552 W EP 0200552W WO 02060877 A1 WO02060877 A1 WO 02060877A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
imidazol
phenyl
imidazole
formula
Prior art date
Application number
PCT/EP2002/000552
Other languages
French (fr)
Inventor
Alexander Alanine
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to MXPA03006773A priority Critical patent/MXPA03006773A/en
Priority to JP2002561027A priority patent/JP4094956B2/en
Priority to CN028042557A priority patent/CN1489580B/en
Priority to KR1020037009992A priority patent/KR100619106B1/en
Priority to BR0206758-7A priority patent/BR0206758A/en
Priority to CA002434813A priority patent/CA2434813C/en
Priority to DK02714095T priority patent/DK1358165T3/en
Priority to DE60231477T priority patent/DE60231477D1/en
Priority to EP02714095A priority patent/EP1358165B1/en
Publication of WO2002060877A1 publication Critical patent/WO2002060877A1/en
Priority to HK04106638.1A priority patent/HK1063794A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

  • the present invention relates to compounds of the general formula
  • A is phenyl, py idin-2-yl, pyridin-3-yl, or piperidin-1-yl;
  • R /R 5 are independently from each other hydrogen or lower alkyl or are together with the carbon atom to which they are attached -(CH 2 ) 4 -;
  • R 6 /R 6 are independently from each other hydrogen or lower alkyl;
  • R' is hydrogen, -CH 2 OH or lower alkyl; n is 0, 1 or 2; m is 0 or 1; and the dotted line may be a bond; and to pharmaceutically acceptable acid addition salts thereof.
  • the heterocyclic aromatic group is hydrogen, -CH 2 OH or lower alkyl; n is 0, 1 or 2; m is 0 or 1; and the dotted line may be a bond; and to pharmaceutically acceptable acid addition salts thereof.
  • NMDA(N-methyl-D-aspartate)- receptor subtype selective blockers which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation.
  • NMDA receptors are composed of members from two subunit families, namely NR-1 (8 different splice variants) and NR-2 (A to D) originating from different genes. Members from the two subunit families show a distinct distribution in different brain areas. Heteromeric combinations of NR-1 members with different NR-2 subunits result in NMDA receptors displaying different pharmaceutical properties.
  • NMDA NR-2B receptor subtype specific blockers Possible therapeutic indications for NMDA NR-2B receptor subtype specific blockers include acute forms of neurodegeneration caused, e.g., by stroke and brain trauma, and chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis) and neurodegeneration associated with bacterial or viral infections, and, in addition, depression and chronic and acute pain.
  • Objects of the invention are the compounds of formula I and pharmaceutically acceptable acid addition salts thereof, the preparation of the compounds of formula I and salts thereof, medicaments containing a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, the manufacture of such medicaments and the use of the compounds of formula I and their pharmaceutically acceptable salts in the control or prevention of illnesses, especially of illnesses and disorders of the kind referred to earlier, and, respectively, for the manufacture of corresponding medicaments.
  • the present invention embraces racemic mixtures and all their corresponding enantiomers.
  • lower alkyl denotes a straight- or branched-chain alkyl group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl and the like.
  • Preferred lower alkyl groups contain from 1 to 4 carbon atoms.
  • lower alkenyl denotes a C 2 -C 7 carbon group, having at least one double bound in the chain.
  • halogen denotes chlorine, iodine, fluorine and bromine.
  • lower alkoxy denotes a group wherein the alkyl residue is as defined above and the alkyl group is connected via a oxygen atom.
  • cycloalkyl denotes a carbon ring with 3 to 6 carbon atoms, preperred is cyclopropyl.
  • pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
  • Preferred compounds of formula I are those, wherein A is phenyl, for example the following group of compounds:
  • R R 2 are independently from each other hydrogen, halogen, lower alkyl, trifluoromethyl, S-lower alkyl, lower alkoxy, -OCHF 2 , phenyl, nitro, benzyloxy, hydroxy or amino or are together with the carbon atoms to which they are attached
  • R 3 is hydrogen, lower alkyl, phenyl, S-lower alkyl, amino, lower alkyl-amino, -NHC(O)-lower alkyl or hydroxy-lower alkyl;
  • R 4 /R 5 are independently from each other hydrogen or lower alkyl or are together with the carbon atom to which they are attached
  • R 6 /R 6 are independently from each other hydrogen or lower alkyl
  • X is -N ⁇ or c ;
  • R 7 is hydrogen or lower alkyl; n is 0, 1 or 2; m is 0 or 1; and the dotted line may be a bond; and pharmaceutically acceptable acid addition salts thereof.
  • R 1 and R 2 are independently from each other lower alkyl, -CHF 2> -CQower alkyl)F 2 , CF 3 or halogen, or are together with the corresponding carbon atoms -(CH 2 ) 3 -, R 3 is lower alkyl or amino and R 4 , R 5 and R 6 , R 6 are hydrogen, for example the following compounds: lH-imidazole, 1 - [ [ l-(4-chloro-3-methylphenyl)- lH-imidazol-4-yl] methyl] -2-ethyl-, IH-imidazole, 1 - [ [ 1 - (4-chloro-3-methylphenyl) - l ⁇ -imidazol-4-yl] methyl] -2-methyl-, IH-imidazole, l-[[l-(2,3-dihydro-lH-inden-5
  • A is phenyl
  • R 1 and R 2 are halogen
  • R 3 is lower alkyl or hydrogen
  • R 4 , R 5 and R 6 , R 6 are hydrogen, for example the following compounds: l-(3,4-dichloro-phenyl)-4-imidazol-l-yl-methyl-lH-pyrazole or l-(3,4-dichloro-phenyl)-4-(2-methyl-imidazol-l-yl-methyl)-l ⁇ -pyrazole.
  • IH-imidazole l-[[4-(3,4-difluorophenyl)-lH-imidazol-2-yl]methyl] -2-methyl- or IH-imidazole, 4-(4-fluoro-3-methylphenyl)-2-(lH-imidazol-l-yl-methyl)-.
  • A is phenyl
  • R 1 and R 2 are lower alkyl, halogen or CF 3
  • R 3 is lower alkyl or hydrogen
  • R , R 5 and R 6 , R 6 are hydrogen, for example the following compounds: 3- ( 3 ,4-dimethyl-phenyl) -5- (2-methyl- imidazol- 1 -yl-methyl) -pyridine,
  • Preferred compounds of formula I are further those, wherein A is pyridin-2-or 3-yl or A is piperidin-1-yl.
  • A is phenyl or pyridin-2 or 3-yl
  • R 1 - R 7 have the significances given above and hal is Br or Cl, or
  • a and R ) 1 - r R.6 - have the significances given above and P is a N-protecting group, such as a 2-(trimethylsilyl)-ethoxymethyl group, or
  • A is phenyl or pyridin-2 or 3-yl and R 1 - R 6 have the significances given above and hal is Cl or Br, and
  • sodium hydride is added to a solution of an imidazole compound of formula N, for example 2-propylimidazole, 2-methylimidazole, imidazole, 4-methylimidazole or 4,5,6,7-tetrahydrobenzimidazole, in DMF. After 30 min.
  • an imidazole compound of formula N for example 2-propylimidazole, 2-methylimidazole, imidazole, 4-methylimidazole or 4,5,6,7-tetrahydrobenzimidazole
  • a compound of formula VI for example IH-imidazole, 2-[(2-methyl-lH-imidazol-l- yl)methyl]-4-[3-(trifluoromethyl)phenyl]-l-[[2-(trimethylsilyl)ethoxy]methyl] or IH- imidazole, 4- (4-fluoro-3-methy ⁇ phenyl) - [ (2-methyl- lH-imidazol- 1 -yl)methyl] - 1 - [ [2- (trimethylsilyl)ethoxy] methyl] is dissolved in EtO ⁇ and treated with ⁇ CL Then the reaction mixture is refluxed overnight, cooled to room temperature, concentrated and purified.
  • IH-imidazole 2-[(2-methyl-lH-imidazol-l- yl)methyl]-4-[3-(trifluoromethyl)phenyl]-l-[[2-(trimethylsilyl)ethoxy]methyl] or IH- imidazole, 4-
  • compositions of formula I can be manufactured according to methods which are known per se and familiar to any person skilled in the art.
  • the acid addition salts of compounds of formula I are especially well suited for pharmaceutical use.
  • DIBAH diisobutylaluminium hydride
  • LAH lithium aluminium hydride
  • LAH lithium aluminium hydride
  • the phenyl group may be replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula la.
  • NBS N-bromosuccinimide
  • AIBN azo-bis-isobutyronitrile
  • the phenyl group may be replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula lb.
  • the phenyl group may be replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula Ie.
  • LAH lithium aluminium hydride
  • the phenyl group may be replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula Ig.
  • BINAP is 2,2'-bis(diphenylphosphino)-l,l'- binaphthyl.
  • the compounds of formula I and their pharmaceutically usable acid addition salts possess valuable pharmacodynamic properties. They are NMDA- receptor subtype 2B selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation.
  • Test method 3 H-Ro 25-6981 binding (Ro 25-6981 is [R-(R*,S > )]- ⁇ -(4-Hydroxy-phenyl)- ⁇ -methyl-4- (phenyl-methyl)-l-piperidine propanol)
  • Membranes were prepared by homogenization of the whole brain minus cerebellum and medulla oblongata with a Polytron (10.000 rpm, 30 seconds), in 25 volumes of a cold Tris-HCl 50 mM, EDTA 10 mM, pH 7.1 buffer. The homogenate was centrifuged at 48,000 g for 10 minutes at 4 °C. The pellet was resuspended using the Polytron in the same volume of buffer and the homogenate was incubated at 37 °C for 10 minutes. After centrifugation the pellet was homogenized in the same buffer and frozen at -80 °C for at least 16 hours but not more than 10 days.
  • the homogenate was thawed at 37 °C, centrifuged and the pellet was washed three times as above in a Tris-HCl 5 mM, pH 7.4 cold buffer. The final pellet was resuspended in the same buffer and used at a final concentration of 200 mg of protein/ml.
  • 3 H-Ro 25-6981 binding experiments were performed using a Tris-HCl 50 mM, pH 7.4 buffer.
  • 5 nM of 3 H-Ro 25-6981 were used and non specific binding was measured using 10 mM of tetrahydroisoquinoline and usually it accounts for 10% of the total.
  • the incubation time was 2 hours at 4 °C and the assay was stopped by filtration on Whatmann GF/B glass fiber filters (Unifilter-96, Packard, Zurich, Switzerland). The filters were washed 5 times with cold buffer. The radioactivity on the filter was counted on a Packard Top-count microplate scintillation counter after addition of 40 mL of microscint 40 (Canberra Packard S.A., Zurich, Switzerland).
  • IC 50 ( ⁇ M) of preferred compounds of formula I, tested in accordance with the above mentioned methods is ⁇ 0,1 ⁇ M.
  • Table below are shown some data for binding activity:
  • the compounds of formula I and their salts, as herein described, can be incorporated into standard pharmaceutical dosage forms, for example, for oral or parenteral application with the usual pharmaceutical adjuvant materials, for example, organic or inorganic inert carrier materials, such as, water, gelatin, lactose, starch, magnesium stearate, talc, vegetable oils, gums, polyalkylene-glycols and the like.
  • the pharmaceutical preparations can be employed in a solid form, for example, as tablets, suppositories, capsules, or in liquid form, for example, as solutions, suspensions or emulsions.
  • Pharmaceutical adjuvant materials can be added and include preservatives stabilizers, wetting or emulsifying agents, salts to change the osmotic pressure or to act as buffers.
  • the pharmaceutical preparations can also contain other therapeutically active substances.
  • the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • the dosage lies in the range of about 0.1 mg per dosage to about 1000 mg per day of a compound of general formula I although the upper limit can also be exceeded when this is shown to be indicated.
  • Examples 2 to 9 were prepared according to the general procedure described in example 1.
  • Examples 11 to 103 were prepared according to the general procedure described in example 10.
  • Examples 105 to 107 were prepared according to the general procedure described in example 104.
  • Example 114 was prepared according to the general procedure described in example 113.
  • IH-Imidazole l-(3,4-dichlorophenyl)-4-[l-(lH-imidazol-l-yl)ethyl]-
  • IH-Imidazole l-(3,4-dichlorophenyl)-3-chloro-4-[l-(lH-imidazol-l-yl)ethyl]-
  • Example 116 was prepared according to the general procedure described in example 115.
  • Examples 119 to 122 were prepared according to the general procedure described in example 118.
  • Examples 124 to 127 were prepared according to the general procedure described in example 123.
  • Examples 130 to 142 were prepared according to the general procedure described in example 129.
  • the title compound was obtained as an off-white crystalline material by reaction of ⁇ l-[3-(l,l-difluoro-ethyl)-phenyl]-lH- imidazol-4-yl ⁇ -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt.
  • Mp. >200 °C dec. (MeO ⁇ / Et 2 O), MS: m/e 303 (M+ ⁇ + ).
  • the title compound was obtained as an off-white crystalline material by reaction of ⁇ l-[3-(l,l-difluoro-ethyl)-4-fluoro- phenyl]-lH-imidazol-4-yl ⁇ -methanol first with thionylchloride and then with 2- methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt.
  • Mp. >200 °C dec. (MeO ⁇ / Et 2 O), MS: m/e 321 (M+ ⁇ + ).
  • Example 161 1 - (3 -Ethyl-phenyl) -4-imidazol- 1 -ylmethyl- IH-imidazole hydrochloride ( 1 :2)
  • Example 203 1 - (2,2-Difluoro-benzo [ 1 ,3] dioxol-5-yl) -4-imidazol- 1 -ylmethyl- IH-imidazole hydrochloride (1:2)
  • Examples 235 to 262 were prepared according to the general procedure described in example 234.
  • the tide compound, MS: m/e 227 [(M- ⁇ ) " ], Mp. 243-251 °C ( ⁇ 2 O / dioxane), was obtained as an off-white crystalline material by reaction of 5-aminoindan with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
  • the tide compound, MS: m/e 233 [(M- ⁇ ) " ], Mp. 233-245 °C ( ⁇ 2 O / dioxane), was obtained as a red crystalline material by reaction of 4- (methylthio) aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
  • the tide compound, MS: m/e 252 (M + ), Mp. 232-236 °C ( ⁇ 2 O / dioxane), was obtained as a light red crystalline material by reaction of 4-chloro-3-methoxy aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
  • Example 263 l-(3,4-Dichloro-phenyl)-5-methyl-lH-imidazole-4-carboxylic acid ethyl ester and 3-(3,4-Dichloro-phenyl)-5-methyl-3H-imidazole-4-carboxylic acid ethyl ester
  • Examples 265 to 292 were prepared according to the general procedure described in example 264.
  • MS: m/e 271 [(M-NO 2 ) + ].
  • Example 302 was prepared according to the general procedure described in example 301.
  • Example 302 was prepared according to the general procedure described in example 301.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention related to compounds of the general formula (I), wherein the substituents are defined in claim 1. These compounds have a good affinity to the NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation. These compounds are therefore suitable in the control or treatment of diseases, related to this receptor.

Description

Imidazole derivatives
The present invention relates to compounds of the general formula
Figure imgf000002_0001
wherein
A is phenyl, py idin-2-yl, pyridin-3-yl, or piperidin-1-yl;
R R2 are independently from each other hydrogen, halogen, lower alkyl, cycloalkyl, lower alkenyl, trifluoromethyl, -O- trifluoromethyl, -S-trifluoromethyl, S-lower alkyl, lower alkoxy, -CHF2, -C(lower alkyl)F2> -OCHF2, phenyl, nitro, benzyloxy, hydroxy or amino or are together with the carbon atoms to which they are attached in any adjacent positions -CH=CH-CH=CH-, -CH=CH-CH=N-, -(CH2)3-, -O-CH2-O-, -O-CF2-O-, -CH2-O-CH2- or -CH2CH2-O-; R3 is hydrogen, lower alkyl, cycloalkyl, phenyl, S-lower alkyl, amino, lower alkyl-amino, -NHC(O)-lower alkyl or hydroxy-lower alkyl;
R /R5 are independently from each other hydrogen or lower alkyl or are together with the carbon atom to which they are attached -(CH2)4-; R6/R6 are independently from each other hydrogen or lower alkyl;
X is -N< or c == : Y is =N-, -NH-, -N=CH- or -CH=; Z is -CR7=, -N=, -NR7-, -N=CR7-, =CH-N=C(R7)- or =N-CH=CH-;
R' is hydrogen, -CH2OH or lower alkyl; n is 0, 1 or 2; m is 0 or 1; and the dotted line may be a bond; and to pharmaceutically acceptable acid addition salts thereof. The heterocyclic aromatic group
Figure imgf000003_0001
in formula I may have the following structure:
Figure imgf000003_0002
Therefore, the following type of compounds are encompassed by the present formula I:
Figure imgf000003_0003
Figure imgf000004_0001
The substituents are described above.
The compounds of formula I and their salts are distinguished by valuable therapeutic properties. Compounds of the present invention are NMDA(N-methyl-D-aspartate)- receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation.
Under pathological conditions of acute and chronic forms of neurodegeneration overactivation of NMDA receptors is a key event for triggering neuronal cell death.
NMDA receptors are composed of members from two subunit families, namely NR-1 (8 different splice variants) and NR-2 (A to D) originating from different genes. Members from the two subunit families show a distinct distribution in different brain areas. Heteromeric combinations of NR-1 members with different NR-2 subunits result in NMDA receptors displaying different pharmaceutical properties. Possible therapeutic indications for NMDA NR-2B receptor subtype specific blockers include acute forms of neurodegeneration caused, e.g., by stroke and brain trauma, and chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis) and neurodegeneration associated with bacterial or viral infections, and, in addition, depression and chronic and acute pain.
Objects of the invention are the compounds of formula I and pharmaceutically acceptable acid addition salts thereof, the preparation of the compounds of formula I and salts thereof, medicaments containing a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, the manufacture of such medicaments and the use of the compounds of formula I and their pharmaceutically acceptable salts in the control or prevention of illnesses, especially of illnesses and disorders of the kind referred to earlier, and, respectively, for the manufacture of corresponding medicaments.
The present invention embraces racemic mixtures and all their corresponding enantiomers.
The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination.
As used herein, the term "lower alkyl" denotes a straight- or branched-chain alkyl group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl and the like. Preferred lower alkyl groups contain from 1 to 4 carbon atoms.
As used herein, the term "lower alkenyl" denotes a C2-C7 carbon group, having at least one double bound in the chain.
The term "halogen" denotes chlorine, iodine, fluorine and bromine.
The term "lower alkoxy" denotes a group wherein the alkyl residue is as defined above and the alkyl group is connected via a oxygen atom.
The term "cycloalkyl" denotes a carbon ring with 3 to 6 carbon atoms, preperred is cyclopropyl.
The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
Preferred compounds of formula I are those, wherein A is phenyl, for example the following group of compounds:
Figure imgf000005_0001
wherein
R R2 are independently from each other hydrogen, halogen, lower alkyl, trifluoromethyl, S-lower alkyl, lower alkoxy, -OCHF2, phenyl, nitro, benzyloxy, hydroxy or amino or are together with the carbon atoms to which they are attached
-(CH2)3-> -O-CH2-O-, -CH2-O-CH2- or -CH2CH2-O-;
R3 is hydrogen, lower alkyl, phenyl, S-lower alkyl, amino, lower alkyl-amino, -NHC(O)-lower alkyl or hydroxy-lower alkyl;
R4/R5 are independently from each other hydrogen or lower alkyl or are together with the carbon atom to which they are attached
-(CH2)4-;
R6/R6 are independently from each other hydrogen or lower alkyl;
X is -N< or c ;
Y is =N-, -NH-, -N=CH- or -CH=; z is -CR7=, -N=, -NH-, -N=CR7-, =CH-N=C(R7)- or
=N-CH=CH-;
R7 is hydrogen or lower alkyl; n is 0, 1 or 2; m is 0 or 1; and the dotted line may be a bond; and pharmaceutically acceptable acid addition salts thereof.
Especially preferred compounds of formula
Figure imgf000006_0001
in the scope of the present formula I are those, wherein A is phenyl, R1 and R2 are independently from each other lower alkyl, -CHF2> -CQower alkyl)F2, CF3 or halogen, or are together with the corresponding carbon atoms -(CH2)3-, R3 is lower alkyl or amino and R4, R5 and R6, R6 are hydrogen, for example the following compounds: lH-imidazole, 1 - [ [ l-(4-chloro-3-methylphenyl)- lH-imidazol-4-yl] methyl] -2-ethyl-, IH-imidazole, 1 - [ [ 1 - (4-chloro-3-methylphenyl) - lΗ-imidazol-4-yl] methyl] -2-methyl-, IH-imidazole, l-[[l-(2,3-dihydro-lH-inden-5-yl)-lff-imidazol-4-yl]methyl] -2-methyl-, IH-imidazole, 1 - [ [ 1- [4-fluoro-3-(trifluoromethyl)phenyl] - lΗ-imidazol-4-yl] methyl] -2- methyl,
1 - [ 1 - (4-chloro-3-methyl-phenyl)- lH-imidazol-4-yl-methyl] - lH-imidazol-2-yl-amϊne, IH-imidazole, 1 - [ [ 1 - [3- ( 1, 1 -difluoroethyl)phenyl] - lH-imidazol-4-yl] methyl] -2-methyl-, IH-imidazole, l-[[l-(3-difluoromethyl-4-fluorophenyl)-lH-imidazol-4-yl]methyl]-2- methyl- or IH-imidazole, l-[[l-[3-(l,l-difluoroethyl)-4-fluorophenyl]-lH-imidazol-4-yl]methyl]-2- methyl-.
Further preferred are compounds of formula
Figure imgf000007_0001
lb in the scope of the present formula I, wherein A is phenyl, R1 and R2 are halogen, R3 is lower alkyl or hydrogen and R4, R5 and R6, R6 are hydrogen, for example the following compound: l-(3,4-dichloro-phenyl)-3-(2-methyl-imidazol-l-yl-methyl)-lH-pyrazole.
Further preferred are compounds of formula
Figure imgf000007_0002
in the scope of the present formula I, wherein A is phenyl, R1 and R2 are halogen, R3 is lower alkyl or hydrogen and R4, R5 and R6, R6 are hydrogen, for example the following compounds: l-(3,4-dichloro-phenyl)-4-imidazol-l-yl-methyl-lH-pyrazole or l-(3,4-dichloro-phenyl)-4-(2-methyl-imidazol-l-yl-methyl)-lΗ-pyrazole.
Further preferred are compounds of formula
Figure imgf000008_0001
Id in the scope of the present formula I, wherein A is phenyl, R1 and R2 are halogen, hydrogen, CF3 or lower alkyl, R3 is lower alkyl or hydrogen and R4, R5 and R6, R6', R7 are hydrogen, for example the following compounds: IH-imidazole, 2-methyl- 1- [ [4- [3-(trifluoromethyl)phenyl] - lH-imidazol-2-yl] methyl] -, IH-imidazole, l-[[4-(4-fluoro-3-methylphenyl)-lH-imidazol-2-yl]methyl]-2- methyl-,
IH-imidazole, l-[[4-(3,4-difluorophenyl)-lH-imidazol-2-yl]methyl] -2-methyl- or IH-imidazole, 4-(4-fluoro-3-methylphenyl)-2-(lH-imidazol-l-yl-methyl)-.
Further preferred are compounds of formula
Figure imgf000008_0002
in the scope of the present formula I, wherein A is phenyl, R1 and R2 are lower alkyl, halogen or CF3, R3 is lower alkyl or hydrogen and R , R5 and R6, R6 are hydrogen, for example the following compounds: 3- ( 3 ,4-dimethyl-phenyl) -5- (2-methyl- imidazol- 1 -yl-methyl) -pyridine,
3-(4-fluoro-3-methyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine,
3 - ( 4-chloro- 3 -methyl-phenyl) - 5 - ( 2-methyl-imidazol- 1 -yl-methyl) -pyridine,
3-(3-chloro-4-fluoro-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine or
3 - ( 4-chloro-3 -trifluoromethyl-phenyl) - 5 - (2-methyl-imidazol- 1 -yl-methyl) -pyridine.
Further preferred are compounds of formula
Figure imgf000009_0001
in the scope of the present formula I, wherein A is phenyl, R1 and R2 are halogen, R3 is lower alkyl and R4, R5 and R6, R6 are hydrogen, for example the following compound:
4-(3,4-dichloro-phenyl)-2-(2-methyl-imidazol-l-yl-methyl)-pyridine.
Further preferred are compounds of formula
Figure imgf000009_0002
in the scope of the present formula I, wherein A is phenyl, R1 and R2 are halogen, R3 is lower alkyl and R4, R5 and R6, R6 are hydrogen, for example the following compound:
2- ( 3,4-dichloro-phenyl) -4- (2-methyl-imidazol- 1 -yl-methyl) -pyridine.
Preferred compounds of formula I are further those, wherein A is pyridin-2-or 3-yl or A is piperidin-1-yl.
The afore-mentioned compounds of formula I can be manufactured in accordance with the invention by
a) reacting a compound of formula
Figure imgf000009_0003
Figure imgf000010_0001
with a compound of formula
Figure imgf000010_0002
to give a compound of formula
Figure imgf000010_0003
Figure imgf000010_0004
or
Figure imgf000010_0005
wherein A is phenyl or pyridin-2 or 3-yl, R1 - R7 have the significances given above and hal is Br or Cl, or
b) cleaving off a N-protecting group from a compound of formula
Figure imgf000011_0001
to obtain a compound of formula
Figure imgf000011_0002
Id
wherein A and R ) 1 - r R.6 - have the significances given above and P is a N-protecting group, such as a 2-(trimethylsilyl)-ethoxymethyl group, or
c) reacting a compound of formula
Figure imgf000011_0003
with a compound of formula
Figure imgf000011_0004
to give a compound of formula
Figure imgf000012_0001
or
Figure imgf000012_0002
or
Figure imgf000012_0003
wherein A is phenyl or pyridin-2 or 3-yl and R1 - R6 have the significances given above and hal is Cl or Br, and
if desired, converting the compound of formula I obtained into a pharmaceutically acceptable salt.
In the following the preparation of compounds of formula I are described in more detail:
In accordance with the process variants, described above, and with schemes 1 - 10, described below, compounds of formula I ma be prepared by known procedures, for example the following:
In accordance with process step a), sodium hydride is added to a solution of an imidazole compound of formula N, for example 2-propylimidazole, 2-methylimidazole, imidazole, 4-methylimidazole or 4,5,6,7-tetrahydrobenzimidazole, in DMF. After 30 min. at room temperature the mixture is cooled in an ice bath and a compound of formulas II, III or IN, for example 4-chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole, 4- chloromethyl- 1 - ( 3,4-dichloro-phenyl) - lH-pyrazole or 4-chloromethyl- 1- (3,4-dichloro- phenyl)-3-methyl- IH-imidazole is added. The resulted mixture is stirred for 30 min. at room temperature and after evaporation of the solvent the compounds of formulas la, lb and Ic are obtained in conventional manner.
Compounds of formulas Id may be prepared in accordance with reaction variant b). A compound of formula VI, for example IH-imidazole, 2-[(2-methyl-lH-imidazol-l- yl)methyl]-4-[3-(trifluoromethyl)phenyl]-l-[[2-(trimethylsilyl)ethoxy]methyl] or IH- imidazole, 4- (4-fluoro-3-methyτphenyl) - [ (2-methyl- lH-imidazol- 1 -yl)methyl] - 1 - [ [2- (trimethylsilyl)ethoxy] methyl] is dissolved in EtOΗ and treated with ΗCL Then the reaction mixture is refluxed overnight, cooled to room temperature, concentrated and purified.
Compounds of formulas If, Ig or Ih are prepared in accordance with reaction variant c) as follows: To a suspension of sodium hydride in mineral oil and DMF is added a compound of formula V, for example 2-propylimidazole, 2-methylimidazole, imidazole or 4-methylimidazole. This mixture is stirred for 1.5 hours at room temperature. Then a compound of formulas VIII, IX or X and triethylamine are added and the mixture is heated to about 100 °C for 4 hours. After cooling the DMF is evaporated and the residue is directly chromatographed.
Pharmaceutically acceptable salts can be manufactured according to methods which are known per se and familiar to any person skilled in the art. The acid addition salts of compounds of formula I are especially well suited for pharmaceutical use.
In the following schemes 1 - 10 are described processes for preparation of compounds of formula I, starting from known compounds, from commercial products or from compounds, which can be prepared in conventional manner.
The preparation of compounds of formula I are described in more detail in working examples 1 - 233. Scheme 1
Figure imgf000014_0001
The substituents R1 to R5 are described above and THF is tetrahydrofuran. In the compounds of formula XI the phenyl group may be replaced by the pyridin 2-or 3-yl groups to obtain the corresponding compounds of formula la.
Or, alternatively, compounds of formula XIV may be prepared
Figure imgf000014_0002
or DIBAH
Figure imgf000014_0003
Figure imgf000014_0004
wherein R1 and R2 are described above and DIBAH is diisobutylaluminium hydride and LAH is lithium aluminium hydride.
Scheme 2
Cu(ll)-acetate
Figure imgf000015_0001
Figure imgf000015_0002
Figure imgf000015_0004
Figure imgf000015_0003
The substituents R1 to R5 and R7 are described above and LAH is lithium aluminium hydride.
In the compounds of formula XV the phenyl group may be replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula la.
Figure imgf000016_0001
NBS, AIBN
Figure imgf000016_0002
The substituents R1 to R5 are described above and NBS is N-bromosuccinimide and AIBN is azo-bis-isobutyronitrile.
In the compounds of formula XX the phenyl group may be replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula lb.
Scheme 4
Figure imgf000016_0003
The substituents R ) 1 ^ to„ r R>5 are described above and THF is tetrahydrofuran.
In the compounds of formula XXIII the phenyl group may be replaced by the pyridin 2-or 3-yl groups to obtain the corresponding compounds of formula Ic. Scheme 5
Figure imgf000017_0001
The substituents R1 to R5 are described above and DMF is N,N-dimethylforrnamide.
In the compounds of formula XV the phenyl group maybe replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula Id.
Scheme 6
Figure imgf000017_0002
The substituents R1 to R5 and R7 are described above and LAH is lithium aluminium hydride. Alternatively, the compound of formula XV maybe replaced by the compound
Figure imgf000018_0001
In the compounds of formula XV the phenyl group may be replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula Ie.
Scheme 7
Figure imgf000018_0002
XXXIII
XXXII
Figure imgf000018_0003
The substituents R1 to R are described above.
In the compounds of formula XV the phenyl group may be replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula If. Scheme 8
Figure imgf000019_0001
The substituents R1 to R5 are described above and LAH is lithium aluminium hydride.
In the compounds of formula XV the phenyl group may be replaced by the pyridin 2-or 3- yl groups to obtain the corresponding compounds of formula Ig.
Scheme 9
Figure imgf000019_0002
The substituents are described above and BINAP is 2,2'-bis(diphenylphosphino)-l,l'- binaphthyl. Scheme 10
Figure imgf000020_0001
In the compounds of formula XV or of the alternative compound the phenyl group ma be replaced by the pyridin 2-or 3-yl groups.
As mentioned earlier, the compounds of formula I and their pharmaceutically usable acid addition salts possess valuable pharmacodynamic properties. They are NMDA- receptor subtype 2B selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation.
The compounds were investigated in accordance with the test given hereinafter.
Test method 3H-Ro 25-6981 binding (Ro 25-6981 is [R-(R*,S> )]-α-(4-Hydroxy-phenyl)-β-methyl-4- (phenyl-methyl)-l-piperidine propanol)
Male Fullinsdorf albino rats weighing between 150-200 g were used. Membranes were prepared by homogenization of the whole brain minus cerebellum and medulla oblongata with a Polytron (10.000 rpm, 30 seconds), in 25 volumes of a cold Tris-HCl 50 mM, EDTA 10 mM, pH 7.1 buffer. The homogenate was centrifuged at 48,000 g for 10 minutes at 4 °C. The pellet was resuspended using the Polytron in the same volume of buffer and the homogenate was incubated at 37 °C for 10 minutes. After centrifugation the pellet was homogenized in the same buffer and frozen at -80 °C for at least 16 hours but not more than 10 days. For the binding assay the homogenate was thawed at 37 °C, centrifuged and the pellet was washed three times as above in a Tris-HCl 5 mM, pH 7.4 cold buffer. The final pellet was resuspended in the same buffer and used at a final concentration of 200 mg of protein/ml.
3H-Ro 25-6981 binding experiments were performed using a Tris-HCl 50 mM, pH 7.4 buffer. For displacement experiments 5 nM of 3H-Ro 25-6981 were used and non specific binding was measured using 10 mM of tetrahydroisoquinoline and usually it accounts for 10% of the total. The incubation time was 2 hours at 4 °C and the assay was stopped by filtration on Whatmann GF/B glass fiber filters (Unifilter-96, Packard, Zurich, Switzerland). The filters were washed 5 times with cold buffer. The radioactivity on the filter was counted on a Packard Top-count microplate scintillation counter after addition of 40 mL of microscint 40 (Canberra Packard S.A., Zurich, Switzerland).
The effects of compounds were measured using a minimum of 8 concentrations and repeated at least once. The pooled normalized values were analyzed using a non-linear regression calculation program which provide IC50 with their relative upper and lower 95% confidence limits.
The IC50 (μM) of preferred compounds of formula I, tested in accordance with the above mentioned methods, is <0,1 μM. In the table below are shown some data for binding activity:
Figure imgf000021_0001
Figure imgf000022_0001
The compounds of formula I and their salts, as herein described, can be incorporated into standard pharmaceutical dosage forms, for example, for oral or parenteral application with the usual pharmaceutical adjuvant materials, for example, organic or inorganic inert carrier materials, such as, water, gelatin, lactose, starch, magnesium stearate, talc, vegetable oils, gums, polyalkylene-glycols and the like. The pharmaceutical preparations can be employed in a solid form, for example, as tablets, suppositories, capsules, or in liquid form, for example, as solutions, suspensions or emulsions. Pharmaceutical adjuvant materials can be added and include preservatives stabilizers, wetting or emulsifying agents, salts to change the osmotic pressure or to act as buffers. The pharmaceutical preparations can also contain other therapeutically active substances.
The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In the case of oral administration the dosage lies in the range of about 0.1 mg per dosage to about 1000 mg per day of a compound of general formula I although the upper limit can also be exceeded when this is shown to be indicated.
The following examples illustrate the present invention in more detail. However, they are not intended to limit its scope in any manner. All temperatures are given in degree Celsius.
Example 1
IH-imidazole, l-[ l-(3,4-dichlorophenyl)-lH-imidazol-4-yllmethyll-2-propyl-, hydrochloride (1:2)
Sodium hydride (0.44 g of a 55 % dispersion in mineral oil, 10 mmol) was slowly added to a solution of 2-propylimidazole (0.55 g, 5 mmol) in DMF. After 30 min at 20 °C the mixture was cooled in an ice bath and 4-chloromethyl-l-(3,4-dichloro-phenyl)-lH- imidazole (1.0 g, 4 mmol) was added in one portion. The resulting mixture was stirred for 30 min at 20 °C. After evaporation of the solvent, the residue was dissolved in AcOEt, washed with Η2O, dried (Na2SO ) and chromatographed [silica, elution with gradient CH2CI2 to 50 % (CH2CI2 / MeOH / aq. NH4OH = 90:10:1)]. The free base of the title compound was obtained as a brownish oil (1.12 g, 84 %). After treatment with a solution of HC1 in MeOH followed by addition of Et2O the title compound was isolated as a white crystalline material. Mp. 241-243 °C (MeOH / Et2O), MS: m/e = 334(M+).
Examples 2 to 9 were prepared according to the general procedure described in example 1.
Example 2 lH-Imidazole, l [l-(3,4-dicMorophenyl)-lH-imidazol-4-yl1methyl]-2 -methyl-, hydrochloride (1:2)
Reaction of 2-methylimidazole with sodium hydride followed by treatment with 4- chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole led after extractive workup and chromatography to the free base of the title compound, which was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 306(M+). Example 3
IH-Imidazole, 1- 17 l-(3,4-dichlorophenyl)- lH-imidazol-4-yll methyl! -2-ethy hydrochloride (1:2)
Reaction of 2-ethylimidazole with sodium hydride followed by treatment with 4- chloromethyl-l-(3,4-dichloro-phenyl)-lΗ-imidazole led after extractive workup and chromatography to the free base of the title compound which was converted into its white hydrochloride salt. Mp. >250 °C (MeOH / Et2O), MS: m/e = 320 (M+).
Example 4
IH-Imidazole, l- ["l-(3,4-dichlorophenyl)-lH-imidazol-4-ynmethyl1-2-(l-methylethyl)-, hydrochloride (1:2)
Reaction of 2-isopropylimidazole with sodium hydride followed by treatment with 4- chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole led after extractive workup and chromatography to the free base of the title compound which was converted into its white hydrochloride salt. Mp. 236-238 °C dec. (MeOΗ / Et2O), MS: m/e = 335 (M+Η+).
Example 5
IH-Imidazole, l-(3,4-dichlorophenyl)-4-(lH-imidazol-l-yl-methyl)-, hydrochloride (1:2)
Reaction of imidazole with sodium hydride followed by treatment with 4-chloromethyl-l- (3,4-dichloro-phenyl)-lH-imidazole led after extractive workup and chromatography to the free base of the title compound which was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 292 (M+).
Example 6
IH-Imidazole, l-(3,4-dichlorophenyl)-4-|"(4-methyl-lH-imidazol-l-yl)methyll-, hydrochloride (1:2) and IH-Imidazole, l-(3,4-dichlorophenyl)-4-[(5-methyl-lH- imidazol-l-yl)methyl1-, hydrochloride ( 1:2) (ratio 3:2)
Reaction of 4-methylimidazole with sodium hydride followed by treatment with 4- chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole led after extractive workup and chromatography to the mixture of the title compounds as free bases which was converted into its white hydrochloride salts. MS: m/e = 306 (M+). Example 7
l-f l-(3,4-Dichloro-phenyl)-lH-imidazol-4-yl-methyll-4,5,6,7-tetrahvdro-lH- benzoimidazole-, hydrochloride (1:2)
Reaction of 4,5,6,7- tetrahydrobenzimidazole with sodium hydride followed by treatment with 4-chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole led after extractive workup and chromatography to the free base of the title compound which was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 346 (M+).
Example 8
IH-Imidazole, l- |"l-(3,4-dichlorophenyl)-lH-imidazol-4-yl1methyll-4,5-dimethyl-, hydrochloride (1:2)
Reaction of 4,5-dimethylimidazole with sodium hydride followed by treatment with 4- chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole led after extractive workup and chromatography to the free base of the title compound which was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 320 (M+).
Example 9
IH-Imidazole, l- ri-(3,4-dichlorophenyl)-lH-imidazol-4-ynmethyll-2-phenyl-, hydrochloride (1:2)
Reaction of 2-phenylimidazole with sodium hydride followed by treatment with 4- chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole led after extractive workup and chromatography to the free base of the title compound which was converted into its white hydrochloride salt. Mp. 197-198 °C (MeOΗ / Et2O), MS: m/e = 369 (M+Η+).
Example 10
IH-Imidazole, 1 - [ 1 - (4-chloro-3-methylphenyl)- lH-imidazol-4-yll methyl] -2-ethyl-, hydrochloride (1:2) [ l-(4-Chloro-3-methyl-phenyl)-lH-imidazol-4-yl] -methanol was treated with thionylchloride and the obtained 4-chloromethyl-l-(4-chloro-3-methyl-phenyl)-lH- imidazole directly used for a further reaction as its hydrochloric salt.
As described for example 1, reaction of 2-ethylimidazole with sodium hydride followed by treatment with 4-chloromethyl-l-(4-chloro-3-methyl-phenyl)-lH-imidazole ΗC1 salt led after extractive workup and chromatography to the free base of the title compound which was converted into its white hydrochloride salt. Mp. 186-187 °C (MeOH / Et2O), MS: m/e = 300 (M+).
Examples 11 to 103 were prepared according to the general procedure described in example 10. Example 11
IH-Imidazole, l-ri'l-(4-chloro-3-methylphenyl)-lH-imidazol-4-yl] methyl] -2- methyl-, hydrochloride (1:2)
[l-(4-Chloro-3-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 218-220 °C (MeOΗ / Et2O), MS: m/e = 286 (M+).
Example 12
lΗ-Imidazole, 1 - (4-chloro-3-methylphenyl) -4- ( lH-imidazol- 1 -yl-methyl) -, hydrochloride (1:2)
[l-(4-Chloro-3-methyl-phenyl)-lH-imidazol-4-yl]-methanoI was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 206-207 °C (MeOΗ / Et2O), MS: m/e = 272 (M+).
Example 13
lΗ-Imidazole, l-\\ l-(4-chloro-3-methylphenyl)- lH-imidazol-4-yl] methyl] -4,5-dimethyl-, hydrochloride (1:2)
[l-(4-Chloro-3-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 4,5- dimethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 300 (M+).
Example 14
1 - T 1 - (4-Chloro-3-methyl-phenyl)- lΗ-imidazol-4-yl-methvn -4,5,6,7-tetrahydro- 1H- benzoimidazole-, hydrochloride (1:2) [l-(4-Chloro-3-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 4,5,6,7- tetrahydrobenzimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 326 (M+).
Example 15
IH-Imidazole, 1- [ f l-(4-chloro-3-methylphenyl)-lH-imidazol-4-yl] methyl] -2- (meth lthio)-, hydrochloride (1:2)
[l-(4-Chloro-3-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- methylthioimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 202- 204 °C dec. (MeOΗ / Et2O), MS: m/e = 319 (M+Η+).
Example 16
IH-Imidazole, l- [l-(2,3-dihydro-lH-inden-5-yl)-lH-imidazol-4-yl]methyn -2-methyl-, hydrochloride (1:2)
[(l-Indan-5-yl-lH-imidazol-4-yl)-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 242-243 °C (MeOΗ / Et2O), MS: m/e =
278 (M+).
Example 17
IH-Imidazole, l- fl-(2,3-dihvdro-lH-inden-5-yl)-lΗ-imidazol-4-yl1methvn-2-ethyl-, hydrochloride (1:2)
[( l-Indan-5-yl-lΗ-imidazol-4-yl)-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 240-241 °C (MeOΗ / Et2O), MS: m/e = 292 (M+).
Example 18
IH-Imidazole, l-(2,3-dihydro-lH-inden-5-yl)-4-(lH-imidazol-l-yl-methyl)-, hydrochloride (1:2) [(l-Indan-5-yl-lH-imidazol-4-yl)-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 214-216 °C (MeOΗ / Et2O), MS: m/e = 264 (M+).
Example 19
IH-Imidazole, l-[[l-(3,4-dimethylphenyl)-lH-imidazol-4-vnmethyl]-2-ethyl-, hydrochloride (1:2)
[l-(3,4-Dimethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 280 (M+).
Example 20
IH-Imidazole, l-[[l-(3,4-dimethylphenyl)-lH-imidazol-4-yl]methyl]-2-methyl-, hydrochloride (1:2)
[ 1 - (3,4-Dimethyl-phenyl) - lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 249-251 °C (MeOΗ / Et2O), MS: m/e = 266 (M+).
Example 21
IH-Imidazole, l-(3,4-dimethylphenyl)-4-(lH-imidazol-l-yl-methyl)-, hydrochloride (1:2)
[l-(3,4-Dimethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 218-219 °C (MeOΗ / Et2O), MS: m/e = 252 (M+).
Example 22
IH-Imidazole, 2-methyl- 1 - [ 1" 1 - (4-methylphenyl) - lΗ-imidazol-4-yl] methyl] -, hydrochloride (1:2) (l-p-Tolyl-lH-imidazol-4-yl)-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOH / Et2O), MS: m/e = 252 (M+).
Example 23
IH-Imidazole, 4-(lH-imidazol-l-yl-methyl)-l-(4-methylphenyl)-, hydrochloride (1:2)
(l-p-Tolyl-lΗ-imidazol-4-yl)-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 228-229 °C (MeOH / Et2O), MS: m/e = 238 (M+).
Example 24
IH-Imidazole, l-[ l-(4-fluoro-3-methylphenyl)-lH-imidazol-4-yl]methyn -2-methyl-, hydrochloride (1:2)
[l-(4-Fluoro-3-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 210-212 °C (MeOΗ / Et2O), MS: m/e = 270 (M+).
Example 25
IH-Imidazole, 2-ethyl-l- ri-(4-fluoro-3-methylphenyl)-lH-imidazol-4-ynmethyn-, hydrochloride (1:2)
[l-(4-Fluoro-3-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 210-212 °C (MeOΗ / Et2O), MS: m/e = 284 (M+).
Example 26
IH-Imidazole, l-(4-fluoro-3-methylphenyl)-4-(lH-imidazol-l-yl-methyl)-, hydrochloride
(1:2)
[l-(4-Fluoro-3-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 242-243 °C (MeOH / Et2O), MS: m/e = 256 (M+).
Example 27
IH-Imidazole, 2-methyl- 1- I" 1- r4-(methylthio)phenyl] -lH-imidazol-4-yl] methyl] -, hydrochloride (1:2)
[l-(4-Methylsulfanyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 242-243 °C (MeOΗ / Et2O), MS: m/e = 284 (M+).
Example 28
IH-Imidazole, 2-ethyl- 1- \ \ 1- f 4-(methylthio) phenyl 1 -lH-imidazol-4-yl]methyll -, hydrochloride (1:2)
[l-(4-Methylsulfanyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its light yellow hydrochloride salt. Mp. 161-162 °C (MeOΗ / Et2O), MS: m/e = 298 (M+).
Example 29
IH-Imidazole, 4-(lH-imidazol-l-yl-methyl)-l- 4-(methylthio)phenyl1-, hydrochloride
[l-(4-Methylsulfanyl-phenyl)-lΗ-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its light yellow hydrochloride salt. Mp. 233-234 °C (MeOH / Et2O), MS: m/e = 270 (M+).
Example 30
IH-Imidazole, 2-methyl- 1- [ 1 - [3-(trifluoromethyl)phenyl] - lH-imidazol-4-yl] methyl] -, hydrochloride (1:2) [l-(3-Trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 218-220 °C (MeOΗ / Et2O), MS: m/e = 306 (M+).
Example 31
lΗ-Imidazole, 2-ethyl-l-f [ 1- f 3-(trifluoromethyl)phenyl] -lΗ-imidazol-4-yl] methyl] -, hydrochloride (1:2)
[l-(3-Trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 216-218 °C (MeOΗ / Et2O), MS: m/e = 320 (M+).
Example 32
IH-Imidazole, 4-(lH-imidazol-l-yl-methyl -l-[3-(trifluoromethyl)phenyl1-T hydrochloride (1:2)
[ l-(3-Trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 224-226 °C (MeOΗ / Et2O), MS: m/e = 292 (M+).
Example 33
IH-Imidazole, 2-ethyl-l-[|"l- 4-fluoro-3-(trifluoromethyl)phenyl]-lH-imidazol-4- yl] methyl]-, hydrochloride (1:2)
[ l-(4-Fluoro-3-trifluoromethyl-phenyl)-lΗ-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its light yellow hydrochloride salt. Mp. >238 °C dec. (MeOH / Et2O), MS: m/e = 338 (M+). Example 34
IH-Imidazole, l-[[l- 4-fluoro-3-(trifluoromethyl)phenyl]-lH-imidazol-4-yl1methyl1-2- methyl-, hydrochloride (1:2)
[l-(4-Fluoro-3-trifluoromethyl-phenyl)-lΗ-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its light yellow hydrochloride salt. Mp. >231 °C dec. (MeOΗ / Et2O), MS: m/e = 324 (M+).
Example 35
lΗ-Imidazole, 1- [4-fluoro-3-(trifluoromethyl)phenyl] -4-( lH-imidazol-1-yl-methyl)-, hydrochloride (1:2)
[l-(4-Fluoro-3-trifluoromethyl-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its light yellow hydrochloride salt. Mp. >246 °C dec. (MeOΗ / Et2O), MS: m/e = 310 (M+).
Example 36
IH-Imidazole, l- 3-fluoro-4-(trifluoromethyl)phenvn-4-(lH-imidazol-l-yl-methyl)-, hydrochloride (1:2)
[ l-(3-Fluoro-4-trifluoromethyl-phenyl)- lΗ-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 232-234 °C (MeOΗ / Et2O), MS: m/e = 311 (M+Η+).
Example 37
IH-Imidazole, l-[ [l- 3-fluoro-4-(trifluoromethyl)phenyl1-lH-imidazol-4-vnmethvn-2- methyl-, hydrochloride (1:2)
[l-(3-Fluoro-4-trifluoromethyl-phenyl)-lΗ-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 238-239 °C (MeOH / Et20), MS: m/e = 325 (M+H+).
Example 38
IH-Imidazole, 2-ethyl-l-!'ri-[3-fluoro-4-(trifluoromethyl)phenyl1-lH-imidazol-4- yl] methyl!-, hydrochloride (1:2)
[l-(3-Fluoro-4-trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 222-224 °C dec. (MeOΗ / Et2O), MS: m/e = 339 (M+Η+).
Example 39
IH-Imidazole, 2-methyl-l- l-[4-methyl-3-(trifluoromethyl)phenyn-lH-imidazol-4- yl] methyl]-, hydrochloride (1:2)
[l-(4-Methyl-3-trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. >235 °C dec. (MeOΗ / Et2O), MS: m/e = 320 (M+).
Example 40
lΗ-Imidazole, 2-ethyl-l-[ [ l-f4-methyl-3-(trifluoromethyl)phenyl] -lΗ-imidazol-4- yl] methyl]-, hydrochloride (1:2)
[l-(4-Methyl-3-trifluoromethyl-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 334 (M+).
Example 41
IH-Imidazole, 4- ( lΗ-imidazol- 1 -yl-methyl) - 1 - [4-methyl-3- (trifluoromethyDphenyll -, hydrochloride (1:2)
[l-(4-Methyl-3-trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. >250 °C (MeOH / Et2O), MS: m/e = 306 (M+).
Example 42
IH-Imidazole, l-[ l-(4-chloro-3-methoxyphenyl)-lH-imidazol-4-yl1methyn-2-ethyl-, hydrochloride (1:2)
[l-(4-Chloro-3-methoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. 244-246 °C dec.(MeOΗ /
Et20), MS: m/e = 316 (M+).
Example 43
1H- Imidazole, 1 - [ [ 1- (4-chloro-3-methoxyphenyl) - lH-imidazol-4-yl] methyl] -2-methyl-, hydrochloride (1:2)
[ l-(4-Chloro-3-methoxy-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. >250 °C (MeOΗ / Et O), MS: m/e = 302 (M+).
Example 44
IH-Imidazole, l-(4-chloro-3-methoxyphenyl)-4-(lH-imidazol-l-yl-methyl)-, hydrochloride (1:2)
[l-(4-Chloro-3-methoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 221-222 °C (MeOΗ / Et2O), MS: m/e = 288 (M+).
Example 45
IH-Imidazole, 2-ethyl- 1 - 1 - ( 4-fluoro-3-methoxyphenyl) - lΗ-imidazol-4-yl] methyl] ,- hydrochloride (1:2) [[l-(4-Fluoro-3-methoxy-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. >250 °C dec. (MeOΗ / Et2O), MS: m/e = 300 (M+).
Example 46
IH-Imidazole, l- [l-(4-fluoro-3-methoxyphenyl)-lΗ-imidazol-4-yl]methyl] -2-methyl-, hydrochloride (1:2)
[[l-(4-Fluoro-3-methoxy-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. >220 °C dec. (MeOΗ / Et2O), MS: m/e = 286 (M+).
Example 47
IH-Imidazole, l-(4-fluoro-3-methoxyphenyl)-4-( lH-imidazol- 1-yl- methyl)-, hydrochloride (1:2)
[ [l-(4-Fluoro-3-methoxy-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. 174-178 °C (MeOΗ / Et2O), MS: m/e = 272 (M+).
Example 48
IH-Imidazole, l-|" l-(4-chlorophenyl)-lH-imidazol-4-ynmethyl]-2-methyl-, hydrochloride (1:2)
[ 1 -(4-Chloro-phenyl)- lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its light yellow hydrochloride salt. Mp. 243-244 °C (MeOΗ / Et2O), MS: m/e = 272 (M+). Example 49
IH-Imidazole, l-[[l-(4-chlorophenyl)-lH-imidazol-4-yl]methyl]-2-ethyl-, hydrochloride
(1:2)
[l-(4-Chloro-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 200-201 °C (MeOΗ / Et2O), MS: m/e = 286 (M+).
Example 50
IH-Imidazole, l-(4-chlorophenyl)-4-(lH-imidazol-l-yl-methyl)-, hydrochloride (1:2)
[l-(4-Chloro-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 228-229 °C (MeOΗ / Et2O), MS: m/e = 258 (M+).
Example 51 lΗ-Imidazole, !-][!-( l,3-benzodioxol-5-yl)-lH-imidazol-4-ynmethyl]-2-ethyl-, hydrochloride (1:2)
(l-Benzo[l, 3 ]dioxol-5-yl-lH-imidazol-4-yl) -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 296 (M+).
Example 52 lΗ-Imidazole, !- [!-( l,3-benzodioxol-5-yl)-lH-imidazol-4-yl]methyl1-2-methyl-, hydrochloride (1:2)
(l-Benzo[l,3]dioxol-5-yl-lH-imidazol-4-yl)-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 282 (M+). Example 53
IH-Imidazole, l-( l,3-benzodioxol-5-yl)-4-(lΗ-imidazol-l-yl-methyl)-, hydrochloride
(1:2)
(l-Benzo[l,3]dioxol-5-yl-lH-imidazol-4-yl)-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 197-198 °C (MeOΗ / Et2O), MS: m/e = 268 (M+).
Example 54
IH-Imidazole, l-[[l-(3-fluoro-4-methylphenyl)-lH-imidazol-4-yl1methyl1-2-methyl-, hydrochloride (1:2)
[ l-(3-Fluoro-4-methyl-phenyl)-lΗ-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOH / Et20), MS: m/e = 270 (M+).
Example 55
IH-Imidazole, 2-ethyl- 1 - \ \ 1 - (3-fluoro-4-methylphenyl)- lH-imidazol-4-yl] methyl] -, hydrochloride (1:2)
[l-(3-Fluoro-4-methyl-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et20), MS: m/e = 284 (M+).
Example 56
IH-Imidazole, l-(3-fluoro-4-methylphenyl)-4-(lH-imidazol-l-ylmethyl)-, hydrochloride
(1:2)
[l-(3-Fluoro-4-methyl-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 223-224 °C (MeOΗ / Et20), MS: m/e = 256 (M+). Example 57
IH-Imidazole, 1- [ [ l-(3-chloro-4-methoxyphenyl)- lH-imidazol-4-yl] methyl! -2-methyl-, hydrochloride (1:2)
[l-(3-Chloro-4-methoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 240-241 °C (MeOΗ / Et2O), MS: m/e = 302 (M+).
Example 58 IH-Imidazole, l-f -(3-cΗoro-4-meτhoxyphenyl)-lH-imidazol-4-yl]methyl]-2-ethyl-, hydrochloride (1:2)
[l-(3-Chloro-4-methoxy-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 220-221 °C (MeOΗ / Et2O), MS: m/e = 316 (M+).
Example 59
IH-Imidazole, l-(3-chloro-4-methoxyphenyl)-4-(lH-imidazol-l-yl-methyl)-, hydrochloride (1:2) [ l-(3-Chloro-4-methoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 245-246 °C (MeOΗ / Et2O), MS: m/e = 288 (M+).
Example 60
IH-Imidazole, l-[[l-(4-chloro-2-fluorophenyl)-lH-imidazol-4-yl]methyl] -2-methyl-, hydrochloride (1:2)
[ l-(4-Chloro-2-fluoro-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 235-236 °C (MeOΗ / Et2O), MS: m/e = 290 (M+). Example 61
IH-Imidazole, l-rri-(4-chloro-2-fluorophenyl)-lH-imidazol-4-yl]methyll-2- ethyl-, hydrochloride (1:2)
[l-(4-Chloro-2-fluoro-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 248-249 °C (MeOΗ / Et2O), MS: m/e = 304 (M+).
Example 62 lΗ-Imidazole, l-(4-chloro-2-fluorophenyl)-4-(lH-imidazol-l-yl-methyl)-, hydrochloride
(1:2)
[l-(4-Chloro-2-fluoro-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >212 °C dec. (MeOΗ / Et2O), MS: m/e = 276 (M+).
Example 63 lΗ-Imidazole, l-[ [l-(4-bromophenyl)-lH-imidazol-4-ynmethyl]-2-ethyl-, hydrochloride
(1121 [ 1 - (4-Bromo-phenyl)- lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 330
(M+).
Example 64
IH-Imidazole, l- l-(4-bromophenyl)-lH-imidazol-4-yl]methyl] -2-methyl-, hydrochloride (1:2)
[l-(4-Bromo-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 316 (M+)- Example 65
IH-Imidazole, l-(4-bromophenyl) -4- (lH-imidazol-1 -yl-methyl)-, hydrochloride (1:2)
[l-(4-Bromo-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 237-239 °C (MeOΗ / Et2O), MS: m/e = 302 (M+).
Example 66
IH-Imidazole, 1 - 1" f 1 - \4- (difluoromethoxy)phenyll - lH-imidazol-4-yl! methyl! -2-ethyl-, hydrochloride ( 1 :2 ) [ [l-(4-Difluoromethoxy-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 199-200 °C (MeOΗ / Et2O), MS: m/e = 318 (M+).
Example 67
IH-Imidazole, 1- [ [ 1- [ 4- (difluoromethoxy) phenyl] -lH-imidazol-4-yl! methyl! -2-methyl-, hydrochloride (1:2)
[[l-(4-Difluoromethoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 228-229 °C (MeOΗ / Et2O), MS: m/e = 304 (M+).
Example 68
IH-Imidazole, 2-methyl-l- [ 1- f 4-(phenylmethoxy)phenyn - lH-imidazol-4-yl! methyl! -, hydrochloride (1:2)
[ l-(4-Benzyloxy-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 225-226 °C (MeOΗ / Et2O), MS: m/e = 344 (M+). Example 69
IH-Imidazole, 2-ethyl- 1 - [ I" 1 - f 4- (phenylmethoxy)phenyl] - lH-imidazol-4-yl] methyl] -, hydrochloride ( 1:2)
[l-(4-Benzyloxy-phenyl)-lΗ-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 222-223 °C (MeOΗ / Et2O), MS: m/e = 358 (M+).
Example 70
IH-Imidazole, 4-(lH-imidazol-l-yl-methyl)-l-[4-(phenylmethoxy)phenyl]-, hydrochloride (1:2)
[l-(4-Benzyloxy-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 224-225 °C (MeOΗ / Et2O), MS: m/e = 330 (M+).
Example 71
lΗ-Imidazole, 2-ethyl-l- [l-(3-methoxy-4-methylphenyl)-lH-imidazol-4-ynmethyl]-, hydrochloride (1:2)
[ l-(3-Methoxy-4-methyl-phenyl)- lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et20), MS: m/e = 296 (M+).
Example 72
IH-Imidazole, l-|"[l-(3-methoxy-4-methylphenyl)-lH-imidazol-4-yl1methyl]-2-methyl-, hydrochloride (1:2)
[l-(3-Methoxy-4-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 232-235 °C (MeOH / Et2O), MS: m/e = 282 (M+).
Example 73
IH-Imidazole, 4- ( lH-imidazol- 1 -yl-methyl) - 1 -( 3-methoxy-4-methylphenyl) -, hydrochloride (1:2)
[l-(3-Methoxy-4-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 249-251 °C (MeOΗ / Et2O), MS: m/e = 268 (M+).
Example 74
IH-Imidazole, 2-ethyl-l-[ l- 4-(trifluoromethyl)phenyl1-lH-imidazol-4-yl1methyl1-, hydrochloride (1:2)
[ l-(4-Trifluoromethyl-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 240-242 °C (MeOΗ / Et2O),
MS: m/e = 320 (M+).
Example 75
lΗ-Imidazole, 2-methyl-l-[ ] 1- [4-(trifluoromethyl)phenyl] -lΗ-imidazol-4-yll methyl] -, hydrochloride (1:2)
[ 1 - (4-Trifluorornethyl-phenyl) - lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 246-248 °C (MeOΗ / Et2O), MS: m/e = 306 (M+).
Example 76
lΗ-Imidazole, 4-( lH-imidazol-l-yl-methyl)-l- [4-(trifluoromethyl)phenyl] -, hydrochloride (1:2)
[l-(4-Trifluoromethyl-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 220-222 °C (MeOH / Et2O), MS: m/e = 292 (M+).
Example 77
IH-Imidazole, l-[[l-(l,3-dihydro-5-isobenzofuranyl)-lH-imidazol-4-yl1methyll-2-ethyl-, hydrochloride (1:2)
[l-(l,3-Dihydro-isobenzofuran-5-yl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. >108 °C dec. (MeOΗ / Et2O), MS: m/e = 294 (M+).
Example 78
IH-Imidazole, l- l-(l,3-dihydro-5-isobenzofuranyl)-lH-imidazol-4-yl1methyl1-2- methyl-, hydrochloride (1:2)
[l-(l,3-Dihydro-isobenzofuran-5-yl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its off-white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 280 (M+).
Example 79
IH-Imidazole, l-[|"l-(3-fluoro-4-methoxyphenyl)-lH-imidazol-4-ynmethyl]-2-methyl-, hydrochloride (1:2)
[l-(3-Fluoro-4-methoxy-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 238-240 °C (MeOΗ / Et2O), MS: m/e = 286 (M+).
Example 80
IH-Imidazole, 2-ethyl-l- [ [ l-(3-fluoro-4-methoxyphenyl)-lH-imidazol-4-yl]methyl] -, hydrochloride (1:2) [l-(3-Fluoro-4-methoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethyUmidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 218-220 °C (MeOΗ / Et2O), MS: m/e = 300 (M+).
Example 81
lΗ-Imidazole, 1 - 1" [ l-(4-methoxyphenyl)- lH-imidazol-4-yl] methyl] -2-methyl-, hydrochloride (1:2)
[l-(4-Methoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 268 (M+).
Example 82
lΗ-Imidazole, 2-ethyl-l-[ [l-(3-methoxyphenyl)-lH-imidazol-4-yl1methyl1-, hydrochloride (1:2)
[ l-(3-Methoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 246-248 °C (MeOΗ / Et2O), MS: m/e = 282 (M+).
Example 83
lΗ-Imidazole, 1- [ [ l-(3-methoxyphenyl)-lH-imidazol-4-yl]methy 1 -2-methyl-, hydrochloride (1:2)
[ l-(3-Methoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 242-243 °C (MeOΗ / Et2O), MS: m/e = 268 (M+).
Example 84
lΗ-Imidazole, 4-(lH-imidazol-l-yl-methyl)-l-(3-methoxyphenyl)-, hydrochloride (1:2) [l-(3-Methoxy-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 219-220 °C (MeOΗ / Et2O), MS: m/e = 254 (M+).
Example 85
IH-Imidazole, 1 - [ 1" 1- 4-methoxy-3-(trifluoromethyl)phenyl] - lH-imidazol-4-yl] methyl! - 2-methyl-, hydrochloride (1:2)
[ 1 - (4-Methoxy-3-trifluoromethyl-phenyl) - lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its light brown hydrochloride salt. Mp. >222 °C dec. (MeOΗ / Et2O), MS: m/e = 337 (M+Η+).
Example 86
IH-Imidazole, 2-ethyl- 1 - 1" \ 1- 4-methoxy-3-(trifluoromethyl)phenyl] - lH-imidazol-4- yll methyl!-, hydrochloride (1:2)
[l-(4-Methoxy-3-trifluoromethyl-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its light brown hydrochloride salt. Mp. >226 °C dec. (MeOΗ / Et2O), MS: m/e = 351 (M+Η+).
Example 87
IH-Imidazole, 1- [ [ l-(3-chloro-4-methylphenyl)-lH-imidazol-4-yl] methyl] -2-methyl-, hydrochloride (1:2)
[l-(3-Chloro-4-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 242-243 °C (MeOΗ / Et2O),
MS: m/e = 286 (M+). Example 88
IH-Imidazole, 1- [ l-(3-chloro-4-methylphenyl)-lH-imidazol-4-yl! methyl! -2-ethyl-, hydrochloride (1:2)
[l-(3-Chloro-4-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 178-179 °C (MeOΗ / Et2O),
MS: m/e = 300 (M+).
Example 89
lΗ-Imidazole, 1 - (3-chloro-4-methylphenyl) -4- ( IH-imidazol- 1 -yl-methyl) -, hydrochloride
Ol2)
[l-(3-Chloro-4-methyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 218-220 °C (MeOΗ / Et2O), MS: m/e = 272 (M+).
Example 90
lΗ-Imidazole, 1- [" \ 1- 4-chloro-3-(trifluoromethyl)phenyl! - lH-imidazol-4-yn methyl! -2- ethyl-, hydrochloride (1:2)
[ 1 - (4-Chloro-3 -trifluoromethyl-phenyl) - lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 179-180 °C (MeOΗ / Et2O), MS: m/e = 354 (M+).
Example 91
IH-Imidazole, l-[ri-f4-chloro-3-(trifluoromethyl)phenyl]-lH-imidazol-4-yl1methyl1 -2- methyl-, hydrochloride (1:2)
[l-(4-Chloro-3-trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2- methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOH / Et2O), MS: m/e = 340 (M+).
Example 92
IH-Imidazole, l-[4-chloro-3-(trifluoromethyl)phenyn-4-(lH-imidazol-l-yImethyl)-, hydrochloride (1:2)
[l-(4-Chloro-3-trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 326 (M+).
Example 93
IH-Imidazole, 1 - f f 1 -(3-chloro-4-fluorophenyl)- lH-imidazol-4-yl] methyl] -2-methyl-, hydrochloride (1:2)
[ l-(3-Chloro-4-fluoro-phenyl)-lΗ-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 224-225 °C (MeOΗ / Et2O), MS: m/e = 290 (M+).
Example 94
lΗ-Imidazole, 1- [ [ l-(3-chloro-4-fluorophenyl)~ lH-imidazol-4-yl! methyl! -2-ethyl-, hydrochloride (1:2)
[l-(3-Chloro-4-fluoro-ρhenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 248-250 °C (MeOΗ / Et2O),
MS: m/e = 304 (M+).
Example 95
IH-Imidazole, l-(3-chloro-4-fluorophenyl)-4-(lH-imidazol-l-yl-methyl)-, hydrochloride
[l-(3-Chloro-4-fluoro-phenyl)-lΗ-imidazol-4-yl]-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 210-212 °C (MeOH / Et2O), MS: m/e = 276 (M+).
Example 96
IH-Imidazole, 1 - 1" ( 1- [ 1 , 1 ' -biphenyl] -4-yl- lH-imidazol-4-yl)methyl! -2-ethyl-, hydrochloride (1:2)
(l-Biphenyl-4-yl-lH-imidazol-4-yl)-methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. 248-253 °C (MeOΗ / Et2O), MS: m/e = 328 (M+).
Example 97
IH-Imidazole, 1- 1" ( 1- 1" 1 , l'-biphenyl! -4-yl- lH-imidazol-4-yl)methyl! -2-methyl-, hydrochloride (1:2)
(l-Biphenyl-4-yl-lΗ-imidazol-4-yl) -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its light yellow hydrochloride salt. Mp. 169-175 °C (MeOH / Et2O), MS: m/e = 314 (M+).
Example 98 IH-Imidazole, 2-ethyl-l-f [l- 3-methyl-4-(l-methylethyl)phenyl1-lΗ-imidazol-4- yl! methyl!-, hydrochloride (1:2)
[l-(4-Isopropyl-3-methyl-phenyl)-lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >180 °C dec. (MeOΗ / Et2O),
MS: m/e = 308 (M+).
Example 99 lΗ-Imidazole, 2-methyl- 1 - f I" 1 - r3-methyl-4- ( 1 -methylethyDphenyl! - lH-imidazol-4- yll methyl!-, hydrochloride (1:2) [ 1 - (4-Isopropyl-3-methyl-phenyl)- lH-imidazol-4-yl] -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >250 °C (MeOH / Et2O), MS: m/e = 294 (M+).
Example 100
IH-Imidazole, 2-methyl-l-[ [l-(4-nitrophenyl)-lH-imidazol-4-ynmethyl1-, hydrochloride Ol2) l-(4-Nitrophenyl)-lH-imidazole-4-methanol (prepared according to I. Antonini et al., Synthesis, 1983, I, 47-49) was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its yellow hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 283 (M+).
Example 101 lΗ-Imidazole, 2-ethyl-l-[ [l-(4-nitrophenyl)-lH-imidazol-4-yllmethyn-, hydrochloride
(1:2)
l-(4-Nitrophenyl)-lH-imidazole-4-methanol (prepared according to I. Antonini et al., Synthesis, 1983, 1, 47-49) was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-ethylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its yellow hydrochloride salt. Mp. 196-197 °C (MeOΗ / Et2O), MS: m/e = 297 (M+).
Example 102 lΗ-Imidazole, 4-(lH-imidazol-l-yl-methyl)-l-(4-nitrophenyl)-, hydrochloride (1:2) l-(4-Nitrophenyl)-lH-imidazole-4-methanol (prepared according to I. Antonini et al., Synthesis, 1983, I, 47-49) was treated first with thionylchloride, then with the reaction mixture of sodium hydride and imidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its yellow hydrochloride salt. Mp. 245-246 °C (MeOΗ / Et2O), MS: m/e = 269 (M+).
Example 103
IH-Imidazole, 1 - ( 3,4-dichlorophenyl) -5-methyl-4- \ (2-methyl- IH-imidazol- 1 -yl) methyl!-, hydrochloride (1:2) [ l-(3,4-Dichloro-phenyl)-5-methyl-lH-imidazol-4-yl! -methanol was treated first with thionylchloride, then with the reaction mixture of sodium hydride and 2-methylimidazole. After extractive workup and chromatography the title compound was obtained as the free base. It was converted into its white hydrochloride salt. Mp. >240 °C dec. (MeOΗ / Et2O),
MS: m/e = 320 (M+). Example 104 l-ri-(3,4-Dichloro-phenyl)-lH-imidazol-4-yl-methyll-lH-imidazol-2-yl-amine-, hydrochloride (1:2) lΗ-Imidazole, l-[[l-(3,4-dichlorophenyl)-lH-imidazol-4-yl]methyl]-2-nitro- (2.1 g, 6.2 mmol) was dissolved in acetic acid (50 ml), iron powder (3.5 g, 62 mmol) was added and the resulting mixture was stirred at 60 °C for 2h. After addition of AcOEt (200 ml), the hot mixture was again brought to reflux and filtered. All volatiles were removed in vacuo and residual acid was removed by co- evaporation with toluene. The semi-solid obtained was purified by chromatography [silica, elution with gradient CΗ2C12 to 100 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] and the free base of the title compound (1.9 g, 100 %) was isolated as an off-white solid. After treatment with a solution of HC1 in MeOH followed by addition of Et 0 the title compound was isolated as a white crystalline solid. Mp. 164-165 °C (MeOH / Et2O), MS: m/e = 308(M+H+).
Examples 105 to 107 were prepared according to the general procedure described in example 104.
Example 105
1- [ l-(4-Chloro-3-methyl-phenyl)- lH-imidazol-4-yl-methyl] - lH-imidazol-2-yl-amine-, hydrochloride (1:2) lΗ-Imidazole, l-[[l-(4-chloro-3-methylphenyl)-lH-imidazol-4-yl]methyl]-2-nitro, was reacted with iron in acetic acid. After filtration, evaporation and chromatography the free base of the title compound was isolated. It was converted into its white hydrochloride salt. Mp. 230-233 °C (MeOΗ / Et2O), MS: m/e = 288(M+Η+).
Example 106 l-(l-p-Tolyl-lH-imidazol-4-yl-methyl)-lH-imidazol-2-yl-amine-, hydrochloride (1:2)
lΗ-Imidazole, l-[[l-(4-methylphenyl)-lH-imidazol-4-yl]methyl]-2-nitro was reacted with iron in acetic acid. After filtration, evaporation and chromatography the free base of the title compound was isolated. It was converted into its white hydrochloride salt. Mp. 232-233 °C (MeOΗ / Et2O), MS: m/e = 253 (M+).
Example 107
1 -( 1 -Phenyl- lΗ-imidazol-4-yl-methyl) - lH-imidazol-2-yl-amine-, hydrochloride ( 1 :2) lΗ-Imidazole, 2-nitro-l-[(l-phenyl-lH-imidazol-4-yl)methyl]-, was reacted with iron in acetic acid. After filtration, evaporation and chromatography the free base of the title compound was isolated. It was converted into its white hydrochloride salt. Mp. 153-155 °C (MeOH / Et2O), MS: m/e = 239(M+).
Example 108
IH-Imidazole, l-[[l-(3,4-dichlorophenyl)-lH-imidazol-4-yn ethyl] -2,5-dimethyl-, hydrochloride (1:2)
A suspension of N- [ 1 -(3,4-dichloro-phenyl)-lH-imidazol-4-ylmethylj -thioacetamide (0.60 g, 2.0 mmol) in acetone (10 ml) was treated with K2CO3 (0.28 g, 2.0 mmol) and iodomethane (0.26 g, 1.8 mmol). The mixture was refluxed for 1 h, evaporated and suspended in EtOΗ (3 ml). After addition of propargylamine (1.1 g, 20 mmol) it was refluxed for 9 h. After filtration and evaporation the residue was purified by chromatography [silica, elution with gradient CΗ2C12 to 30 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] and the free base of the title compound (0.20 g, 28 %) was isolated as a light brown oil. After treatment with a solution of HO in MeOH followed by addition of Et2O the title compound was isolated as a white crystalline material. Mp. >250 °C (MeOH / Et2O), MS: m/e = 321 (M+H+).
Example 109
{ l- l-(3,4-Dichloro-phenyl)-lH-imidazol-4-yl-methyl1 -lH-imidazol-2-yll-methanol
A solution of l-[l-(3,4-dichloro-phenyl)-lH-imidazol-4-ylmethyl]-lH-imidazole-2- carbaldehyde (0.52 g, 1.6 mmol) in MeOΗ (16 ml) was treated with sodium borohydride (0.12 g, 3.2 mmol). The mixture was stirred at rt for 2h. Then all volatiles were evaporated and the residue was partitioned (AcOEt / Η2O). The organic phase was dried (Na2SO4) and concentrated to approximately 30 ml. The title compound was obtained as a white crystalline material (0.21 g, 41 %). Mp. 202-203 °C (AcOEt), MS: m/e = 322 (M+).
Example 110 N-{l-f l-(3,4-Dichloro-phenyl)-lH-imidazol-4-yl-methyl]-lH-imidazol-2-yl}-acetamide
A solution of l-[l-(3,4-dichloro-phenyl)-lH-imidazol-4-yl-methyl!-lH-imidazol-2- ylamine (1.0 g, 3.2 mmol) in TΗF (32 ml) was treated at rt with triethylamine (0.33 g, 3.2 mmol) and acetyl chloride (0.25 g, 3.2 mmol). The mixture was stirred at rt for 2h, filtered and the organic phase was evaporated to dryness. After chromatography [silica, elution with gradient CΗ2C12 to 50 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] the title compound (0.19 g, 17 %) was isolated as a light brown solid. Mp. >236 °C dec.(AcOEt), MS: m/e = 350 (M+H+). Example 111
{ 1- 1" 1 -(3,4-Dichloro-phenyl)- lH-imidazol-4-yl-methyl] - lH-imidazol-2-y -ethyl-amine hydrochloride (1:2)
N- { 1 - [ 1 - (3,4-Dichloro-phenyl) - lH-imidazol-4-ylm ethyl] - lΗ-imidazol-2-yl} -acetamide (0.30 g, 0.86 mmol) was treated with IM BH3 THF complex (1.6 ml) and refluxed for 2 h. The mixture was cooled to 5°C and MeOH (5 ml) was added slowly. After evaporation of all volatiles the residue was taken up in 2N HC1 solution (3 ml) and refluxed for 20 min. The mixture was cooled and 2N NaOH solution (3ml) was added. After extraction with AcOEt (50 ml), the organic phase was dried (Na2SO4) and evaporated to dryness. Purification by chromatography [silica, elution with gradient CH2C12 to 50 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] gave the free base of the title compound. After treatment with a solution of HC1 in MeOH followed by addition of Et20 the title compound was isolated as an off-white crystalline material (0.062 g, 22 %). Mp. >250 °C (MeOH / Et2O), MS: m/e = 336 (M+H+).
Example 112
l-(3,4-Dichloro-phenyl)-3-(2-methyl-imidazoI-l-yl-methyl)-lH-pyrazole hydrochloride mi
A solution of l-(3,4-dichloro-phenyl)-3-methyl-lH-pyrazole (1.4 g, 6.1 mmol) in carbon tetrachloride was treated with N-bromosuccinimide (1.2g, 6.8 mmol) and a catalytic amount of 2,2'azobis-(isobutyronitrile). The mixture was refluxed for 2 h, cooled, filtered and evaporated. The oily residue was dissolved in DMF (10 ml) and added to a solution of sodium hydride (0.32 g, 7.3 mmol, cf example 1) deprotonated 2-metylimidazole (0.60 g, 7.3 mmol) in DMF (10 ml). After stirring for 12 h at rt all volatiles were removed in vacuo and the residue obtained was dissolved in AcOEt. The organic phase was washed with Η2O (3x), dried (Na2SO4) and concentrated. Purification by chromatography [silica, elution with gradient CH2C12 to 60 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] gave the free base of the title compound (0.98 g, 52 %) as a light brown oil. After treatment with a solution of HC1 in MeOH followed by addition of Et2O the title compound was isolated as a white crystalline material. Mp. 204-205 °C (MeOH / Et2O), MS: m/e = 306 (M+).
Example 113
l-(3,4-Dichloro-phenyl)-4-imidazol-l-yl-methyl-lH-pyrazole
Sodium hydride (0.24 g of a 55 % dispersion in mineral oil, 5.5 mmol) was slowly added to a solution of imidazole (0.19 g, 2.8 mmol) in DMF (15 ml). After 30 min at 60 °C the mixture was cooled in an ice bath and 4-chloromethyl-l-(3,4-dichloro-phenyl)-lH- pyrazole (0.50 g, 1.9 mmol) was added in one portion. The resulting mixture was stirred for 1 h at 20 °C. After evaporation of the solvent the residue was dissolved in AcOEt, washed with H O, dried (Na2S04) and chromatographed [silica, elution with gradient CH2C12 to 30 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] to obtain 0.23 g (41 %) of the title compound. Mp. 103-104 °C (iPr2O), MS: m/e = 293(M+H+)
Example 114 was prepared according to the general procedure described in example 113.
Example 114
l-(3,4-Dichloro-phenyl)-4-(2-methyl-imidazol-l-yl-methyl)-lH-pyrazole
2 -Methylimidazole was deprotonated with sodium hydride and then treated with 4- chloromethyl-l-(3,4-dichloro-phenyl)-lH-pyrazole. Extractive and chromatographic workup gave the title compound as a white crystalline solid. Mp. 176-177 °C (AcOEt), MS: m/e = 307(M+Η+).
Example 115
IH-Imidazole, l-(3,4-dichlorophenyl)-4-[l-(lH-imidazol-l-yl)ethyl]-, and IH-Imidazole, l-(3,4-dichlorophenyl)-3-chloro-4-[l-(lH-imidazol-l-yl)ethyl]-
A mixture of l-[l-(3,4-dichloro-phenyl)-lΗ-imidazol-4-yl]-ethanol (0.2 g, 0.78 mmol) and thionyl chloride (3 ml, excess) was stirred at rt for 1.5 h. The solvent was removed by a gentle air stream. Imidazole (3.5 g, excess) was then added to the residue and the mixture was stirred at 90° C for 30 min. After the addition of H2O (10 ml), the mixture was extracted with CH2C12. The organic phase was dried (Na2SO4) and the solvent was evaporated. Purification of the residue by chromatography (silica, elution with CH2C12 / MeOH / aq. NH4OH =140:10:1) gave IH-imidazole, l-(3,4-dichlorophenyl)-4-[l-(lH- imidazol-1-yl) ethyl]- (82 mg, 34 %) as a light brown solid [MS: m/e=306.1 (M+) ] together with a side product (IH-imidazole, l-(3,4-dichlorophenyl)-3-chloro-4-[l-(lH-imidazol-l- yl)ethyi]- , 102 mg, 38 %) as a light yellow oil. MS: m/e=341.1 (M+Η+).
Example 116 was prepared according to the general procedure described in example 115.
Example 116
IH-Imidazole, l-[l-[l-(3,4-dichlorophenyl)-lH-imidazol-4-yl]ethyl1-2-methyl-
Reaction of l-[l-(3,4-dichloro-phenyl)-lH-imidazol-4-yl]-ethanol with thionyl chloride followed by treatment with 2-methylmidazole led after extractive workup and chromatography to the title compound as a light brown solid. MS: m/e=320.1 (M+). Example 117
IH-Imidazole, 1 - (3,4-dichlorophenyl) -4- [ 1 - ( IH-imidazol- 1 -yl) - 1 -methylethyl] -
A mixture of 2-[l-(3,4-dichloro-phenyl)-lH-imidazol-4-yl]-propan-2-ol (150 mg, 0.55 mmol) and boron tribromide (IM in CΗ2C1 , 3 ml) was stirred at rt for 2 h. After removal of the solvent in an air stream, the residue was dried overnight. Imidazole (226 mg, 33.2 mmol) was added, and the mixture was stirred at 100° C for 45 min. After the addition of H2O, the mixture was extracted with CH2C1 . The organic phase was dried (Na2SO4), evaporated and the residue was purified by chromatography (silica, elution first with AcOEt, then CH2C12 / MeOH = 95:5) to give the title compound (15 mg, 8 %) as a light yellow solid. MS: m/e=320.0 (M+).
Example 118
IH-Imidazole, 2-methyl-l-[[4-[3-(trifluoromethyl)phenyl]-lH-imidazol-2-yl]methyl1-, hydrochloride (1:2)
IH-Imidazole, 2-[(2-methyl-lH-imidazol-l-yl)methyl]-4-[3-(trifluoromethyl)phenyl] -l-[[2-(trimethylsilyl)ethoxy]methyl]- (0.034 g, 0.078 mmol) was dissolved in EtOΗ
(0.8ml) and treated with 2N ΗC1 (0.86 ml). The reaction mixture was refluxed overnight, cooled to rt and concentrated. The crude residue was taken up in AcOEt and stirred at rt for 30 min. Filtration provided IH-Imidazole, 2-methyl-l-[[4-[3- (trifluoromethyl)phenyl]-lH-imidazol-2-yl] methyl]-, hydrochloride (24 mg, 81 %) as a light yellow solid, MS: m/e = 307.2 (M+Η+).
Examples 119 to 122 were prepared according to the general procedure described in example 118.
Example 119
IH-Imidazole, l-[[4-(4-fluoro-3-methylphenyl)-lH-imidazol-2-yl]methvn-2- methyl-, hydrochloride (1:2)
The title compound, MS: m/e = 270.1 (M+) was prepared from IH-imidazole, 4-(4-fluoro-3-methylphenyl)-2-[(2-methyl-lH-imidazol-l-yl)methyl]-l-[[2- (trimethylsilyl) ethoxy] methyl] .
Example 120 IH-Imidazole, l-[[4-(3,4-difluorophenyl)-lH-imidazol-2-yl]methyl]-2-methyl-, hydrochloride (1:2) The title compound, MS: m/e = 275.2 (M+H+) was prepared from IH-imidazole, 4-(3,4-difluorophenyl)-2-[(2-mefhyl-lH-imidazol-l-yl)methyl]-l-[[2-(trimethyl silyl) ethoxy] methyl] .
Example 121 IH-Imidazole, 2-methyl- 1- \ [4- 4-(methylthio)phenyl! - lH-imidazol-2-yl! methyl)-, hydrochloride (1:2)
The title compound, MS: m/e = 285.2 (M+Η+) was prepared from IH-imidazole,
2- [ (2-methyl- IH-imidazol- 1 -yl)methyl) -4- [4- (methylthio )phenyl] - 1 - [ [2- (trimethylsilyl) ethoxy] methyl].
Example 122
IH-Imidazole, 4-(4-fluoro-3-methylphenyl)-2-( IH-imidazol- 1 -yl-methyl)-, hydrochloride Iii2l
The title compound, MS: m/e = 257.1 (M+Η+) was prepared from IH-imidazole, 4-(4- fluoro-3-methylphenyl)-2-(lH-imidazol-l-yl-methyl)-l-[ [2-(trimethylsilyl) ethoxy] methyl] .
Example 123
3-(3,4-Dichloro-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1)
To a suspension of sodium hydride (17 mg of a 55 % dispersion in mineral oil, 0.39 mmol) in DMF (5 ml) was added 2-methylimidazole (32 mg, 0.39 mmol). This mixture was stirred for 1.5 h at 20 °C. Following this, 3-chloromethyl-5-(3,4-dichloro-phenyl)-pyridine hydrochloride (1:1) (100 mg, 0.32 mmol) and triethylamine (78 mg, 0.78 mmol) were added and the mixture heated to 100 °C for 4 h. After cooling, the DMF was evaporated and the residue was directly chromatographed [silica, elution with CΗ2C12 /(2M NH3 in MeOH) = 85:15] to afford the free base of the title compound as a yellow oil. This material was dissolved in MeOH, cooled to 4 °C with stirring and treated with HCl/EtOH ( 1.46 M 1.1 eq) for 15 min. Evaporation of the solvent and drying under high vacuum at 50 °C for 2 h afforded the title compound (71 mg, 62 %) as a light yellow solid. MS: m/e = 317.1 (M+)
Examples 124 to 127 were prepared according to the general procedure described in example 123. Example 124
4-(3,4-Dichloro-phenyl)-2-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1) The title compound, MS: m/e = 317.0 (M+) was obtained as a light brown solid (60 % yield) by the reaction of 2-chloromethyl-3-(3,4-dichloro-phenyl)-pyridine hydrochloride (1:1) with 2-methylimidazole, using sodium hydride and triethylamine as base followed by formation of the hydrochloride salt.
Example 125
2-(3,4-Dichloro-phenyl)-4-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:2)
The tide compound, MS: m/e = 317.0 (M+) was obtained as a beige solid (51 % yield) by the reaction of 4-chloromethyl-2-(3,4-dichloro-phenyl)-pyridine hydrochloride (1:1) with 2-methylimidazole, using sodium hydride and triethylamine as base followed by formation of the hydrochloride salt.
Example 126
3-(3,4-Dichloro-phenyl)-5-imidazol-l-yl-methyl-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 304.1 (M+H+) was obtained as a solid (56 % yield) by the reaction of 3-chloromethyl-5-(3,4-dichloro-phenyl)-pyridine hydrochloride (1:1) with imidazole, using sodium hydride and triethylamine as base followed by formation of the hydrochloride salt.
Example 127
3-(3,4-Dichloro-phenyl)-5-(2-ethyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 332.2 (M+H+) was obtained as an orange solid (49 % yield) by the reaction of 3-chloromethyl-5-(3,4-dichloro-phenyl)-pyridine hydrochloride (1:1) with 2-ethylimidazole, using sodium hydride and triethylamine as base followed by formation of the hydrochloride salt.
Example 128
5-(3,4-Dimethyl-phenyl)-2-methyl-3-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 292.2 (M+H+) was obtained as a beige solid (77 % yield) by the reaction of 3-chloromethyl-5-(3,4-dimethyl-phenyl)-2-mefhyl-pyridine hydrochloride (1:1) with 2-methylimidazole (5 eq.), using sodium hydride (3 eq.) as base followed by formation of the hydrochloride salt. Example 129
3-(4-Chloro-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1)
A mixture of 3-bromo-5-(2-methyl-imidazol-l-ylmethyl)-pyridine (120 mg, 0.48 mmol), bis(triphenylphosphine)palladiurn (II) choride (10 mg, 0.01 mmol) and KOAc (140 mg, 0.14 mmol) were stirred in dioxane (10 ml) for 1 h at 20 °C. 4-Chlorophenyl boronic acid (78 mg, 0.05 mmol) and 2N Na2CO3 solution (1.2 ml) were then added and the mixture heated to 100 °C for 7 -24 h under an argon atmosphere. After cooling, the solvent was evaporated and 2N NaOH (5 ml) and AcOEt were added. The mixture was shaken and the aqueous phase separated and further extracted with AcOEt, the combined organic extracts were washed with brine then dried over Na2SO4, filtered and evaporated. The residue was chromatographed [silica, elution with CH2C12 /(2M NH3 in MeOH) = 97:3)]. The product was dissolved in MeOH, cooled to 4 °C with stirring and treated with HCl/EtOH (1.46 M 1.1 eq) for 45 min. Evaporation of the solvent and drying under high vacuum at 50 °C for 2 h afforded the title compound (98 mg, 64 %) as a light brown solid. MS: m/e = 284.2 (M+H+).
Examples 130 to 142 were prepared according to the general procedure described in example 129.
Example 130
3-(3,4-Dimethyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 277 (M+) was obtained as a light yellow foam (54 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-ylmethyl)-pyridine with 3,4- dimethylphenyl boronic acid.
Example 131
3-(4-Fluoro-3-methyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride Oil)
The title compound, MS: m/e = 281.1 (M+) was obtained as a light brown foam (63 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-ylmethyl)-pyridine with 4- fluoro-3-methyl-phenyl boronic acid.
Example 132
3- (3 ,4-Difluoro-phenyl) -5- (2-methyl-imidazol- 1 -yl-methyl) -pyridine hydrochloride (1:1) The title compound, MS: m/e = 286.2 (M+H+) was obtained as a light yellow foam (85 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-ylmethyl)-pyridine with 3,4- difluoro-phenylboronic acid.
Example 133
3 - (4-Fluoro-phenyl) -5- (2-methyl-imidazol- 1 -yl-methyl) -pyridine hydrochloride (1:1)
The title compound, MS: m/e = 268.3 (M+H+) was obtained as a light yellow solid (90 % yield) by the reaction of 3-bromo-5-(2-mefhyl-imidazol-l-ylmethyl)-pyridine with 4- fluoro phenylboronic acid.
Example 134
3-(2-Methyl-imidazol-l-yl-methyl)-5-(3-trifluoromethyl-phenyl)-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 318.3 (M+H+) was obtained as a beige foam (74 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-ylmethyl)-pyridine with 3- trifluoromethyl phenylboronic acid.
Example 135
3-(2-Methyl-imidazol-l-yl-methyl)-5-(4-trifluoromethyl-phenyl)-pyridine hydrochloride inn
The title compound, MS: m/e = 318.3 (M+H+) was obtained as a beige solid (77 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-yl-methyl)-pyridine with 4- trifluoromethyl phenylboronic acid.
Example 136
3-(3-Chloro-4-mefhyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 298.3 (M+H+) was obtained as a beige solid (78 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-yl-methyl)-pyridine with 2-(3-chloro- 4-methyl-phenyl)-4,4,5,5-tetramethyl[l,3,2]-dioxaborolane.
Example 137
3-(4-Chloro-3-methyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1) The title compound, MS: m/e = 298.3 (M+H+) was obtained as a white solid (73 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-yl-methyl)-pyridine with 2-(4-chloro- 3-methyl-phenyl)-4,4,5,5-tetramethyl[ 1,3,2] -dioxaborolane.
Example 138
3-(2,3-Dihydro-benzofuran-5-yl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 292.2 (M+H+) was obtained as a light yellow foam (18 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-yl-methyl)-pyridine with 5- (4,4,5,5-tetramethyl[l,3,2]-dioxaborolan-2-yl)-2,3-dihydro-benzofuran.
Example 139
3-Indan-5-yl-5-(2-methyl-imidazol-l-yl-methyl)-ρyridine hydrochloride (1:1)
The title compound, MS: m/e = 289.1 (M+) was obtained as a white solid (91 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-ylmethyl)-pyridine with 2-indan-5-yl- 4,4,5,5-tetramethyl[l,3,2] -dioxaborolane.
Example 140
3-(3-Chloro-4-fluoro-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride
Hill
The title compound, MS: m/e = 301.1 (M+) was obtained as a yellow solid (53 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-yl-methyl)-pyridine with 3-chloro-4- fluoro-phenyl boronic acid.
Example 141
3-(4-Chloro-3-trifluoromethyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 352.3 (M+H+) was obtained as a beige foam (49 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-yl-methyl)-pyridine with 2-(4-chloro- 3-trifluoromethyl-phenyl)-4,4,5,5-tetramethyl- [1,3,2] dioxaborolane.
Example 142
3-(4-Fluoro-3-trifluoromethyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine hydrochloride (1:1) The title compound, MS: m/e = 336.3 (M+H+) was obtained as a white solid (60 % yield) by the reaction of 3-bromo-5-(2-methyl-imidazol-l-ylmethyl)-pyridine with 2-(4-fluoro- 3-trifluoromethyl-phenyl)-4,4,5,5-tetramethyl- [ 1,3,2] dioxaborolane.
Example 143
IH-Imidazole, 2-ethyl- !- [!- [ 3- (trifluoromethylthio)phenyll - lH-imidazol-4-yl] methyll -, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-trifluoromethylsulfanyl-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 234-236 °C (MeOΗ / Et2O), MS: m/e = 353(M+Η+).
Example 144
IH-Imidazole, 2-methyl- 1- [ [ 1- [3-(trifluoromethylthio)phenyl] - lH-imidazol-4- yl! methyl!-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-trifluoromethylsulfanyl-phenyl)-lΗ- imidazol-4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 169-170 °C (MeOH / Et2O), MS: m/e = 339(M+H+).
Example 145
4-Imidazol-l-ylmethyl-l-(3-methylsulfanyl-phenyl)-lH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-trifluoromethylsulfanyl-phenyl)-lΗ- imidazol-4-yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 213-215 °C (MeOH / Et2O), MS: m/e = 325 (M+H+).
Example 146
IH-Imidazole, 1- [ [ 1- 3-( l,l-difluoroethyl)phenyl1 -lH-imidazol-4-yl] methyl] -2-ethyl-, hydrochloride (1:2) Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of {l-[3-(l,l-difluoro-ethyl)-phenyl]-lH- imidazol-4-yl}-methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 130-134 °C dec.(MeOH / Et2O), MS: m/e = 317 (M+H+).
Example 147 IH-Imidazole, 1- [ [ 1- [3-( l,l-difluoroethyl)phenyl1 -lH-imidazol-4-yl! methyl! -2-methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of {l-[3-(l,l-difluoro-ethyl)-phenyl]-lH- imidazol-4-yl} -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 303 (M+Η+).
Example 148
1 - 3 - ( 1 , 1 -Difluoroethyl) -phenyl! -4-imidazol- 1 -ylmethyl- IH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of {l-[3-(l,l-difluoro-ethyl)-phenyl]-lH- imidazol-4-yl} -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 303 (M+Η+).
Example 149
IH-Imidazole, 1- [ [ 1- [3-( l,l-difluoroethyl)-4-fluorophenyl! - lH-imidazol-4-yl! methyl! -2- methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of {l-[3-(l,l-difluoro-ethyl)-4-fluoro- phenyl]-lH-imidazol-4-yl}-methanol first with thionylchloride and then with 2- methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 321 (M+Η+).
Example 150
1 - \ 3 - ( 1 , 1 -Difluoro-ethyl ) -4-fluoro-phenyl 1 -4-imidazol- 1 -ylmethyl- IH-imidazole hydrochloride (1:2) Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of {l-[3-(l,l-difluoro-ethyl)-4-fluoro- phenyl] -lH-imidazol-4-yl}-methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 307 (M+Η+).
Example 151
IH-Imidazole, l-[[l-[3-(l,l-difluoroethyl)-4-fluorophenyl]-lH-imidazol-4-ynmethyn-2- ethyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of { 1- [3-( l,l-difluoro-efhyl)-4-fluoro- phenyl]-lH-imidazol-4-yl}-methanol first with thionylchloride and then with 2- ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 335 (M+Η+).
Example 152
IH-Imidazole, l-[[l-(3-isopropylphenyl)-lH-imidazol-4-yl!methyl! -2-methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-isopropyl-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 281 (M+Η+).
Example 153 IH-Imidazole, 2-ethyl- 1 - [ [ 1 -(3 -isopropylphenyl) - lH-imidazol-4-yl] methyl] -, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-isopropyl-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 295 (M+Η+).
Example 154
4-Imidazol-l-ylmethyl-l-(3-isopropyl-phenyl)-lH-imidazole hydrochloride (1:2) Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-isopropyl-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 200-206 °C (MeOΗ / Et20), MS: m/e = 267 (M+Η+).
Example 155
IH-Imidazole, 2-methyl- 1 - [ [ 1 - (naphtalen-2-yl) - lH-imidazol-4-yl] methyl] -, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of (l-naphthalen-2-yl-lH-imidazol-4-yl)-methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 247-248 °C (MeOΗ / Et2O), MS: m/e = 288 (M+).
Example 156
IH-Imidazole, l- l-(3-bromo-4-fluorophenyl)-lH-imidazol-4-yl]methyl1-2-ethyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-bromo-4-fluoro-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 238-239 °C (MeOΗ / Et2O), MS: m/e = 349 (M+Η+).
Example 157
IH-Imidazole, 1- [ [ l-(3-bromo-4-fluorophenyl)- lH-imidazol-4-yl1 methyl! -2-methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-bromo-4-fluoro-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 232-233 °C (MeOΗ / Et2O), MS: m/e = 335 (M+Η+)
.Example 158
1 - ( 3 -Bromo-4-fluoro-phenyl) -4-imidazol- 1 -ylmethyl- IH-imidazole hydrochloride (1:2) Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-bromo-4-fluoro-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 229-230 °C (MeOΗ / Et2O), MS: m/e = 321 (M+Η+).
Example 159
IH-Imidazole, 1- [ [l-(3-ethyIphenyl)-lH-imidazol-4-yl]methyl] -2-methyl-, hydrochloride
(1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-ethyl-phenyl)-lΗ-imidazol-4-yl]- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOH / Et2O), MS: m/e = 267 (M+H+).
Example 160
IH-Imidazole, 2-ethyl-l-[[l-(3-ethylphenyl)-lH-imidazol-4-vnmethyn-, hydrochloride
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-ethyl-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 281 (M+Η+).
Example 161 1 - (3 -Ethyl-phenyl) -4-imidazol- 1 -ylmethyl- IH-imidazole hydrochloride ( 1 :2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-ethyl-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >190 °C dec. (MeOΗ / Et2O), MS: m/e = 253 (M+Η+).
Example 162 IH-Imidazole, 1- [ [ l-(3-cyclopropylphenyl)- lH-imidazol-4-yl] methyl] -2-methyl-, hydrochloride (1:2) Following the general method described in example 10, the title compound was obtained as a light brown crystalline material by reaction of [l-(3-cyclopropyl-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 174-175 °C (MeOΗ / Et2O), MS: m/e = 279 (M+Η+).
Example 163
IH-Imidazole, 1- [ l-(3-difluoromethyl-4-fluorophenyl)-lH-imidazol-4-yl]methyl1 -2- methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-difluoromethyl-4-fluoro-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 223-225 °C dec. (MeOΗ / Et2O), MS: m/e = 306 (M+).
Example 164
IH-Imidazole, l-[[l-(3-difluoromethyl-4-fluorophenyl)-lH-imidazol-4-yl!methyll-2- ethyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-difluoromethyl-4-fluoro-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 229-232 °C (MeOΗ / Et2O), MS: m/e = 320 (M+).
Example 165 l-(3-Difluoromethyl-4-fluoro-phenyl)-4-imidazol-l-ylmethyl-lH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-difluoromethyl-4-fluoro-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 239-241 °C (MeOΗ / Et2O), MS: m/e = 292 (M+). Example 166
IH-Imidazole, 2-ethyl-l-[[l-[3-(methylthio)phenyl]-lH-imidazol-4-yl1methyn-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-methylsulfanyl-phenyl)-lH-imidazol- 4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 299 (M+Η+).
Example 167
IH-Imidazole, 2-methyl- 1- [ [ 1 - [3-(methylthio)phenyl1 - lH-imidazol-4-yl] methyl] -, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [ l-(3-methylsulfanyl-phenyl)-lH-imidazol- 4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 285 (M+Η+).
Example 168 4-Imidazol-l-ylmethyl-l-(3-methylsulfanyl-phenyl)-lH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-methylsulfanyl-phenyl)-lH-imidazol- 4-yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 271 (M+Η+).
Example 169
IH-Imidazole, 2-ethyl-l- [ 1- [3-(trifluoromethoxy)phenyl] - lH-imidazol-4-yl] methyl] -, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-trifluoromethoxy-phenyl)-lΗ-imidazol-4- yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 237-239 °C (MeOH / Et2O), MS: m/e = 336 (M+). Example 170
IH-Imidazole, 2-methyl- 1- [ [ 1- [3-(trifluoromethoxy)phenyl] - lH-imidazol-4-yl] methyl] -, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [ l-(3-trifluoromethoxy-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 221-223 °C (MeOΗ / Et2O), MS: m/e = 322 (M+).
Example 171 4-Imidazol-l-ylmethyl-l-(3-trifluoromethoxy-phenyl)-lH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-trifluoromethoxy-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 233-234 °C (MeOΗ / Et2O), MS: m/e = 308 (M+).
Example 172
IH-Imidazole, 2-methyl-l-[[l-(3-vinylphenyl)-lH-imidazol-4-yl1methyl1-, hydrochloride
(1:2) Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-vinyl-phenyl)-lH-imidazol-4-yl]-methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 207-208 °C (MeOΗ / Et2O), MS: m/e = 265 (M+Η+).
Example 173
IH-Imidazole, 1 - [ [ l-(3-chlorophenyl)- lH-imidazol-4-yl] methyl] -2-methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [ l-(3-chloro-phenyl)-lH-imidazol-4-yl] - methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 273 (M+Η+). Example 174
IH-Imidazole, 1 - [ [ 1 - (3-chlorophenyl) - lH-imidazol-4-yl] methyl! -2-ethyl-, hydrochloride
(1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-chloro-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 287 (M+Η+).
Example 175
1 - ( 3-Chloro-phenyl) -4-imidazol- 1 -ylmethyl- IH-imidazole hydrochloride ( 1 :2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-chloro-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 259 (M+Η+).
Example 176
IH-Imidazole, 1 - [ 1 -( 3-iodophenyl) - lH-imidazol-4-yl] methyl] -2-methyl-, hydrochloride ( 1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-iodo-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >222 °C dec. (MeOΗ / Et2O), MS: m/e = 365 (M+Η+).
Example 177
IH-Imidazole, 2-ethyl- 1- [ [ 1- [3-fluoro-5(trifluoromethyl)phenyπ - lH-imidazol-4- yl] methyl]-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-fluoro-5-trifluoromethyl-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 243-244 °C (MeOΗ / Et2O), MS: m/e = 338 (M+). Example 178
IH-Imidazole, !-[[!- [3-fluoro-5 (trifluoromethyl)phenyl] - lH-imidazol-4-yll methyl! -2- methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [ l-(3-fluoro-5-trifluoromethyl-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 325 (M+Η+).
Example 179
l-(3-Fluoro-5-trifluoromethyl-phenyl)-4-imidazol-l-ylmethyl-lH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [ l-(3-fluoro-5-trifluoromethyl-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 233-234 °C (MeOΗ / Et2O), MS: m/e = 310 (M+).
Example 180
IH-Imidazole, l-[[l- 3-methoxy-5(trifluoromethyl)phenyl1-lH-imidazol-4-yl1methyn-2- methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-methoxy-5-trifluoromethyl-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 246-247 °C (MeOΗ / Et2O), MS: m/e = 337 (M+Η+).
Example 181
IH-Imidazole, 2-ethyl-l-[[l-[3-methoxy-5(trifluoromethyl)phenyl1-lH-imidazol-4- yl! methyl!-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [ l-(3-fluoro-5-trifluoromethyl-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 245-246 °C (MeOH / Et2O), MS: m/e = 350 (M+).
Example 182
4-Imidazol-l-ylmethyl-l-(3-methoxy-5-trifluoromethyl-phenyl)-lH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-fluoro-5-trifluoromethyl-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 244-246 °C (MeOΗ / Et2O), MS: m/e = 322 (M+).
Example 183
IH-Imidazole, 1- [ l-(3-tgrt-butylphenyl)-lH-imidazol-4-yl1 methyl! -2-methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-terτ-butyl-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 295 (M+Η+).
Example 184
IH-Imidazole, l-[[l-(3-ter -butylphenyl)-lH-imidazol-4-yllmethyn -2-ethyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a light brown crystalline material by reaction of [l-(3-tert-butyl-phenyl)-lΗ-imidazol-4- yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 205 °C dec. (MeOH / Et2O), MS: m/e = 309 (M+H+).
Example 185 l-(3-tgrt-Butyl-phenyl)-4-imidazol-l-ylmefhyl-lH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-terr-butyl~phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOH / Et2O), MS: m/e = 281 (M+H+).
Example 186
IH-Imidazole, 1 - [ [ 1- r3-chloro-4(trifluoromethoχy)phenyl] - lH-imidazol-4-yl] methyl! -2- methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-chloro-4-trifluoromethoxy-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 221-222 °C (MeOΗ / Et20), MS: m/e = 357 (M+Η+).
Example 187
IH-Imidazole, !-[[!- [3-chloro-4(trifluoromethoxy)phenyl! -lH-imidazol-4-yll methyl! -2- ethyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [ 1 - (3-chloro-4-trifluoromethoxy-phenyl) - 1H- imidazol-4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 370 (M+).
Example 188
1 - ( 3-Chloro-4-trifluoromethoxy-phenyl) -4-imidazol- 1-ylmethyl- lΗ-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-chloro-4-trifluoromethoxy-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 212-213 °C (MeOΗ / Et2O), MS: m/e = 342 (M+).
Example 189 lΗ-Imidazole, l-[[l-[3-(difluoromethoxy)phenyl1-lH-imidazol-4-yl1methvn -2-ethyl-, hydrochloride (1:2) Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-difluoromethoxy-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 216-217 °C (MeOH / Et2O), MS: m/e = 319 (M+H+).
Example 190 IH-Imidazole, 1- [ [ 1- [3-(difluoromethoxy)phenyl1 -lH-imidazol-4-yll methyl! -2-methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-difluoromethoxy-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 220-222 °C (MeOΗ / Et2O), MS: m/e = 305 (M+Η+).
Example 191 l-(3-Difluoromethoxy-phenyl)-4-imidazol-l-ylmethyl- IH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [ l-(3-difluoromethoxy-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 205-206 °C (MeOΗ / Et2O), MS: m/e = 291 (M+Η+).
Example 192 IH-Imidazole, l-[[l-(3-bromophenyl)-lH-imidazol-4-yl]methyl]-2-methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a light brown crystalline material by reaction of [l-(3-bromo-phenyl)-lH-imidazol-4-yl]- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 205-207 °C (MeOΗ / Et2O), MS: m/e = 317 (M+Η+).
Example 193
IH-Imidazole, !-[[!- [3-(difluoromethyl)phenyl1 -lH-imidazol-4-vH methyl! -2-ethyl-, hydrochloride (1:2) Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-difluoromethyl-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 219-220 °C (MeOH / Et2O), MS: m/e = 303 (M+H+).
Example 194
IH-Imidazole, l-[[l-[3-(difluoromethyl)phenyl]-lH-imidazol-4-yl]methyl1 -2-methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [ l-(3-difluoromethyl-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 195-196 °C (MeOΗ / Et2O), MS: m/e = 289 (M+Η+).
Example 195
1 - ( 3-Difluoromethyl-phenyl) -4-imidazol- 1 -ylmethyl- IH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [ l-(3-difluoromethyl-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 216-217 °C (MeOΗ / Et20), MS: m/e = 275 (M+Η+).
Example 196 jl-[l-(3,4-Dichloro-phenyl)-lH-imidazol-4-ylmethyl]-lH-imidazol-2-yU-methyl-amine hydrochloride (1:1)
A suspension of l-[l-(3,4-dichloro-phenyl)-lH-imidazol-4-ylmethyl]-lH-imidazol-2- ylamine (0.7 g, 2.3 mmol) in triethyl orthoformate (10 ml) was stirred under reflux for 2 h. The reaction mixture was evaporated to dryness, dissolved in ethanol (10 ml) and cooled in an ice bath. Sodium borohydride (0.091 g, 2.4 mmol) was added and the mixture was allowed to slowly reach 20 °C. After 18 h AcOEt and brine was added and the organic phase was separated, dried (Na2SO4) and concentrated. After chromatography [silica, elution with gradient CΗ2C12 to 100 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] the free base of the title compound was obtained. It was crystallized as the off-white hydrochloride salt (0.25 g, 16 %). Mp. >250 °C (MeOH / Et2O), MS: m/e = 322 (M+H+).
Example 197
[3-(3,4-Dichloro-phenyl)-5-(2-methylamino-imidazol-l-ylmethyl)-3H-imidazol-4-yl1- methanol hydrochloride (1:1) A solution of {l-[ l-(3,4-dichloro-phenyl)-lH-imidazol-4-ylmethyl]-lH-imidazol-2-yl}- methyl-amine (0.60 g, 1.7 mmol) in acetic acid (7 ml) and aqueous formaldehyde (2 ml of a 37 % solution) was stirred at 20 °C for 96 h. The reaction mixture was evaporated to dryness and chromatographed [silica, elution with gradient CΗ2C1 to 50 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] to obtain the free base of the title compound. It was crystallized as the off-white hydrochloride salt (0.030g, 5 %). Mp. >180 °C dec. (MeOH / Et2O), MS: m/e = 352 (M+H+).
Example 198
IH-Imidazole, 1- [ [ l-(3-bromo-5-fluorophenyl)-lH-imidazol-4-vn methyl] -2-methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-bromo-5-fluoro-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 335 (M+Η+).
Example 199
IH-Imidazole, l- [l-(3-bromo-5-fluorophenyl)-lH-imidazol-4-yl]methyl]-2-ethyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [ 1- (3-bromo-5-fluoro-phenyl)- 1H- imidazol-4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 349 (M+Η+).
Example 200 l-(3-Bromo-5-fluoro-phenyl)-4-imidazol-l-ylmethyl-lH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [l-(3-bromo-5-fluoro-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >200 °C dec. (MeOΗ / Et2O), MS: m/e = 321 (M+Η+).
Example 201
IH-Imidazole, l-[ l-(2,2-difluoro-l,3-benzodioxol-5-yl)-lH-imidazol-4-yl1methyn-2- ethyl-, hydrochloride (1:2) Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(2,2-difluoro-benzo[l,3]dioxol-5-yl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 237-239 °C dec. (MeOH / Et2O), MS: m/e = 333 (M+H+).
Example 202
IH-Imidazole, l-f [l-(2,2-difluoro-l,3-benzodioxol-5-yl)-lH-imidazol-4-ynmethyl]-2- methyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(2,2-difluoro-benzo[l,3]dioxol-5-yl)-lΗ- imidazol-4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >250 °C (MeOH / Et2O), MS: m/e = 319 (M+H+).
Example 203 1 - (2,2-Difluoro-benzo [ 1 ,3] dioxol-5-yl) -4-imidazol- 1 -ylmethyl- IH-imidazole hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(2,2-difluoro-benzo[l,3]dioxol-5-yl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 245-246 °C (MeOΗ / Et2O), MS: m/e = 319 (M+Η+).
Example 204
2- f 4-(2-Methyl-imidazol-l-ylmethyl)-imidazol-l-yl] -quinoline
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-quinolin-2-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. 160 °C (AcOEt / hexane), MS: m/e = 290 (M+Η+).
Example 205
2- [4- (2-Ethyl-imidazol-l -ylmethyl) -imidazol-l-yl] -quinoline
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-quinolin-2-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. >80 °C dec. (AcOEt / hexane), MS: m/e = 304 (M+H+).
Example 206
2-(4-Imidazol-l-ylmethyl-imidazol-l-yl)-quinoline
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-quinolin-2-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. >150 °C dec. (AcOEt / hexane) , MS: m/e = 276 (M+Η+) .
Example 207
IH-Imidazole, l-[[l-[3-chloro-4-(trifluoromethylthio)phenyl!-lH-imidazol-4-yl1methyn- 2-ethyl-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [ l-(3-chloro-4-trifluoromethylsulfanyl-phenyl)- lH-imidazol-4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 214-215 °C (MeOΗ / Et2O), MS: m/e = 387 (M+Η+).
Example 208 IH-Imidazole, l-[[l-[3-chloro-4-(trifluoromethylthio)phenyl!-lH-imidazol-4-ynmethyll- 2-methyI-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-chloro-4-trifluoromethylsulfanyl-phenyl)- lH-imidazol-4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 195-198 °C (MeOΗ / Et2O), MS: m/e = 373 (M+Η+).
Example 209 l-(3-Chloro-4-trifluoromethylsulfanyl-phenyl)-4-imidazol-l-ylmethyl- IH-imidazole hydrochloride (1:2) Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(3-chloro-4-trifluoromethylsulfanyl-phenyl)- lH-imidazol-4-yl] -methanol first with thionylchloride and then with imidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 244-245 °C (MeOH / Et2O), MS: m/e = 359 (M+H+).
Example 210
3-[4-(2-Ethyl-imidazol-l-ylmethyl)-imidazol-l-yl]-quinoline
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-quinolin-3-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. 132-136 °C (AcOEt / hexane), MS: m/e = 304 (M+Η+).
Example 211
3- [4-(2-Methyl-imidazol-l-ylmethyl)-imidazol-l-yl] -quinoline
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-quinolin-3-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. 168-172 °C (AcOEt / hexane), MS: m/e = 290 (M+Η+).
Example 212
5-Chloro-2-[4-(2-methyl-imidazol-l-ylmethyl)-imidazol-l-yl] -pyridine
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [ l-(5-chloro-pyridin-2-yl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. 192-196 °C (AcOEt / hexane), MS: m/e = 274 (M+H+).
Example 213
5-Chloro-2- [4- (2-ethyl-imidazol- 1 -ylmethyl) -imidazol- 1 -yl] -pyridine
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of [ l-(5-chloro-pyridin-2-yl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. 182-185 °C (AcOEt / hexane), MS: m/e = 288 (M+H+).
Example 214
3- [4-(2-Methyl-imidazol-l-ylmethyl)-imidazol-l-yl] -isoquinoline hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-isoquinolin-3-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. >250 °C (MeOΗ / Et2O), MS: m/e = 290 (M+Η+).
Example 215
IH-Imidazole, 2-ethyl-l-[[l-[4-(trifluoromethoxy)phenyl]-lH-imidazol-4-yl1methyn-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(4-trifluoromethoxy-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 216-218 °C (MeOΗ / Et2O), MS: m/e = 337 (M+Η+).
Example 216
IH-Imidazole, 2-methyl-l- [ 1- [4-(trifluoromethoxy)phenyl] - lH-imidazol-4-yl] methyl] -, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(4-trifluoromethoxy-phenyl)-lH-imidazol-4- yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 231-233 °C (MeOΗ / Et2O), MS: m/e = 323 (M+Η+).
Example 217
IH-Imidazole, 1- [ [ l-( l-biphenyl-3-yl)-lH-imidazol-4-yl1 methyl] -2-methyl-, hydrochloride (1:2)
A suspension of IH-Imidazole, l-[[l-(3-iodophenyl)-lH-imidazol-4-yl]mefhyl]-2-methyl- (0.20 g, 0.55 mmol) in toluene (10 ml) was treated (under an Ar-atmosphere) with tetrakis(triphenylphosphine)palladium (0.023 g, 0.02 mmol). After 30 min, phenylboronic acid (0.080 g, 0.66 mmol) and 2M aqueous K2CO3 solution (2.0 ml) was added. The reaction mixture was refluxed for 2 h and then extracted with AcOEt and H2O. The organic phase was dried (Na2SO ), concentrated and chromatographed [silica, elution with gradient CH2C12 to 30 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)]. The free base of the title compound was obtained as a colorless oil (0.13 g, 75 %). It was crystallized as the white hydrochloride salt. Mp. 241-243 °C (MeOH / Et2O), MS: m/e = 315 (M+H+).
Example 218
IH-Imidazole, 2-ethyl- !-[[!- r4-(trifluoromethylthio)phenyl] - lH-imidazol-4-yll methyl] -, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a light yellow crystalline material by reaction of [l-(4-trifluoromethylsulfanyl-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 183-185 °C (MeOΗ / Et2O), MS: m/e = 352(M+).
Example 219
IH-Imidazole, 2-mefhyl-l-[ [l- 4-(trifluoromethylthio)phenyl]-lH-imidazol-4- yllmethyl!-, hydrochloride (1:2)
Following the general method described in example 10, the title compound was obtained as a white crystalline material by reaction of [l-(4-trifluoromethylsulfanyl-phenyl)-lH- imidazol-4-yl] -methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the hydrochloride salt. Mp. 249-250 °C (MeOΗ / Et2O), MS: m/e = 339(M+Η+).
Example 220
6- [4- (2-Methyl-imidazol-l -ylmethyl) -imidazol-l-yl] -quinoline
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-quinolin-6-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. >125 °C dec. (AcOEt / hexane), MS: m/e = 290 (M+Η+).
Example 221
6- [4-(2-Ethyl-imidazol-l-ylmethyl)-imidazol-l-yl] -quinoline Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-quinolin-6-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. >79 °C dec. (AcOEt / hexane), MS: m/e = 304 (M+Η+).
Example 222
8 - [ 4- ( 2-Methyl-imidazol- 1 -ylmethyl ) -imidazol- 1 -yl! - quinoline
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-quinolin-8-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with 2-methylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. 150-154 °C (AcOEt / hexane), MS: m/e = 290 (M+Η+).
Example 223
8- [4-(2-Ethyl-imidazol- 1 -ylmethyP-imidazol- 1 -yl! -quinoline
Following the general method described in example 10, the title compound was obtained as an off-white crystalline material by reaction of (l-quinolin-8-yl-lH-imidazol-4-yl)- methanol first with thionylchloride and then with 2-ethylimidazole and sodium hydride followed by chromatography and crystallization of the free base. Mp. 78-81 °C (AcOEt / hexane), MS: m/e = 304 (M+Η+).
Example 224
1 - ( 1 -Benzo [ 1 ,31 dioxol-5-yl- lH-imidazol-4-ylmethyl) - lH-imidazol-2-ylamine hydrochloride (1:2)
Following the general method described in example 104, IH-imidazole, 1-[[1-(1,3- benzodioxol-5-yl)-lH-imidazol-4-yl] methyl] -2-nitro- was reacted with iron in acetic acid. After filtration, evaporation and chromatography, the free base of the title compound was isolated. It was converted into its light yellow hydrochloride salt. Mp. >245 °C dec. (MeOΗ / Et2O), MS: m/e = 284 (M+Η+).
Example 225
3-(3-Difluoromethyl-4-fluoro-phenyl)-5-(2-methyl-imidazol-l-ylmethyl)-pyridine
The title compound was obtained according to example 129 (DMF instead of dioxane, 4 h, 100 °C) as a light brown solid (73 % yield) by the reaction of 2-(3-difluoromethyl-4- fluoro-phenyl)-4,4,5,5-tetramethyl- [1,3,2] dioxaborolane with 3-bromo-5-(2-methyl- imidazol-l-ylmefhyl)-pyridine. MS: m/e = 318.3 (M+H+).
Example 226
3- [ 3- ( 1 , 1 -Difluoro-ethvD-phenyl] -5- (2-methyl-imidazol- 1 -ylmethyl) -pyridine
The title compound was obtained according to example 129 (DMF instead of dioxane, 4 h, 100 °C) as a light brown oil (70 % yield) by the reaction of 2-[3-(l,l-difluoro-ethyl)- phenyl]-4,4,5,5-tetramethyl-[ 1,3,2] dioxaborolane with 3-bromo-5-(2-methyl-imidazol-l- ylmethyl) -pyridine. MS: m/e = 314.3 (M+H+).
Example 227
3-(3-Fluoro-5-trifluoromethyl-phenyl)-5-(2-methyl-imidazol-l-ylmethyl)-pyridine
The title compound was obtained according to example 129 (DMF instead of dioxane, 4 h, 100 °C) as a light brown solid (67 % yield) by the reaction of 2-(3-fluoro-5- trifluoromethyl-phenyl)-4,4,5,5-tetramethyl- [1,3,2] dioxaborolane with 3-bromo-5-(2- methyl-imidazol-1-ylmethyl) -pyridine. MS: m/e = 336.3 (M+H+).
Example 228
3-[3-(l,l-Difluoro-etbyl)-4-fluoro-phenyl]-5-(2-methyl-imidazol-l-ylmethyl)-pyridine
The title compound was obtained according to example 129 (DMF instead of dioxane, 4 hours, 100°C) as a light brown oil (73% yield) by the reaction of 2-[3-(l,l-difluoro-ethyl)- 4-fluoro-phenyl] -4,4,5,5-tetramethyl- [ 1,3,2] dioxaborolane with 3-bromo-5-(2-methyl- imidazol-1-ylmefhyl) -pyridine. MS: m/e = 332.3 (M+H+).
Example 229
IH-Imidazole, 2-cyclopropyl- 1- [ [ 1- (3,4-dichlorophenyl) - lH-imidazol-4-yl] methyl] -
Following the general method described in example 1, the title compound was obtained by reaction of 4-chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole with 2-cyclopropyl- 1H- imidazole and sodium hydride followed by chromatography to yield the title compound as a yellow oil. MS: m/e = 334 (M+Η+).
Example 230
5- (4-Fluoro-3-mefhyl-phenyl) - 1 -methyl-2-( 2-methyl-imidazol- 1 -ylmethyl) - 1 -H- imidazole hydrochloride (1:1) 5-Bromo-l-methyl-2-(2-methyl-imidazol-l-ylmethyl)-lH-imidazole (0.1 g, 0.392 mmol) was dissolved in toluene (4 ml) and MeOΗ (0.8 ml), treated with aqueous 2N Na2CO3 (0.2 ml), 4-fluoro-3-methylphenylboronic acid (0.078 g, 0.510 mmol) and tetrakis(triphenylphosphine)palladium (0.023 g, 0.020 mmol). The reaction mixture was refluxed under argon for 12 h, then cooled to room temperature and dried with Na2SO4. After filtration and evaporation of the solvent, the residue was chromatographed (silica, elution with CΗ2C12 / MeOH = 95:5). The product was dissolved in MeOH, cooled to 0 °C and treated with HCl / ether. Evaporation of the solvent and drying under high vacum afforded the title compound (0.11 g, 88 %) as a light yellow solid. MS: m/e = 285.2 (M+H+).
Example 231 5- (4-Fluoro-3-trifluoromethyl-phenyl) - 1 -methyl-2- (2-methyl-imidazol- 1 -ylmethyl) - 1 -H- imidazole-hydrochloride (1:1)
5-Bromo-l-methyl-2-(2-methyl-imidazol-l-ylmethyl)-lH-imidazole (0.1 g, 0.392 mmol) was dissolved in DMF (1.5 ml), treated with K2CO3 (0.1 g, 0.784 mmol), 2-(4-fluoro-3- trifluoromethyl-phenyl)-4,4,5,5-tetramethyl-[ 1,3,2] -dioxaborolane (0.148 g, 0.510 mmol) and tetrakis(triphenylphosphine)palladium (0.047 g, 0.040 mmol). The reaction mixture was heated at 100 °C under argon for 12 h, then cooled to room temperature and dried with Na2SO . After filtration and evaporation of the solvent, the residue was chromatographed (silica, elution with CΗ2C12 / MeOH = 95 : 5). The product was dissolved in MeOH, cooled to 0 °C and treated with HCl / ether. Evaporation of the solvent and drying under high vacum afforded the tide compound (0.089 g, 88 %) as a light brown solid. MS: m/e = 339.2 (M+H+).
Example 232 5-(4-Chloro-3-methyl-phenyl)-l-methyl-2-(2-methyl-imidazol-l-ylmethyl)-l-H- imidazole-hydrochloride hydrochloride (1:1)
Following the general method described in example 231, the title compound was obtained from 5-bromo-l-methyl-2-(2-methyl-imidazol-l-ylmethyl)-lH-imidazole and 2-(4- chloro-3-methyl-phenyl)-4,4,5,5-tetramethyl-[ 1,3,2] -dioxaborolane. MS: m/e = 300.1 (M+).
Example 233 2-[5-(2-Methyl-imidazol-l-ylmethyl)-pyridin-3-yl]-l,2,3,4-tetrahvdro-isoquinoline hydrochloride (1:2) This compound was prepared according to a procedure described in the following reference:
S. Wagaw; S. L. Buchwald; J. Org. Chem. 1996, 61, 7240-7241
3-Bromo-5-(2-methyl-imidazol-l-ylmethyl)-pyridine (0.1 g, 0.397 mmol) was dissolved in toluene (1 ml) and treated successively with 1,2,3,4-tetrahydroisoquinoline (61 μl, 0.476 mmol), sodium tert.-butoxide (53 mg, 0.556 mmol), Pd2(dba)3 chloroform complex (8.2 mg, 0.0079 mmol) and R(+)-BINAP (10 mg, 0.0159 mmol). The reaction mixture was heated at 70 °C under argon for 6 h, cooled to room temperature and quenched with water. The aqueous layer was extracted 3 times with ethyl acetate. The combined extracts were dried over Na2SO4, filtered and the solvent was removed in vacuo. The residue was chromatographed (silica, elution with CH2C12 / MeOH = 95 : 05) The product was dissolved in MeOH, cooled to 0 °C and treated with HCl / ether. Evaporation of the solvent and drying under high vacum afforded the title compound (0.09 g, 60%) as a yellow foam. MS: m/e = 305.3 (M+H+).
Processes for preparation of intermediates
Example 234
1 - (3,4-Dichloro-phenyl)- lH-imidazole-4-carboxylic acid
A mixture of 3,4-dichloroaniline (24.3 g, 150 mmol), triethyl orthoformate (24.0 g, 162 mmol), ethyl nitroacetate (20.0 g, 150 mmol) and acetic acid (1ml) was refluxed for 1 h. After addition of additional triethyl orthoformate (300 ml, 1.8 mol), iron powder (25.1 g, 450 mmol) and acetic acid (300ml, 5.2 mol) the mixture was refluxed for 5h. During this time, additional iron powder (25.1 g, 450 mmol) was added in 3 portions. The mixture was cooled to 60 °C and AcOEt ( 11) was added. After refluxing for 10 min, the precipitate was filtered and the filtrate was concentrated. Residual acetic acid was azeotropically removed by co-evaporation with toluene (500 ml). The crystalline residue was dissolved in dioxane (300 ml), 2N NaOΗ solution (300 ml) and charcoal (ca. 10 g) was added. The mixture was refluxed for 2 h, filtered and cooled to 5 °C. ΗC1 solution (37 %) was added until precipitation was complete. Filtration and drying afforded the title compound (25.8 g, 67 %) as light brown crystalline material. Mp. >235 °C dec. (Η2O), MS: m/e = 255 [(M-H) "]
Examples 235 to 262 were prepared according to the general procedure described in example 234.
Example 235
l-(4-Chloro-3-methyl-phenyl)-lH-imidazole-4-carboxylic acid The title compound, MS: m/e= 236 (M+), Mp. 231-236 °C (H2O / dioxane), was obtained as an off-white crystalline material by reaction of 4-chloro-3-methylaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 236
1 -Indan-5-yl- lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 227 [(M-Η) "], Mp. 243-251 °C (Η2O / dioxane), was obtained as an off-white crystalline material by reaction of 5-aminoindan with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 237
1 - ( 3,4-Dimethyl-phenyl) - lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 216 (M+), Mp. >250 °C (Η2O / dioxane), was obtained as an off- white crystalline material by reaction of 3,4-dimethylaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 238
1 -p-Tolyl- lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 202 (M+), Mp. >250 °C (DMF), was obtained as a rose crystalline material by reaction of p-toluidine with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 239
l-(4-Fluoro-3-methyl-phenyl)-lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 219 [(M-Η) "], Mp. 192-198 °C (Η2O / dioxane), was obtained as an off-white crystalline material by reaction of 4-fluoro-3-methylaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. Example 240
l-(4-Methylsulfanyl-phenyl)-lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 233 [(M-Η) "], Mp. 233-245 °C (Η2O / dioxane), was obtained as a red crystalline material by reaction of 4- (methylthio) aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 241
l-(3-Trifluoromethyl-phenyl)-lH-imidazole-4-carboxyric acid
The title compound, MS: m/e = 256 M+, Mp. 233-245 °C (Η20 / DMF), was obtained as a light orange crystalline material by reaction of 3-(trifluoromethyl)aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 242
l-(4-Fluoro-3-trifluoromethyl-phenyl)-lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 274 M+, Mp. 188-193 °C (Η2O / dioxane), was obtained as an off-white crystalline material by reaction of 4-fluoro-3(trifluoromethyl)aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 243
l-(3-Fluoro-4-trifluoromethyl-phenyl)-lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 274 M+, Mp. >250 °C (Η2O / dioxane), was obtained as an off-white crystalline material by reaction of 3-fluoro-4(trifluoromethyl)aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 244
1 - (4-Methyl-3-trifluoromethyl-phenyl) - lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 269 [(M-Η) "], Mp. >233 °C dec. (Η2O / dioxane), was obtained as an off-white crystalline material by reaction of 4-methyl-
3 (trifluoromethyl) aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 245
1 - (4-Chloro-3 -methoxy-phenyl) - lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 252 (M+), Mp. 232-236 °C (Η2O / dioxane), was obtained as a light red crystalline material by reaction of 4-chloro-3-methoxy aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 246
l-(4-Fluoro-3-methoxy-phenyl)-lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 236 (M+), Mp. >182 °C dec. (Η2O / dioxane), was obtained as a light brown crystalline material by reaction of 4-fluoro-3-methoxy aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 247
l-(4-Chloro-phenyl)-lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 222 (M+), Mp. >250 °C (DMF/ Η2O) was obtained as a rose crystalline material by reaction of 4-chloroaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 248
l-Benzo[l,3]dioxol-5-yl-lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 232 (M+), Mp. >250 °C (Η2O/dioxane) was obtained as a grey crystalline material by reaction of 3,4-methylenedioxyaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 249
1 - (3 -Fluoro-4-methyl-phenyl) - lH-imidazole-4-carboxylic acid The title compound, MS: m/e = 220 (M+), Mp. >250 °C (H2O/dioxane) was obtained as an off- white crystalline material by reaction of 3-fluoro-4-methylaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 250
l-(3-Chloro-4-methoxy-phenyl)-lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 252 (M+), Mp. 224-226 °C (Η2O/dioxane) was obtained as a white crystalline material by reaction of 3-chloro-4-methoxyaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 251
l-(4-Chloro-2-fluoro-phenyl)-lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 239 [(M-Η) "], Mp. 234-238 °C (Η2O/dioxane) was obtained as a light yellow crystalline material by reaction of 4-chloro-2-fluoroaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 252
l-(4-Bromo-phenyl)-lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 266 (M+), Mp. >250 °C (Η2O/dioxane) was obtained as a light yellow crystalline material by reaction of 4-bromoaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 253
1 - (4-Difluoromethoxy-phenyl) - lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 253 [(M-Η) "] , Mp. 218-225 °C (Η2O/dioxane) was obtained as a white crystalline material by reaction of 4-difluoromethoxyaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. Example 254
1 - (4-Benzyloxy-phenyl) - lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 293 [(M-Η) "], Mp. 238-243 °C dec. (Η2O/dioxane) was obtained as an off-white crystalline material by reaction of 4-benzyloxyaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 255
1 -(3-Methoxy-4-methyl-phenyl)-lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 232 (M+), Mp. 226-230 °C (Η2O/dioxane) was obtained as a rose crystalline material by reaction of 3-methoxy-4-methylaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 256
l-(4-Trifluoromethyl-phenyl)-lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 256 (M+), Mp. >250 °C (Η2O/dioxane) was obtained as a light yellow crystalline material by reaction of 4-(trifluoromethyl)aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 257
l-(l,3-Dihydro-isobenzofuran-5-yl)-lH-imidazole-4-carboxylic acid
The title compound, MS: m/e = 230 (M+), Mp. 245-247 °C (DMF/Η2O) was obtained as a light brown crystalline material by reaction of l,3-dihydro-5-isobenzofuranamine (prepared according to T.Y. Shen et al., /. Med. Chem., 1978, 21, 965) with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 258
l-(4-Fluoro-3-methoxy-phenyl)-lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 236 (M+), Mp. >182 °C dec. (Η2O/dioxane) was obtained as a light brown crystalline material by reaction of 4-fluoro-3-methoxyaniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 259
1 -Phenyl- lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 188 (M+), Mp. 220-221 °C (DMF/Η2O) was obtained as a white crystalline material by reaction of aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 260
1 - (4-Methoxy-phenyl) - lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 218 (M+), Mp. >240 °C dec.(Η2O/dioxane) was obtained as a light brown crystalline material by reaction of p-anisidine with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 261
1 - ( 3-Methoxy-phenyl) - lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 218 (M+), Mp. 196-201 °C (Η2O/dioxane) was obtained as a light red crystalline material by reaction of m-anisidine with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 262
l-(4-Methoxy-3-trifluoromethyl-phenyl)-lH-imidazole-4-carboxylic acid
The tide compound, MS: m/e = 286 (M+), Mp. >141 °C dec. (Η2O/dioxane) was obtained as a light brown crystalline material by reaction of 4-methoxy-3-(trifluoromethyl)aniline with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis.
Example 263 l-(3,4-Dichloro-phenyl)-5-methyl-lH-imidazole-4-carboxylic acid ethyl ester and 3-(3,4-Dichloro-phenyl)-5-methyl-3H-imidazole-4-carboxylic acid ethyl ester A suspension of 3,4-dichlorophenylboronic acid (8.22 g , 43.1 mmol), ethyl 4-methyl-5- imidazolecarboxylate (6.64 g, 43.1 mmol) and copper(II) acetate (7.83 g, 43.1 mmol) in CH2C1 (86 ml) was stirred at 20 °C for 48 h. All solids were filtered, the organic phase diluted with AcOEt (500 ml) and stirred with saturated aqueous Seignette salt solution. After filtration and evaporation the residue was chromatographed (silica, eluation with gradient hexane to AcOEt) to obtain 2.8 g (22 %) of 3-(3,4-dichloro-phenyl)-5-methyl- 3H-imidazole-4-carboxylic acid ethyl ester [Mp. 135-136 °C (AcOEt / hexane), MS: m/e = 298 (M+)] and 1.0 g (8 %) of l-(3,4-dichloro-phenyl)-5-methyl-lH-imidazole-4- carboxylic acid ethyl ester [Mp. 163-164 °C (AcOEt / hexane), MS: m/e = 298 (M+)].
Example 264
[ l-(3,4-Dichloro-phenyl)-lH-imidazol-4-yll -methanol
l-(3,4-Dichloro-phenyl)-lH-imidazole-4-carboxylic acid (20.0 g, 77.8 mmol) was treated with IM BΗ3 THF complex (100 ml) and refluxed for 2 h. The mixture was cooled to 5°C and MeOH (20 ml) was added slowly. After evaporation of all volatiles the residue was taken up in 2N HCl solution ( 100 ml) and refluxed for 2 h. After filtration the hot aqueous phase was slowly treated with 2N NaOH solution until pH 10. On cooling the tide compound crystallizes as a white material (12.2 g, 65 %). Mp. 146-147 °C (H2O), MS: m/e = 242 (M+).
Examples 265 to 292 were prepared according to the general procedure described in example 264.
Example 265
[ l-(4-Chloro-3-methyl-phenyl)-lH-imidazol-4-yl] -methanol
The tide compound, MS: m/e = 222 (M+), Mp. 126-133 °C (Η2O) was obtained as a light brown crystalline material by reaction of l-(4-chloro-3-methyl-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 266
(l-Indan-5-yl-lH-imidazol-4-yl)-methanol
The title compound, MS: m/e = 214 (M+), Mp. 128-133 °C (Η2O) was obtained as a light brown crystalline material by reaction of l-indan-5-yl-lH-imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup. Example 267
[l-(3,4-Dimethyl-phenyl)-lH-imidazol-4-yl]-methanol
The title compound, MS: m/e = 202 (M+), Mp. 110-116 °C (Η2O) was obtained as an off- white crystalline material by reaction of l-(3,4-dimethyl-phenyl)-lH-imidazole-4- carboxylic acid with BH3 THF complex followed by hydrolytic workup.
Example 268
( 1 -p-Tolyl- lH-imidazol-4-yl) -methanol
The title compound, MS: m/e = 188 (M+), Mp. 101-102°C (Η2O) was obtained as an off- white crystalline material by reaction of l-p-tolyl-lH-imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 269
[ l-(4-Fluoro-3-methyl-phenyl)-lH-imidazol-4-yl] -methanol
The title compound, MS: m/e = 206 (M+), Mp. 138-144 °C (Η2O) was obtained as an off- white crystalline material by reaction of l-(4-fluoro-3-methyl-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 270
[l-(4-Methylsulfanyl-phenyl)-lH-imidazol-4-yl]-methanol
The tide compound, MS: m/e = 220 (M+), Mp. 108-114 °C (H2O) was obtained as a light brown crystalline material by reaction of l-(4-methylsulfanyl-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 271
[l-(3-Trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol
The tide compound, MS: m/e = 242 (M+), Mp. 96-100 °C (Η2O) was obtained as a white crystalline material by reaction of l-(3-trifluoromethyl-phenyl)-lH-imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 272
[ 1 - (4-Fluoro-3-trifluoromethyl-phenyl) - lH-imidazol-4-yll -methanol The tide compound, MS: m/e = 260 (M+), Mp. 142-146 °C (H2O) was obtained as a white crystalline material by reaction of l-(4-fluoro-3-trifluoromethyl-phenyl)-lH-imidazole-4- carboxylic acid with BH3 THF complex followed by hydrolytic workup.
Example 273
[l-(3-Fluoro-4-trifluoromethyl-phenyl)-lH-imidazol-4-yl1 -methanol
The tide compound, MS: m/e = 260 (M+), Mp. 142-144 °C (Η2O) was obtained as a white crystalline material by reaction of l-(3-fluoro-4-trmuoromethyl-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 274
[l-(4-Methyl-3-trifluoromethyI-phenyl)-lH-imidazol-4-yl! -methanol
The tide compound, MS: m/e = 257 (M+Η+), Mp. 116-119 °C (H20) was obtained as a white crystalline material by reaction of l-(4-methyl-3-trifluoromethyl-phenyl)-lH- imidazole-4-carboxylic acid with BH3 THF complex followed by hydrolytic workup.
Example 275
[l-(4-Chloro-3-methoxy-phenyl)-lH-imidazol-4-yl1 -methanol
The tide compound, MS: m/e = 238 (M+), Mp. 116-119 °C (Η2O) was obtained as a white crystalline material by reaction of l-(4-chloro-3-methoxy-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 276
[l-(4-Fluoro-3-methoxy-phenyl)-lH-imidazol-4-yl! -methanol
The title compound, MS: m/e = 222 (M+), Mp. 174-177 °C (Η2O) was obtained as an off- white crystalline material by reaction of l-(4-fluoro-3-methoxy-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 277
[ 1 - (4-Chloro-phenyl) - lH-imidazol-4-yl] -methanol
The tide compound, MS: m/e = 208 (M+), Mp. 115-116 °C (AcOEt) was obtained as a white crystalline material by reaction of l-(4-chloro-phenyl)-lH-imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup. Example 278
(l-Benzofl,3]dioxol-5-yl-lH-imidazol-4-yl)-methanol
The tide compound, MS: m/e = 218 (M+), Mp. 150-157 °C (Η2O) was obtained as a white crystalline material by reaction of l-benzo[l,3]dioxol-5-yl-lH-imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 279
1 - ( 3-Fluoro-4-methyl-phenyl ) - lH-imidazol-4-yl ] -methanol
The tide compound, MS: m/e = 206 (M+), Mp. 115-122 °C (Η2O) was obtained as a light yellow crystalline material by reaction of l-(3-fluoro-4-methyl-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 280
[l-(3-Chloro-4-methoxy-phenyl)-lH-imidazol-4-yl1 -methanol
The tide compound, MS: m/e = 238 (M+), Mp. 133-138 °C (Η2O) was obtained as an off- white crystalline material by reaction of l-(3-chloro-4-methoxy-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 281
[ l-(4-Chloro-2-fluoro-phenyl)-lH-imidazol-4-yl] -methanol
The title compound, MS: m/e = 226 (M+), Mp. 120-130 °C (Η2O) was obtained as an off- white crystalline material by reaction of l-(4-chloro-2-fluoro-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 282
[l-(4-Bromo-phenyl)-lH-imidazol-4-yl]-mefhanol
The title compound, MS: m/e = 252 (M+), Mp. 132-139 °C (Η2O) was obtained as a light yellow crystalline material by reaction of l-(4-bromo-phenyl)-lH-imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 283
[ [ 1 - (4-Difluoromethoxy-phenyl) - lH-imidazol-4-yll -methanol The tide compound, MS: m/e = 240 (M+), Mp. 66-72 °C (H2O) was obtained as a light brown crystalline material by reaction of l-(4-difluoromethoxy-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 284
[ l-(4-Benzyloxy-phenyl)-lH-imidazol-4-yl1 -methanol
The tide compound, MS: m/e = 280 (M+), Mp. 151-152 °C (AcOEt) was obtained as a white crystalline material by reaction of l-(4-benzyloxy-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 285
[ l-(3-Methoxy-4-methyl-phenyl)-lH-imidazol-4-yl] -methanol
The title compound, MS: m/e = 218 (M+), Mp. 141-147°C (Η2O) was obtained as a white crystalline material by reaction of l-(3-methoxy-4-methyl-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 286
[l-(4-Trifluoromethyl-phenyl)-lH-imidazol-4-yl]-methanol
The tide compound, MS: m/e = 242 (M+), Mp. 153-156 °C (Η2O) was obtained as an off- white crystalline material by reaction of l-(4-trifluoromethyl-phenyl)-lH-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 287
[ l-( l,3-Dihydro-isobenzofuran-5-yl)-lH-imidazol-4-yl] -methanol
The title compound, MS: m/e = 216 (M+), Mp. 161-165 °C (AcOEt) was obtained as an off-white crystalline material by reaction of l-(l,3-dihydro-isobenzofuran-5-yl)-lH- imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 288
[ l-(3-Fluoro-4-methoxy-phenyl)-lH-imidazol-4-yl1 -methanol
The tide compound, MS: m/e = 222 (M+), Mp. 112-120 °C (CΗ2C12 / iPr2O) was obtained as a white crystalline material by reaction of l-(4-fluoro-3-methoxy-phenyl)-lH- imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup. Example 289
[ ( 1 -Phenyl- lH-imidazol-4-yl)-methanol
The tide compound, MS: m/e = 174(M+), Mp. 116-118 °C (Η2O) was obtained as a white crystalline material by reaction of 1 -phenyl- lH-imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 290
[ 1 - (4-Methoxy-phenyl) - lH-imidazol-4-yl] -methanol
The tide compound, MS: m/e = 204(M+), Mp. 107-109 °C (AcOEt) was obtained as a white crystalline material by reaction of l-(4-methoxy-phenyl)-lH-imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 291
[ l-(3-Methoxy-phenyl)-lH-imidazol-4-yl] -methanol
The title compound, MS: m/e = 204(M+), Mp. 80-85 °C (AcOEt / hexane) was obtained as a white crystalline material by reaction of l-(3-methoxy-phenyl)-lΗ-imidazole-4- carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 292
[ 1 - ( 4-Methoxy- 3 -trifluor omethyl-phenyl ) - lH-imidazol-4-yl] -methanol
The tide compound, MS: m/e = 272 (M+), Mp. 147-150 °C (Η2O) was obtained as an off- white crystalline material by reaction of l-(4-methoxy-3-trifluoromethyl-phenyl)-lH- imidazole-4-carboxylic acid with BΗ3 THF complex followed by hydrolytic workup.
Example 293
[ l-(3-Chloro-4-methyl-phenyl)-lH-imidazol-4-yl] -methanol
According to example 234 3-chloro-4-methylaniline (21.5 g, 150 mmol) was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid (10.0 g) was directiy reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the tide compound was obtained as a white crystalline solid (5.2 g, 16 %). Mp. 126-133 °C (AcOEt/hexane), MS: m/e = 222 (M+) Examples 294 to 297 were prepared according to the general procedure described in example 293.
Example 294
[l-(4-Chloro-3-trifluoromethyl-phenyl)-lH-imidazol-4-yl1 -methanol
3-Trifluoromethyl-4-chloroaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directiy reduced with BΗ3 THF complex followed by hydrolytic workup and the title compound, Mp. 148-153 °C (AcOEt / iPr2O), MS: m/e = 276 (M+), was obtained as a white crystalline solid.
Example 295
[l-(3-Chloro-4-fluoro-phenyl)-lH-imidazol-4-yl] -methanol
3-Chloro-4-fluoroaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directiy reduced with BΗ3 THF complex followed by hydrolytic workup and the title compound, Mp. 130-135 °C (H2O), MS: m/e = 226 (M+), was obtained as an off-white crystalline solid.
Example 296
( 1 -Biphenyl-4-yl- lH-imidazol-4-yl)-methanol
4-Phenylaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directiy reduced with BΗ3 THF complex followed by hydrolytic workup and the title compound, Mp. 173-177 °C (CH2C12 / iPr2O), MS: m/e = 250 (M+), was obtained as a yellow crystalline solid.
Example 297
[l-(4-lsopropyl-3-methyl-phenyl)-lH-imidazol-4-yl1 -methanol
4-Isopropyl-3-methylaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directly reduced with BΗ3 THF complex followed by hydrolytic workup and the tide compound, Mp. 98-102 °C (CH2C12 / iPr2O), MS: m/e = 230 (M+), was obtained as a yellow crystalline solid. Example 298
[ 1 -(3,4-Dichloro-phenyl)-5-methyl-lH-imidazol-4-yl! -methanol
To a solution of l-(3,4-dichloro-phenyl)-5-methyl-lH-imidazole-4-carboxylic acid ethyl ester (0.82 g, 2.7 mmol) in TΗF (27 ml) lithium aluminum hydride (0.21 g, 5.4 mmol) was added portionwise keeping T < 10 °C. The mixture was stirred in an ice-bath for 2 h, then 1 ml saturated aqueous Seignette salt solution was slowly added. After dilution with AcOEt (100 ml) the mixture was filtered, concentrated and chromatographed [silica, elution with gradient CΗ2C12 to 80 % (CH2C12 / MeOH = 9:1)]. The title compound was obtained as a white crystalline solid (0.46 g, 66 %). Mp. 174-175 °C (CH2C12 / iPr2O), MS: m/e = 256 (M+)
Example 299
4-Chloromethyl- l-(3,4-dichloro-phenyl)- IH-imidazole
In an ice-bath thionyl chloride (39.5 ml, excess) was slowly added to [l-(3,4-dichloro- phenyl)-lH-imidazol-4-yl! -methanol (9.6 g, 39.5 mmol). The resulting mixture was stirred for 24 h. After evaporation, the oily residue was triturated with ether and 10.12 g (86 %) of the hydrochloride salt of the tide compound was obtained as an off- white solid. To obtain the free base, the salt was carefully neutralized with aqueous NaOΗ (2N) and extracted with AcOEt. The organic phase was dried (Na2SO4) and concentrated to obtain 8.43 g (95 %) of the title compound as an off-white solid. Mp. 146-147 °C dec. (AcOEt / hexane), MS: m/e = 260 (M+)
Example 300
lΗ-Imidazole, l-[[l-(3,4-dichlorophenyl)-lH-imidazol-4-yl1methyn-2-nitro-
4-Chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole (2.0 g, 7.5 mmol) was dissolved in DMF (25 ml), 2-nitroimidazole (1.0 g, 8.8 mmol) and cesium carbonate (1.43 g, 4.4 mmol) was added and the resulting mixture was stirred at 70 °C for 3 h. After evaporation of the solvent, the residue was dissolved in AcOEt and washed with Η2O. The organic phase was dried (Na2S04), concentrated and chromatographed [silica, elution with gradient CH2CI2 to 50 % (CH2C12 / MeOH = 9:1)] to obtain 2.48g (98 %) of the tide compound as an off- white solid. Mp. 130-131 °C (CH2C12 / iPr2O), MS: m/e = 291 [(M-NO2)+].
Example 301
IH-Imidazole, l-[[l-(4-chloro-3-methylphenyl)-lH-imidazol-4-ynmethyl!-2-nitro- According to example 299 [l-(4-chloro-3-methyl-phenyl)-lH-imidazol-4-yl] -methanol was reacted with thionylchloride and the obtained 4-chloromethyl-l-(4-chloro-3-methyl- phenyl)-lΗ-imidazole directiy reacted further as its hydrochloric salt. Thus, as described for example 300, reaction of 4-chloromethyl-l-(4-chloro-3-methyl-phenyl)-lH-imidazole ΗC1 salt with 2-nitroimidazole (1.2 eq.) and cesium carbonate (1.2 eq.) led, after evaporation and extractive workup, to the crude product, which was purified by chromatography. Mp. 147-148 °C (CΗ2C12 / hexane), MS: m/e = 271 [(M-NO2)+].
Examples 302 and 303 were prepared according to the general procedure described in example 301. Example 302
IH-Imidazole, 1- [ [ l-(4-methylphenyl)- lH-imidazol-4-yl] methyl] -2-nitro-
(l-p-Tolyl-lH-imidazol-4-yl)-methanol was treated first with thionylchloride, then with 2- nitroimidazole and cesium carbonate. After evaporation, extractive workup and chromatography the tide compound was obtained as a white solid. Mp. 147-148 °C (CΗ2C12 / iPr2O), MS: m/e = 237 [(M-NO2)+].
Example 303
IH-Imidazole, 2-nitro-l-[(l-phenyl-lH-imidazol-4-yl)methyl1-
[(l-Phenyl-lH-imidazol-4-yl)-methanol was treated first with thionylchloride, then with 2-nitroimidazole and cesium carbonate. After evaporation, extractive workup and chromatography the tide compound was obtained as a white solid. Mp. 126-127 °C (CΗ2C12 / iPr2O), MS: m/e = 223 [(M-NO2)+].
Example 304
l-(3,4-Dichloro-phenyl)-lH-imidazole-4-carboxylic acid amide
Carbonyldiimidazole (0.49 g, 3 mmol) was added to a stirred suspension of l-(3,4- dichloro-phenyl)-lH-imidazole-4-carboxylic acid (0.64 g, 2.5 mmol) in DMF (10 ml). After lh at 60 °C, the reaction mixture was cooled to rt, aqueous ammonia (25 %, 20ml) was added and stirring was continued for 12 h. Then Η2O (100 ml) was added and the precipitated product was filtered. RecrystaUisation from EtOH afforded the tide compound as off-white crystals. Mp. 244-245 °C (EtOH), MS: m/e = 255 (M+).
Example 305
l-(3,4-Dichlorophenyl)-lH-imidazole-4-methanamine fumarate (1:1) l-(3,4-Dichloro-phenyl)-lH-imidazole-4-carboxylic cid amide (4.32 g, 16.9 mmol) was treated withlM BΗ3 THF complex (100 ml) and refluxed for 6 h. The mixture was cooled to 5°C and MeOH (50 ml) was added slowly. After evaporation of all volatiles, the residue was taken up in 6N HCl solution (30 ml) and refluxed for 15 min. The reaction mixture was filtered, slowly treated with 6N NaOH (30 ml) and extracted with AcOEt (3 x 200 ml). The organic phase was dried (Na2SO4), concentrated and the crude product obtained was chromatographed [silica, elution with (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] to obtain the free base of the tide compound as a light brown semi-solid mass (2.62 g, 64 %). After treatment with an equimolar amount of fumaric acid, the title compound was isolated as a white crystalline material. Mp. 176-177 °C (MeOH / Et2O), MS: m/e = 241 (M+).
Example 306
N- [ l-(3,4-Dichloro-phenyl)- lH-imidazol-4-yl-methyn -acetamide
To a solution of l-(3,4-dichlorophenyl)-lH-imidazole-4-methanamine (0.20 g, 0.83 mmol) in TΗF (30 ml) was added triethylamine (0.079 g, 0.78 mmol) and acetyl chloride (0.082 mg, 1.0 mmol). The reaction mixture was stirred at rt for 12 h. After evaporation of the solvent, the residue was dissolved in AcOEt and washed with Η2O. The organic phase was dried (Na2SO4), concentrated and the obtained crude product was chromatographed [silica, elution with gradient CH2C12 to 100 % (CH2C12 / MeOH = 9:1)]. The title compound was obtained as an off-white crystalline material (0.17 g, 74 %). Mp. 177-180 °C (MeOH / CH2C12), MS: m/e = 284 (M+H+).
Example 307
N- [ l-(3,4-Dichloro-phenyl)-lH-imidazol-4-yl-methyn -thioacetamide
To a suspension of N-[l-(3,4-dichloro-phenyl)-lH-imidazol-4-ylmethyl]-acetamide (1.1 g, 3.7 mmol) in 1,2 dimethoxyethane (11 ml) was added Lawesson's reagent (0.82 g, 2.0 mmol) and the mixture refluxed for 90 min. After addition of saturated NaΗCO3 solution (50 ml) and extraction with CH2C12 (3 x 100 ml) the combined organic phases were dried (Na2SO4), concentrated and the obtained crude product was chromatographed [silica, elution with gradient CH2C12 to 100 % (CH2C12 / MeOH = 9:1)]. The title compound was obtained as a brown crystalline material (0.75 g, 68 %). Mp. 166-170 °C (MeOH / CH2C12), MS: m/e = 299 (M+).
Example 308
1 - [ 1 - (3,4-Dichloro-phenyl) - lH-imidazol-4-yl-methyll - lH-imidazole-2-carbaldehyde 4-Chloromethyl-l-(3,4-dichloro-phenyl)-lH-imidazole (1.31 g, 5.0 mmol) was dissolved in DMF (10 ml), 2-imidazolecarboxaldehyde (0.48 g, 5.0 mmol) and cesium carbonate (0.82 g, 2.5 mmol) was added and the resulting mixture was stirred at 60 °C for 12h. After evaporation of the solvent the residue was dissolved in AcOEt and washed with Η2O. The organic phase was dried (Na2SO4), concentrated and chromatographed [sihca, elution with gradient CH2C12 to 100 % (CH2C12 / MeOH = 9:1)] to obtain 0.98 g (61 %) of the tide compound as an off-white solid. Mp. 130-131 °C (CH2C12 / iPr2O), MS: m/e = 320 (M+).
Example 309
l-(3,4-Dichloro-phenyl)-3-methyl-lH-pyrazole and l-(3,4-Dichloro-phenyl)-5-methyl- lH-pyrazole
A solution of of 3,4-dichlorophenylhydrazine (4.27 g , 20.0 mmol) in EtOΗ (50 ml) and Η20 (50 ml) was treated with 3-oxobutyraldehyde dimethyl acetal (2.64 g, 20.0 mmol) and refluxed for 1 h. The alcohol was removed in vacuo and the aqueous residue was extracted with AcOEt (2x 150 ml). The organic phase was dried (Na2SO4), filtered and evaporated. The remaining oil was chromatographed [silica, elution with gradient hexane to 10 % (hexane/ AcOEt = 1:1)] to obtain 3.01 g (66 %) of l-(3,4-dichloro-phenyl)-3- methyl-lH-pyrazole [Mp. 57-58 °C (AcOEt / hexane), MS: m/e = 226 (M+)] as off-white crystals and 1.32 g (29 %) of l-(3,4-dichloro-phenyl)-5-methyl-lH-pyrazole [Mp. 46-47 °C (hexane), MS: m/e = 226 (M+)] as white crystals.
Example 310
4-Chloromethyl-l-(3,4-dichloro-phenyl)-lH-pyrazole
1 -(3,4-Dichloro-phenyl)- lH-pyrazole-4-carboxylic acid (3.0 g, 12 mmol) ( US 5064851) as treated with IM BΗ3 THF complex (50 ml) and refluxed for 90 min. The mixture was cooled to 5°C and MeOH (50 ml) was added slowly. After evaporation of all volatiles the residue was taken up in 25 % HCl solution (50 ml) and refluxed for 15 min. After filtration the aqueous phase was cooled in an ice-bath and slowly treated with 28 % NaOH solution (50ml). The title compound crystallizes as a light yellow material (2.6 g, 86 %). Mp. 66-67 °C (H2O), MS: m/e = 260 (M+).
Example 311
l-(3,4-Dichloro-phenyl)-lH-imidazole-4-carbaldehyde
A solution of [l-(3,4-dichloro-phenyl)-lH-imidazol-4-yl]-methanol (10.8 g, 44.3 mmol) in a mixture of TΗF (270 ml) and Η2O (30 ml) was treated with manganese(IV) oxide (5 g, 57.5 mmol) and the mixture was refluxed for 4h. A second portion of manganese(IV) oxide (1.5 g) was added and reflux continued for 1.5 h. The mixture was filtered over Celite, and the residue was washed with MeOH. Toluene was added to the filtrate, and the H20 was removed azeotropically. The brown residue was taken up in CH2C12 and upon standing white crystals formed. Filtration afforded l-(3,4-dichloro-phenyl)-lH-imidazole- 4-carbaldehyde (2.5 g, 25 %). MS: m/e = 240.0 (M+).
Example 312
1- [ 1 -(3,4-Dichloro-phenyl)- lH-imidazol-4-yl] -ethanol
To a solution of methylmagnesium iodide in ether (3 M, 13,7 ml, 41.1 mmol) and ether (40 ml), l-(3,4-dichloro-phenyl)-lH-imidazole-4-carbaldehyde (2.58 g, 10.7 mmol) was added in portions. TΗF (50 ml) was then added slowly and stirring was continued for 1 h at reflux. After the addition of aqueous ammonium chloride (saturated, 30 ml), the mixture was extracted with AcOEt. The organic phase was dried (Na2SO4) and evaporated to give l-[l-(3,4-dichloro-phenyl)-lΗ-imidazol-4-yl]-ethanol (2.56 g, 93 %) as a light brown solid. MS: m/e = 257.0 (M+H+).
Example 313
l-(3,4-Dichloro-phenyl)-lH-imidazole-4-carboxylic acid methyl ester
A mixture of l-(3,4-dichloro-phenyl)-lH-imidazole-4-carboxylic acid (7.0 g, 27 mmol), methanol (150 ml) and cone, sulfuric acid (25 ml) was refluxed for 3h. The solution was then concentrated to ~80 ml and a solution of sodium carbonate (60g) in Η2O at 0° C(500 ml) was added. Extraction with CH C12, drying of the organic phase and evaporation of the solvent gave a brown residue, which upon triturating with ether gave the title compound (6.0 g, 81%) as a light brown solid. MS: m/e = 269.9 (M+).
Example 314
2-f l-f3,4-Dichloro-phenyl)-lH-imidazol-4-yn-propan-2-ol
In analogy to example 312, l-(3,4-dichloro-phenyl)-lH-imidazole-4-carboxylic acid methyl ester (1.5 g, 5.53 mmol) was treated with excess methyl magnesium iodide. After extractive workup the title compound (1.3 g, 86 %) was obtained. MS: m/e = 270.1 (M+).
Example 315
IH-Imidazole, 2- [ (2-methyl- lH-imidazol-l-yl)methyl1 - 4- [3-(trifluoromethyl)phenyl! - 1 - [ [2- (trimethylsilyl) ethoxy] methyl! - lH-Imidazole, 4-iodo-2- [ (2-methyl- IH-imidazol- l-yl)methyl] - 1- [ [2- (trimethylsilyl)ethoxy]methyl]- (0.080 g, 0.191 mmol) was dissolved in toluene (4ml) and MeOΗ (0.8 ml), treated with 2N Na2CO3 (0.2 ml), 3-(trifluoromethyl)phenylboronic acid (0.049 g, 0.248 mmol) and tetrakis(triphenylphosphine) palladium (0.0114 g, 0.0095 mmole). The reaction mixture was refluxed under argon for 150 h then cooled to rt and dried (Na2SO4). After filtration and evaporation of the solvent, the residue was chromatographed (silica, elution with CΗ2C12 / MeOH = 95:5) to provide the tide compound (0.036 g, 43%) as a brown oil. MS: m/e = 437.4 (M+H+).
Examples 316 to 319 were prepared according to the general procedure described in example 315.
Example 316
IH-Imidazole, 4-(4-fluoro-3-methylphenyl)-2-[(2-methyl-lH-imidazol-l- yPmefhvH -1- [ [2-(trimethylsilyl)ethoxy1 methyl] -
The title compound, MS: m/e = 400.2 (M+) was prepared from IH-imidazole, 4-iodo-2- [ (2-methyl- IH-imidazol- 1 -yl)methyl] - 1 - [ [2- (trimethylsilyl) ethoxy] methyl] - and 4-fluoro-3-methylphenylboronic acid.
Example 317 IH-Imidazole, 4-(3,4-difluorophenyl)-2-[(2-methyl-lH-imidazol-l- vDmethyl] -1- [ [2-(trimethylsilyl)ethoxy1 methyl] -
The title compound, MS: m/e = 404.2 (M+) was prepared from IH-imidazole,
4-iodo-2- [ (2-methyl- IH-imidazol- l-yl)methyl] - 1 - [ [2-(trimethylsilyl)ethoxy] methyl] - and 3,4-difluorophenylboronic acid.
Example 318
IH-Imidazole, 2-[(2-methyl-lH-imidazol-l-yl)methyl)-4-[4-(methylthio)phenyl]-l- [ [2-(trimethylsilyl)ethoxy] methyl] -
The title compound, MS: m/e = 414.2 (M+) was prepared from from IH-imidazole, 4-iodo-2- [ (2-methyl- IH-imidazol- 1 -yl)methyl] -1- [ [2-(trimethylsilyl)ethoxy] methyl] - and 4-methylfhiophenylboronic acid.
Example 319
IH-Imidazole, 4- (4-fluoro-3-methylphenyl) -2- ( IH-imidazol- 1 -ylmethyl) - 1 - f \2- (trimethylsilyl)ethoxy!methyn - The tide compound, MS: m/e = 387.3 (M+H+) was prepared from from IH-imidazole, 2-( IH-imidazol- l-ylmethyl)-4-iodo-l- [ [2-(trimethylsilyl)ethoxy] methyl] - and 4-fluoro-3- methylphenylboronic acid.
Example 320
IH-Imidazole, 4-iodo-2- [ (2-methyl- IH-imidazol- l-vDmethyl! - 1- [ [2- (trimethylsilyl) ethoxy! methyl! -
[4-Iodo-l-(2-trimethylsilanyl-ethoxymethyl)-lH-imidazol-2-yl]-methanol (1.0 g, 2.8 mmol) and tetrabromomethane (1.3 g, 4.0 mmole) were dissolved in TΗF (10.0 ml) and cooled to 0° C. Triphenylphosphine (1.07 g, 3.95 mmol) was added portionwise over a period of 30 min. The reaction mixture was stirred at 0° C for 1 h to provide a white suspension. In a second flask, sodium hydride (0.615 g, 14.1 mmol, 55 % in mineral oil) was suspended in DMF (20 ml) and cooled to 0 °C. 2-Methylimidazole (1.16 g, 14.1 mmol) was added portionwise. The reaction mixture was stirred at 60 °C for 30 min, cooled to 0° C and treated with the above suspension. After 2 h stirring at rt, the reaction mixture was quenched with saturated NaΗCO3 (50 ml). The aqueous layer was extracted 3 times with AcOEt. The combined extracts were dried over Na2SO4, filtered and the solvent was removed in vacuo. The residue was chromatographed (silica, elution with CH2C12 / MeOH = 97:3) to provide the tide compound (0.835 g, 71%) as a brown oil. MS: m/e = 419.0 (M+H+).
Example 321 was prepared according to the general procedure described in example 320.
Example 321
IH-Imidazole, 2-(lH-imidazol-l-ylmethyl)-4-iodo-l-[[2-(trimethylsilyl)ethoχy!methvn-
The tide compound, MS: m/e = 405.3 (M+Η+) was prepared from [4-iodo-l-(2- trimethylsilanyl-ethoxymethyl) - lH-imidazol-2-yl] -methanol and imidazole.
Example 322
[4-Iodo-l-(2-trimethylsilanyl-ethoxymethyl)-lH-imidazol-2-yll-methanol
4-Iodo-l-(2-trimethylsilanyl-ethoxymethyl)-lH-imidazole-2-carbaldehyde (4.6 g, 13.1 mmol) was dissolved in ethanol (50 ml) under argon. Sodium borohydride (0.514 g, 13.1 mmol) was added and the mixture was stirred at room temperature for 45 min. Η2O (200 ml) was added. The aqueous layer was extracted 3 times with AcOEt. The combined extracts were dried over Na2SO4, filtered and the solvent was removed in vacuo. The crude residue was taken up in hexane and stirred at rt. Filtration provided [4-iodo-l-(2- trimethylsilanyl-ethoxymethyl)-lH-imidazol-2-yl] -methanol (4.0 g, 87 %) as a white solid. MS: m/e = 354.0 (M+).
Example 323
4-Iodo-l-(2-trimethylsilanyl-ethoχymethyl)-lH-imidazole-2-carbaldehyde
A solution of 4,5-diiodo-l-(2-trimethylsilanyl-ethoxymethyl) -IH-imidazole (8.86 g, 19.68 mmol) in anhydrous TΗF (110 ml) under argon was cooled to -78 °C and was treated dropwise with n-butyllithium (13.5 ml, 21.65 mmol, 1.6M in hexane). After 10 minutes stirring at -78 °C and 30 minutes at -45 °C, the reaction mixture was cooled to -78 °C and treated at once with DMF (10 ml). The mixture was allowed to warm to room temperature and saturated NΗ4C1 (150 ml) was added. The aqueous layer was extracted 2 times with AcOEt. The combined extracts were dried over Na2SO4, filtered and the solvent was removed in vacuo. The residue was chromatographed (silica, elution with hexane / AcOEt = 98:2) to provide the title compound (5.18 g, 75%) as a light yellow oil. MS: m/e = 352.1 (M+).
Example 324
4,5-Diiodo- 1 - (2-trimethylsilanyl-ethoxymethyl) - IH-imidazole
4,5-Diiodoimidazole (prepared according to D.S. Carver, S.D. Lindell, and E.A. Saville- Stones, Tetrahedron, 1997, 53, 42, 14481-14496) (10.1 g, 31.6 mmol) was added portionwise to a room temperature suspension of sodium hydride (1.38 g, 31.6 mmol, 55% in mineral oil) in dry DMF (45 ml). The reaction mixture was stirred at room temperature for 90 min, then cooled to 0 °C and treated slowly with a solution of 2-(trimethylsilyl)- ethoxymethylchloride (6.81 ml, 34.7 mmol) in DMF (10 ml). After 2 h stirring at 0 °C, the reaction mixture was poured onto a mixture of Η2O (200 ml) and AcOEt (50 ml). The mixture was filtered and the mother liquor was extracted 3 times with AcOEt. The combined extracts were dried over Na2SO , filtered and the solvent was removed in vacuo. The residue was chromatographed (silica, elution with hexane / AcOEt = 9:1) to provide the tide compound (9.44 g, 66.4%) as a pale yellow oil. MS: m/e = 450.0 (M+).
Example 325
3-CHoromethyl-5-(3,4-dichloro-phenyl)-pyridine hydrochloride (1:1)
A solution of [5-(3,4-dichloro-phenyl)-pyridine-3-yl] -methanol (470 mg, 1.9 mmol) in thionyl chloride (4.9 ml) was stirred at 20 °C for 15 h. Evaporation of the thionyl chloride and drying under high vacuum at 50 °C for 2 h afforded the title compound (558 mg, 98 %) as a light yellow solid. MS: m/e = 271.0 (M+). Examples 326-328 were prepared according to the general procedure described in example 325.
Example 326
2-Chloromethyl-3-(3,4-dichloro-phenyl)-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 271.0 (M+) was obtained as a light brown foam (99 % yield) by the reaction of [4-(3,4-dichloro-phenyl)-pyridine 2-yl] -methanol with thionyl chloride at 20 °C for 15 h.
Example 327
4-Chloromethyl-2-(3,4-dichloro-phenyl)-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 271.0 (M+) was obtained as a light brown foam (100 % yield) by the reaction of [2-(3,4-dichloro-phenyl)-pyridine-4-yl] -methanol with thionyl chloride at 20 °C for 1 h.
Example 328
3-Chlor omethyl- 5- ( 3 ,4-dimethyl-phenyl) - 2- methyl-pyridine hydrochloride (1:1)
The title compound, MS: m/e = 245.1 (M+) was obtained as a yellow solid (98 % yield) by the reaction of [5-(3,4-dimethyl-phenyl)-2-methyl-pyridin-3-yl] -methanol hydrochloride (1:1) with thionyl chloride at 20 °C for 1 h then 2 h at reflux.
Example 329
f 5- ( 3,4-Dichloro-phenyl) -pyridin e-3-yll -methanol
To a suspension of L1AIH4 (161 mg, 4.2 mmol) in THF (20 ml) at 0 °C was added dropwise 5-(3,4-dichloro-phenyl)-nicotinic acid methyl ester (2.0 g, 7.0 mmol) in THF (20 ml) and stirred for a further 2 h at this temperature. The reaction was quenched by careful addition of THF/H2O (9:1) and then dried directiy with Na2SO4, filtered and the solvent was evaporated. The residue was chromatographed [silica, elution with CH2C12 / (2M NH3 MeOH) = 97:3] to afford the tide compound (480 mg, 27 %) as an orange solid. MS: m/e = 254.0 (M+H+).
Examples 330-332 were prepared according to the general procedure described in example 329. Example 330
[2-(3,4-Dichloro-phenyl)-pyridine-4-yn -methanol
The title compound, MS: m/e = 252.0 ([M-H]") was obtained as a light yellow solid (53 % yield) by the reaction of 2-(3,4-dichloro-phenyl)-isonicotinic acid methyl ester with lithium aluminum hydride in THF at 20 °C for 1 h followed by chromatography [silica, elution with CH2C12 / (2M NH3 MeOH) = 19:1]
Example 331
4- ( 3 ,4-Dichloro-phenyl) -pyridine 2-yl] -methanol
The title compound, MS: m/e = 252.0 ([M-H]") was obtained as a light brown oil (94 % yield) by the reaction of 4-(3,4-dichloro-phenyl)-pyridine-2-carboxylic acid methyl ester with IM lithium aluminum hydride /THF solution in THF at 20 °C for 1 h followed by chromatographic purification.
Example 332
[5-(3,4-Dimethyl-phenyl)-2-methyl-pyridin-3-yl1 -methanol hydrochloride (1:1)
The tide compound, MS: m/e = 227.2 (M+) was obtained as a beige solid (58 % yield) by the reaction of 5-(3,4-dimethyl-phenyl)-2-mefhyl-nicotinic acid ethyl ester with sodium borohydride (5 eq.) in EtOH (5 ml) stirred for 23 h at 20 °C followed by chromatographic purification.
Example 333
5-(3,4-Dichloro-phenyl)-nicotinic acid methyl ester
To a solution of 5-bromopyidine-3-carboxylic acid methyl ester (2 g, 9.3 mmol) in toluene (50 ml) was added tetrakis-(triphenylphosphine)-palladium (0) (320 mg, 0.28 mmol) followed by LiCl (785 mg, 18.5 mmol) and the mixture was stirred 30 min at 20 °C. Then 3,4-dichlorophenyl boronic acid (50 wt% in THF/H2O 9:1) (3.7 g, 3.3 ml, 9.7 mmol) and 2N aq. 2CO3 ( 11.3 ml, 2.5 eq.) were added and the stirred mixture heated under an argon atmosphere at 100 °C for 23 h. After cooling, H O was added (25 ml) and the aqueous phase separated and extracted with AcOEt. The combined organic extracts were washed with saturated NaCl solution, dried with Na2SO4, filtered and the solvent evaporated and the product dried under high vacuum at 50 °C for 2 h to afford the title compound (2.48g, 95%) as a beige solid. MS: m/e = 281.0 (M+H+). Examples 334-336 were prepared according to the general procedure described in example 333.
Example 334
4-(3,4-Dichloro-phenyl)-pyridine-2-carboxylic acid methyl ester
The title compound, MS: m/e = 281.0 (M+) was obtained as a light yellow solid (10 % yield) by the reaction of 4-bromo-pyridine-2-carboxylic acid methyl ester with 3,4- dichlorophenyl boronic acid.
Example 335
[2-(3,4-Dichloro-phenyl)-isonicotinic acid methyl ester
The title compound, MS: m/e = 281.0 (M+) was obtained as a light brown solid (59 % yield) by the reaction of 2-iodo-isonicotinic acid methyl ester with 3,4-dichlorophenyl boronic acid.
Example 336
6-(3,4-Dichloro-phenyl)-pyridine 2-carboxylic acid methyl ester
The tide compound, MS: m/e = 282.0 (M+) was obtained as a light yellow solid (7 % yield) by the reaction of 6-bromo-pyridine-2-carboxylic acid methyl ester with 3,4- dichlorophenyl boronic acid.
Example 337
2-Iodo-isonicotinic acid methyl ester
A solution of 2-chloro-pyridine-4-carboxylic acid (5g, 31.7 mmol) in butan-2-one (150 ml) was heated under reflux with sodium iodide for 6 h to afford the 2-iodo-isonicotinic acid (7.3 g, 92.4 % yield) following extractive aqueous workup. This material was dissolved in THF (50 ml) and esterified with fresh etheral diazomethane solution (44 ml, 0.55 mol/1). After evaporation of the solvent and filtration through a pad of silica gel, [elution with CH2C12 / (2M NH3 MeOH) = 19:1] the tide compound (2.3 g, 44%) was obtained as a dark yellow oil. MS: m/e = 263.0 (M+).
Example 338
3-Bromo-5-(2-methyl-imidazol-l-ylmethyl)-pyridine To a stirred suspension of sodium hydride (0.54 g, 12.3 mmol) in THF (40 ml) at 20 °C was added 2-methylimidazole in portions over 45 min. 3-Bromo-5-(chloromethyl)- pyridine (1 g, 4.1 mmol) in ethanol (8 ml) was then added and this mixture was heated under reflux for 1 h under an argon atmosphere. After cooling and evaporation of solvents the residue was suspended in MeOH, filtered and adsorbed onto silica gel.
Chromatographic elution with CH2C12/ (2M NH3 MeOH) = 98:2 afforded the title compound (0.56 g, 53 %) as a yellow oil. MS: m/e = 251.0 (M+).
Example 339
3-Bromo-5-(chloromethyl)-pyridine
To a cooled solution of thionylchloride (41ml, 344 mmol) at 0 °C was added cautiously (highly exothermic) portionwise (5-bromo-pyridm-3-yl)-methanol (10 g, 44.5 mmol). After complete addition the mixture was heated to reflux for 1 h to complete the reaction. After cooling, ether (50 ml) was added and the mixture cooled to 4 °C. The precipitated solid was filtered off and washed with cold ether then dried at 50 °C under vacuum for 2 h to afford the title compound (9.1g, 84 %) as a light yellow solid. MS: m/e = 206.9 (M+).
Example 340
(5-Bromo-pyridin-3-yl)-methanol hydrochloride (1:1)
5-Bromo nicotinic acid ethyl ester (25 g, 108 mmol) was dissolved in ethanol (500ml) and treated with fresh sodium borohydride (25 g, 660 mmol) added portionwise over 30 min. at 20 °C. Stirring was continued overnight under an argon atmosphere. Following this IN HCl (50 ml) was added slowly (over 20 min) followed by 2N NaOH (25 ml) and H2O (75 ml) and this mixture was stirred for 2h at ambient temperature. After evaporation of the alcohol the aqueous phase was extracted with dichloromethane (4x150 ml) and the combined extracts were washed with brine then dried with Na2SO4, filtered and evaporated. The resulting yellow oil was dissolved in a small volume of ethanol and treated with 0.93 M HCl/EtOH (62 ml, 1.2 eq.) at 4 °C over lh to afford, after removal of solvent and drying under high vacuum at 50 °C for 16 h, the title compound (10.9 g, 44 %) as a light yellow solid. MS: m/e = 186.9 (M+).
Example 341
5-(3,4-Dimethyl-phenyl)-2-methyl-nicotinic acid ethyl ester
Obtained from [3-dimethylamino-2-(3,4-dimethyl-phenyl) allylidine] -dimethyl- ammonium tetrafluoroborate (1:1) in turn prepared from 3,4-dimethyl-phenyl acetic acid (prepared according to A. J. Liepa; Aust. }. Chem., 1981, 34(12), 2647-55). Example 342
2-(4-chloro-3-trifluoromethyl-phenyl)-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane
This compound was prepared in a modification of the literature known method (Y. Masuda, M. Murata, S. Watanabe, /. Org. Chem., 1997, 62, 6458-9). To a flask containing KOAc (3.4 g, 34.7 mmol), PdCl2(PPh3)2 (234 mg, 0.34 mmol) and bis(pinacolato)diboron (3.2 g, 12.7 mmol) was added a solution of 5-bromo-2-chloro-benzotrifluoride (3 g, 11.5 mmol) in dioxane. This mixture was heated to 100 °C under an argon atmosphere for 3 h. After cooling, AcOEt was added then the organic mixture was washed with saturated NaCl solution then dried with Na2SO4 and the solvent evaporated. The residue was chromatographed (silica, elution with hexane / AcOEt= 9:1) to afford the title compound (2.35g, 66 %) as a light brown solid. MS: m/e = 306.1 (M+).
Examples 343 to 347 were prepared according to the general procedure described in example 342.
Example 343
2-(3-Chloro-4-methyl-phenyl)-4,4,5,5-tetramethyl[l,3,2!-dioxaborolane
The titie compound, MS: m/e = 252.1 (M+) was obtained as a light yellow semi-solid (30 % yield) using 2-chloro-4-iodo-toluene as the starting material.
Example 344
2-(4-Chloro-3-methyl-phenyl)-4,4,5,5-tetramethyl[l,3,2] -dioxaborolane
The tide compound, MS: m/e = 252.1 (M+) was obtained as a colorless liquid (16 % yield) using 5-bromo-2-chloro-toluene.
Example 345
5-(4,4,5,5-Tetramethyl[ 1,3,2] -dioxaborolan-2-yl)-2,3-dihydro-benzofuran
The titie compound, MS: m/e = 246.1 (M+) was obtained as a light yellow oil (51 % yield) using 2,3-dihydro-5-iodobenzo[b]furan.
Example 346
2-Indan-5-yl-4,4,5,5-tetramethyl[ 1,3,2] -dioxaborolane
The tide compound, MS: m/e = 244.1 (M+) was obtained as a light yellow oil (96 % yield) using trifluoro-methanesulfonic acid indan-5-yl ester obtained in turn from indan-5-ol by treatment with trifluoro-methanesulfonic anhydride, DMAP and triethylamine in CH2C12 at-70 °C to 20 °C.
Example 347
2-(4-Fluoro-3-trifluoromethyl-phenyl)-4,4,5,5-tetramethyl-[l,3,2ldioxaborolane
The titie compound, MS: m/e = 290.1 (M+) was obtained as a colourless oil (76 % yield) using 5-bromo-2-fluoro-benzotrifluoride.
Example 348
[l-(3-Trifluoromethylsulfanyl-phenyl)-lH-imidazol-4-vn-methanol
Following the general method described in example 293, 3-(trifluoromethylthio)aniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directly reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the title compound was obtained as a light brown crystalline solid. Mp. 73-75 °C (H2O), MS: m/e = 274 (M+).
Example 349
{ 1 - [ 3- ( 1 , 1 -Difluoro-ethyl) -phenyl] - lH-imidazol-4-yl? -methanol
Following the general method described in example 293, 3-(l,l-difluoro-ethyl)-aniline [R.O. Neri, J.G. Topliss, Ger. Offen. (1972), DE 2130452 19721221 CAN 78:124310] was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directiy reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the title compound was obtained as a white crystalline solid. Mp. 104-108 °C (H2O), MS: m/e = 238 (M+).
Example 350
|l-[3-(l,l-Difluoro-ethyl)-4-fluoro-phenyl1-lH- imidazol-4-yll-methanol
Following the general method described in example 293, 3-(l,l-difluoro-ethyl)-4-fluoro phenylamine was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directly reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the title compound was obtained as a white crystalline solid. MS: m/e = 257 (M+H+). Example 351
3- ( 1 , 1 -Difluoro-ethyl) -4-fluoro-phenylamine
To a solution of 2- (1,1 -difluoro-ethyl) -l-fluoro-4-nitro-benzene (10.4 g, 50.6 mmol) in methanol (200 ml) palladium on carbon (10 %, 4g) was added and the resulting mixture was hydrogenated for 2 h at 20 °C. After filtration of the catalyst the solvent was evaporated to yield the title compound as a yellow semi solid mass. (8.5 g, 96 %). MS: m/e = 175 (M+).
Example 352
2- ( 1 , 1 -Difluoro-ethyl)- 1 -fluoro-4-nitro-benzene
A solution of l-(2-fluoro-5-nitro-phenyl)-ethanone (10.8 g, 59.0 mmol) in diethylaminosulfur trifluoride (15.5 ml, 118 mmol) was stirred at 50 °C for 6 h. The mixture was cooled in an ice bath and slowly added to ice cooled aqueous 2N NaOH solution (100 ml). After extraction with CH2C12 the organic phase was dried (Na2SO4), and concentrated. After chromatography (silica, elution with AcOEt / hexane = 1:4) the title compound was obtained as a dark brown oil (9.8 g, 81 %). MS: m/e = 205 (M+).
Example 353
1 - ( 3 -Isopropyl-phenyl) - lH-imidazole-4- carboxylic acid
Following the general method described in example 234, 3-isopropylaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The title compound was obtained as a light brown crystalline solid. Mp. >122 °C dec. (Η2O / dioxane), MS: m/e = 231 (M+H+).
Example 354
[ l-(3-Isopropyl-phenyl)-lH-imidazol-4-yl] -methanol
Following the general method described in example 264, l-(3-isopropyl-phenyl)-lH- imidazole-4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The titie compound was obtained as a light brown crystalline solid. Mp. 76-77 °C (H2O), MS: m/e = 216 (M+).
Example 355
l-Naphthalen-2-yl-lH-imidazole-4-carboxylic acid methyl ester - Ill -
A suspension of 2-naphtylboronic acid (1.4 g, 8 mmol), lH-imidazole-4-carboxylic acid methyl ester (1.0 g, 8 mmol) and cupric acetate (1.4 g, 8 mmol) in CΗ2C12 (20 ml) was stirred at 20 °C for 24 h. AcOEt (100 ml) and saturated aqueous Seignette salt solution (50 ml) was added and the resulting mixture was stirred for another 2 h. After separation the organic phase was dried (Na2SO4), concentrated and chromatographed (silica, elution with CH2C12 / MeOH = 99:1) to yield the title compound (0.49 g, 24 %) of the titie compound as a white crystalline material. Mp. 143-144 °C (AcOEt), MS: m/e = 252 (M+).
Example 356
(l-Naphthalen-2-yl-lH-imidazol-4-yl)-methanol
Following the general method described in example 298, l-naphthalen-2-yl-lH-imidazole- 4-carboxylic acid methyl ester was reacted with lithium aluminum hydride followed by hydrolytic workup and chromatography. The title compound was obtained as a light brown gum. MS: m/e = 225 (M+).
Example 357
[l-(3-Bromo-4-fluoro-phenyl)-lH-imidazol-4-yl] -methanol
Following the general method described in example 293, 3-bromo-4-fluoroaniline (K.S.Y. Lau et al., J. Org. Chem., 1981, 46, 2280-6) was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directiy reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the title compound was obtained as a white crystalline solid. Mp. 151-152 °C (H2O), MS: m/e = 270 (M+).
Example 358
1 - ( 3 -Bromo-phenyl) - lH-imidazole-4-carboxylic acid
Following the general method described in example 234, 3-bromoaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The titie compound was obtained as a light brown crystalline solid. Mp. 205-207 °C (Η20 / dioxane), MS: m/e = 267 (M-H").
Example 359
[ 1 - ( 3-Bromo-phenyl) - lH-imidazol-4-yl] -methanol Following the general method described in example 264, l-(3-bromo-phenyl)-lH- imidazole-4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The title compound was obtained as an off-white solid. MS: m/e = 253 (M+H+).
Example 360
[ 1 - ( 3 -Vinyl-phenyl) - lH-imidazol-4-yl 1 -methanol
Under an Ar atmosphere, a solution of [l-(3-bromo-phenyl)-lH-imidazol-4-yl]-methanol (3.0 g, 12 mmol) in DMF (90 ml) was successively treated with PdCl2(PPh3)2 (0.87 g, 0.1 mmol) and vinyltributylstannane (4.1 g, 13 mmol). The resulting mixture was heated to 60 °C for 8 h. After evaporation of the solvent the residue was stirred for 30 min with AcOEt (60 ml) and aqueous 10 % KF solution. The organic phase was separated and the aqueous phase was extracted 3 times with AcOEt. The combined organic phases were dried (Na SO4), concentrated and chromatographed [silica, elution with gradient CΗ2C12 to 40 % (CH2C12 / MeOH = 9:1)] to yield the title compound as a colorless oil (1.2 g, 51 %). MS: m/e = 201 (M+H+).
Example 361
[ l-(3-Cyclopropyl-phenyl)-lH-imidazol-4-yl] -methanol
Under an Ar atmosphere, a mixture of [l-(3-vinyl-phenyl)-lH-imidazol-4-yl] -methanol (0.10 g, 0.5 mmol) in toluene (20 ml) was successively treated with diethylzinc (3.8 ml of a 1.1 M solution in hexane, 4.2 mmol) and diiodomefhane (6.6 g, 25 mmol). The resulting mixture was stirred at 20 °C for 12 h. The preciptate was filtered and stirred for 30 min with AcOEt and saturated aqueous NΗ4C1 solution. The organic phase was separated, dried (Na2SO4) and concentrated to yield the title compound as a yellow oil (0.10 g, 93 %). MS: m/e = 215 (M+H+).
Example 362
2-Difluoromethyl-l-fluoro-4-nitro-benzene
A solution of 2-fluoro-5-nitrobenzaldehyde (1.7 g, 10 mmol) in CH2C12 (50 ml) was treated with diethylaminosulfur trifluoride (1.8 ml, 14 mmol) and stirred at 20 °C for 72 h. Then saturated aqueous NaHCO3 solution (200 ml) was added and the mixture was stirred for 1 h. The organic phase was separated, dried (Na2SO4) and chromatographed [silica, elution with gradient hexane to 100 % (hexane/ AcOEt = 3:1)] to yield the title compound as a colorless oil (1.4g, 74%). MS: m/e = 191 (M+). Example 363
3-Difluoromethyl-4-fluoroaniline hydrochloride (1:1)
To a mixture of powdered iron (88.0 g, 1.58 mol) in acetic acid (500 ml) at 120 °C 2- difluoromethyl-l-fluoro-4-nitro-benzene (25.0 g, 131 mmol) was slowly added. After completed addition stirring was continued for 15 min, the reaction mixture was cooled to 20 °C, filtered and evaporated. The residue was stirred with AcOEt (11), filtered, evaporated and chromatographed [silica, elution with gradient hexane to 100 % (hexane/ AcOEt = 2:1)] to yield the free base of the titie compound as a dark brown oil (15.11g, 72 %). An analytical sample was treated with HCl and crystallized as the white hydrochloride salt. Mp. >240 °C dec. (MeOH / Et2O), MS: m/e = 161 (M+).
Example 364
l-(3-Difluoromethyl-4-fluoro-phenyl)-lH-imidazole-4-carboxylic acid
Following the general method described in example 234, 3-difluoromethyl-4-fluoroaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The titie compound was obtained as a light brown crystalline solid. Mp. >247 °C dec. (Η2O / dioxane), MS: m/e = 255 (M-H").
Example 365
[ l-(3-Difluoromethyl-4-fluoro-phenyl)-lH-imidazol-4-yl1 -methanol
Following the general method described in example 264, l-(3-difluoromethyl-4-fluoro- phenyl)-lH-imidazole-4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The title compound was obtained as an off-white solid. Mp. 133-134 °C (H2O), MS: m/e = 242 (M+).
Example 366
l-(3-Methylsulfanyl-phenyl)-lH-imidazole-4-carboxylic acid
Following the general method described in example 234, 3-(methylthio)aniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The title compound was obtained as a grey crystalline solid. Mp. 190-192 °C (Η2O / dioxane), MS: m/e = 234 (M+). Example 367
[l-(3-Methylsulfanyl-phenyl)-lH-imidazol-4-yn -methanol
Following the general method described in example 264, l-(3-methylsulfanyl-phenyl)-lH- imidazole-4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The tide compound was obtained as an off-white solid. Mp. >120 °C dec. (H2O), MS: m/e = 221 (M+H+).
Example 368
l-(3-Trifluoromethoxy-phenyl)-lH-imidazole-4-carboxylic acid
Following the general method described in example 234, 3-(trifluoromethoxy)aniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The title compound was obtained as a grey crystalline solid. Mp. 173-175 °C (Η2O / dioxane),
MS: m/e = 273 (M+H+).
Example 369
[ 1 -(3-Trifluoromethoxy-phenyl)- lH-imidazol-4-yl] -methanol
Following the general method described in example 264, l-(3-trifluoromethoxy-phenyl)- lH-imidazole-4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The title compound was obtained as an off-white solid. MS: m/e = 258
(M+).
Example 370
[l-(3-Chloro-phenyl)-lH-imidazol-4-yl]-methanol
Following the general method described in example 293, 3-chloroaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directly reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the title compound was obtained as an off-white crystalline solid. Mp. 78-79 °C (H2O), MS: m/e = 209 (M+H+).
Example 371
l-(3-Iodo-phenyl)-lH-imidazole-4-carboxylic acid Following the general method described in example 234, 3-iodoaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The title compound was obtained as an off-white crystalline solid. Mp. 229-230 °C (H2O / dioxane), MS: m/e = 313(M-H").
Example 372
[l-(3-Iodo-phenyl)-lH-imidazol-4-yl] -methanol
Following the general method described in example 264, l-(3-iodo-phenyl)-lH-imidazole- 4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The title compound was obtained as a yellow oil. MS: m/e = 301 (M+H+).
Example 373
l-(3-Fluoro-5-trifluoromethyl-phenyl)-lH-imidazole-4-carboxylic acid
Following the general method described in example 234, 3-fluoro-5-trifluoromethylaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The titie compound was obtained as a white crystalline solid. Mp. >250 °C (Η2O / dioxane), MS: m/e = 273 (M-H").
Example 374
[l-(3-Fluoro-5-trifluoromethyl-phenyl)-lH-imidazol-4-yn-methanol
Following the general method described in example 264, l-(3-fluoro-5-trifluoromethyl- phenyl)-lH-imidazole-4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The titie compound was obtained as a white crystalline solid. Mp. 144- 145 °C (H2O), MS: m/e = 261 (M+H+).
Example 375
[l-(3-Methoxy-5-trifluoromethyl-phenyl)-lH-imidazol-4-yll -methanol
Following the general method described in example 293, 3-methoxy-5- trifluoromethylaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directiy reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the titie compound was obtained as a light brown crystalline solid. Mp. 133-134 °C (H2O), MS: m/e = 272
(M+).
Example 376
[ l-(3-tgrt-Butyl-phenyl)-lH-imidazol-4-yl1 -methanol
Following the general method described in example 293, 3-tert-butylaniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directiy reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the title compound was obtained as a colorless oil. MS: m/e = 230 (M+).
Example 377
l-(3-Chloro-4-trifluoromethoxy-phenyl)-lH-imidazole-4-carboxylic acid
Following the general method described in example 234, 3-chloro-5- (trifluoromethoxy) aniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The titie compound was obtained as a light brown crystalline solid. Mp. 230-231 °C (Η2O / dioxane), MS: m/e = 305 (M-H").
Example 378
[l-(3-Chloro-4-trifluoromethoxy-phenyl)-lH-imidazol-4-yl] -methanol
Following the general method described in example 264, l-(3-chloro-4-trifluoromethoxy- phenyl)-lH-imidazole-4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The titie compound was obtained as a white crystalline solid. Mp. 115- 116 °C (H20), MS: m/e = 292 (M+).
Example 379
l-(3-Difluoromethoχy-phenyl)-lH-imidazole-4-carboxylic acid
Following the general method described in example 234, 3-(difluoromethoxy)aniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The titie compound was obtained as a light brown crystalline solid. Mp. 190-191 °C (Η2O / dioxane), MS: m/e = 253 (M-H"). Example 380
[ l-(3-Difluoromethoxy-phenyl)-lH-imidazol-4-yH -methanol
Following the general method described in example 264, l-(3-difluoromethoxy-phenyl)- lH-imidazole-4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The title compound was obtained as a white crystalline solid. MS: m/e
= 240 (M+).
Example 381
[ 1 -(3-Difluoromethyl-phenyl)-lH-imidazol-4-yl1 -methanol
Following the general method described in example 293, 3-difluoromethylaniline (G.E. Wright et al., J. Med. Chem., 1995, 38, 49-57) was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directiy reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the title compound was obtained as a light brown solid. MS: m/e = 225 (M+H+).
Example 382
[ l-(3-Bromo-5-fluoro-phenyl)-lH-imidazol-4-yl] -methanol
Following the general method described in example 293, 3-bromo-5-fluoroaniline (K. Yoshiizumi et al, Bioorg.Med.Chem.Lett., 1998, 8, 3397-3402) was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directiy reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the title compound was obtained as a light brown solid. Mp. 134-138 °C (AcOEt / hexane), MS: m/e = 271 (M+H+).
Example 383
[l-(2,2-Difluoro-benzo[l,3]dioxol-5-yl)-lH-imidazol-4-yn-methanol
Following the general method described in example 293, 2,2-difluoro-benzo[l,3]dioxol-5- ylamine was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directly reduced according to example 264, by reaction with BH3 THF complex followed by hydrolytic workup and the title compound was obtained as a light brown solid. Mp. 163-164 °C (H2O), MS: m/e = 254 (M+).
Example 384
l-Ouinolin-2-yl-lH-imidazole-4-carboxylic acid ethyl ester
A mixture of 2-aminoquinoline (10.0 g, 69 mmol), triethyl orthoformate (140 ml, excess), ethyl nitroacetate (9.2 g, 69 mmol) and acetic acid (1 ml) was refluxed for 3 h. Acetic acid (140 ml) and iron powder (11.6 g, 208 mmol) was added and the mixture was refluxed for 5 h. During this time 3 additional portions of iron powder (each 11.6 g, 208 mmol) were added. The mixture was cooled to 60 °C and AcOEt (500 ml) was added. After refluxing for 10 min the precipitate was filtered and the filtrate was concentrated. Residual acetic acid was azeotropically removed by coevaporation with toluene (500 ml). After chromatography (silica, elution with gradient hexane to AcOEt) the title compound was obtained as an off-white crystalline material (12.2 g, 66 %). Mp. 129-130 °C (AcOEt / hexane), MS: m/e = 268 (M+Η+).
Example 385
(l-Quinolin-2-yl-lH-imidazoI-4-yI)-methanol
Following the general method described in example 298, l-quinolin-2-yl-lH-imidazole-4- carboxylic acid ethyl ester was reacted with lithium aluminum hydride followed by hydrolytic workup and chromatography. The title compound was obtained as an off-white crystalline material. Mp. 136-137 °C (EtOΗ), MS: m/e = 225 (M+).
Example 386
[ l-(3-Chloro-4-trifluoromethylsulfanyl-phenyl)-lH-imidazol-4-yl] -methanol
Following the general method described in example 293, 3-chloro-4- (trifluoromethylthio)aniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directly reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the titie compound was obtained as a light brown crystalline solid. Mp. 105-106 °C (H2O), MS: m/e = 308 (M+).
Example 387
l-Ouinolin-3-yl-lH-imidazole-4-carboxylic acid ethyl ester Following the general method described in example 384, 2-aminoquinoline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid. After workup and chromatography the title compound was obtained as a beige crystalline solid. Mp. 170-171 °C (AcOEt / hexane), MS: m/e = 267 (M+).
Example 388
( 1 -Quinolin-3-yl- lH-imidazol-4-yl)-methanol
A suspension of l-quinolin-3-yl-lH-imidazole-4-carboxylic acid ethyl ester (5.0 g, 18.7 mmol) in toluene (100 ml) was cooled to -78 °C. Diisobutylaluminum hydride (19 ml of a IM solution in TΗF, 19 mmol) was added dropwise keeping T < -70 °C. The mixture was stirred at this temperature for 2h, then the reaction mixture was allowed to slowly reach 0 °C. After addition of saturated aqueous Seignette salt solution (10 ml) stirring was continued for 1 h. The mixture was diluted with AcOEt (100 ml), filtered, concentrated and chromatographed [silica, elution with gradient CΗ C12 to 80 % (CH2C12 / MeOH / aq. NH4OH = 90:10:1)] ] . The title compound was obtained as a light brown crystalline solid (1.20 g, 28 %). Mp. 142-145 °C (AcOEt), MS: m/e = 226 (M+H+).
Example 389
l-(5-Chloro-pyridin-2-yl)-lH-imidazole-4-carboxylic acid ethyl ester
Following the general method described in example 384, 2-amino-5-chloropyridine was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid. After workup and chromatography the title compound was obtained as a beige crystalline solid. Mp. 163-164 °C (AcOEt), MS: m/e
= 252 (M+Η+).
Example 390
[ 1 - ( 5-Chloro-pyridin-2-yl) - lH-imidazol-4-yll -methanol
Following the general method described in example 388, l-(5-chloro-pyridin-2-yl)-lH- imidazole-4-carboxylic acid ethyl ester was reacted with diisobutylaluminum hydride. After hydrolytic workup and chromatography the title compound was obtained as a light brown crystalline solid. Mp. 82-87 °C (AcOEt / Et2O), MS: m/e = 210 (M+Η+).
Example 391
l-Isoquinolin-3-yl-lH-imidazole-4-carboxylic acid ethyl ester Following the general method described in example 384, 3-aminoquinoline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid. After workup and chromatography the tide compound was obtained as a beige crystalline solid. Mp. 161-162 °C (AcOEt), MS: m/e = 268 (M+H+).
Example 392
( l-Isoquinolin-3-yl- lH-imidazol-4-yl) -methanol
Following the general method described in example 298, l-isoquinolin-3-yl-lH-imidazole- 4-carboxylic acid ethyl ester was reacted with lithium aluminum hydride followed by hydrolytic workup and chromatography. The title compound was obtained as an off-white waxy solid. MS: m/e = 226 (M+Η+).
Example 393
[ 1 - (4-Trifluoromethoxy-phenyl) - lH-imidazol-4-yl] -methanol
Following the general method described in example 293, 4- (trifluoromethoxy) aniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The isolated acid was directly reduced according to example 264, by reaction with BΗ3 THF complex followed by hydrolytic workup and the title compound was obtained as a white crystalline material. Mp. 105-106°C (Et2O), MS: m/e = 258 (M+).
Example 394
l-(4-Trifluoromethylsulfanyl-phenyl)-lH-imidazole-4-carboxylic acid
Following the general method described in example 234, 4-(trifluoromethylthio)aniline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid and subsequent alkaline hydrolysis. The title compound was obtained as a light brown crystalline solid. Mp. 247- 248 °C (Η2O / dioxane), MS: m/e = 288 (M+).
Example 395
[ 1 - (4-Trifluoromethylsulfanyl-phenyl) - lH-imidazol-4-yl] -methanol
Following the general method described in example 264, l-(4-trifluoromethylsulfanyl- phenyl)- lH-imidazole-4-carboxylic acid was reacted with BΗ3 THF complex followed by hydrolytic workup. The title compound was obtained as an off-white crystalline solid. Mp. 145-147 °C (H2O), MS: m/e = 275 (M+H+).
Example 396
l-Quinolin-6-yl-lH-imidazole-4-carboxylic acid ethyl ester
Following the general method described in example 384, 6-aminoquinoline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid. After workup and chromatography the title compound was obtained as a brown crystalline solid. Mp. 90-94 °C (AcOEt / hexane), MS: m/e = 268 (M+Η+).
Example 397
(l-Ouinolin-6-yl-lH-imidazol-4-yl)-methanol
Following the general method described in example 388, l-quinolin-6-yl-lH-imidazole-4- carboxylic acid ethyl ester was reacted with diisobutylaluminum hydride. After hydrolytic workup and chromatography the titie compound was obtained as a light brown crystalline solid. Mp. 183-187 °C (AcOEt / hexane), MS: m/e = 226 (M+Η+).
Example 398
l-Quinolin-8-yl-lH-imidazole-4-carboxylic acid ethyl ester
Following the general method described in example 384, 8-aminoquinoline was reacted with triethyl orthoformate, ethyl nitroacetate and acetic acid followed by treatment with triethyl orthoformate, iron and acetic acid. After workup and chromatography the titie compound was obtained as a light brown crystalline solid. Mp. >92 °C dec. (AcOEt / hexane), MS: m/e = 267 (M+).
Example 399
(l-Ouinolin-8-yl-lH-imidazol-4-yl)-methanol
Following the general method described in example 388, l-quinolin-8-yl-lΗ-imidazole-4- carboxylic acid ethyl ester was reacted with diisobutylaluminum hydride. After hydrolytic workup and chromatography the title compound was obtained as a light brown crystalline solid. Mp. 168-170 °C (Et2O), MS: m/e = 225 (M+). Example 400
IH-Imidazole, 1- [ [ l-( l,3-benzodioxol-5-yl)-lH-imidazol-4-yl]methyl] -2-nitro-
Following the general method described in example 301 (l-benzo[l,3]dioxol-5-yl-lH- imidazol-4-yl)-methanol was treated first with thionylchloride, then with 2-nitroimidazole and cesium carbonate. After evaporation, extractive workup and chromatography the title compound was obtained as a light brown solid. Mp. >156 °C dec. (CΗ2C12 / iPr2O), MS: m/e = 314 (M+H+).
Example 401
2-(3-Difluoromethyl-4-fluoro-phenyl)-4,4,5,5-tetramethyl-[l,3,2ldioxaborolane
The tide compound was obtained according to example 342 as a colorless oil (54 % yield) using 4-bromo-2-difluoromethyl-l-fluoro-benzene and bis(pinacolato)diboron as the starting materials. MS: m/e= 272 (M+).
Example 402
2- [3-( l,l-Difluoro-ethyl)-phenyl] -4,4,5,5-tetramethyl- [1,3,2] dioxaborolane
The title compound was obtained according to example 342 as a colorless oil (60% yield) using l-bromo-3-(l,l-difluoro-ethyl)-benzene and bis(pinacolato)diboron as the starting materials. MS: m/e = 268 (M+).
Example 403
2- (3-Fluoro-5-trifluoromethyl-phenyl)-4,4,5,5-tetramethyl- [ 1 ,3,2] dioxaborolane
The titie compound was obtained according to example 342 as a colorless oil (48% yield) using 3-bromo-5-fluorobenzotrifluoride and bis(pinacolato)diboron as the starting materials MS: m/e = 290 (M+).
Example 404
2- [3-( 1,1 -Difluoro-ethyl) -4-fluoro-phenyl] -4,4,5,5-tetramethyl- [ l,3,2]dioxaborolane
The titie compound was obtained according to example 342 as an orange oil (28% yield) using 4-bromo-2-(l,l-difluoro-ethyl)-l-fluoro-benzene and bis(pinacolato)diboron as the starting materials. MS: m/e = 286.2 (M+). Example 405
4-Bromo-2-difluoromethyl-l-fluoro-benzene
5-Bromo-2-fluorobenzaldehyde (2 g, 9.85 mmol) was dissolved in CH2CI2 (50 ml). The reaction mixture was put under an argon atmosphere and cooled to 0 °C. Diethylaminosulfur trifluoride (2.04 ml, 14.78 mmol) was added dropwise. The mixture was allowed to warm up to room temperature and stirred overnight. It was then quenched with a saturated aqueous NaHCO3 solution. The layers were separated and the aqueous one was extracted with CH2C12. The combined organic phases were dried with Na2SO4 and the solvent evaporated. The brown oil was chromatographed (silica, elution hexane/AcOEt) to afford the title compound (1.55 g, 70 %) as a colorless oil. MS: m/e = 226.0 (M+H+).
Example 406
l-Bromo-3-(l,l-difluoro-ethyl)-benzene
The title compound was obtained according to example 405 (neat diethylaminosulfur trifluoride) as a colorless oil (15% yield) using 3-bromoacetophenone as the starting material. MS: m/e = 220.0 (M+).
Example 407
l-(2-Fluoro-5-nitro-phenyl)-ethanone
The title compound was prepared following the literature method M. Q. Zhang, A. Haemers, D. Vanden Berghe, S. R. Pattyn, W. BoUaert, /. Heterocyclic Chem., 1991, 28, 673- 683, using 2'-fluoroacetophenone as the starting material. The reaction afforded a light yellow solid (85%). MS: m/e = 205.0 (M+).
Example 408
4-Bromo-2-(l,l-difluoro-ethyl)-l-fluoro-benzene
The titie compound was prepared following the literature method (A. Takahashi, T. Agatsuma, M. Matsuda, T. Ohta, T. Nunozawa, T. Endo, S. Nozoe, Chem. Pharm. Bull, 1992, 40, 3185-3188), using 3- (1,1 -difluoro-ethyl) -4-fluoro-phenylamine as the starting material. The reaction afforded a dark red liquid (yield 46 %). 1H-NMR (400MHz) δ = 1.99 (t, J = 11.75 Hz, 3H), 7.02 ( t, J = 6.0 Hz, 1H), 7.50-7.55 (m, 1H), 7.65-7.69 (m, 1H). Example 409
2-Cyclopropyl- IH-imidazole
To a solution of cyclopropanecarboximidic acid ethyl ester (32.9 g , 291 mmol) in MeOΗ (40 ml) was added aminoacetaldehyddimethylacetal (34.5 ml, 320 mmol) and the reaction mixture was stirred for 2 days. The reaction mixture was concentrated, cone ΗC1 and water was added and the mixture was concentrated again. The residue was dissolved in water and the pΗ was adjusted to 8 by additon of Na2CO3 and the mixture was concentrated. The brown residue was suspended in EtOΗ and filtered. The filtrate was concentrated to give 30.6 g (283 mmol, 97 %) of the title compound. MS: m/e =1 07.1 (M-Η).
Example 410
Cyclopropanecarboximidic acid ethyl ester hydrochloride
A steady stream of ΗC1 gas was slowly passed through a solution of cyclopropancarbonitril (25 g, 373 mmol) in EtOΗ (17.2 ml). After 15 h the reaction mixture was cooled to 0 °C and diethylether was added dropwise. The precipitated title compound was filtered and obtained as a colourless crystalline material (32.9 g , 220 mmol, 59 %). MS: m/e = 112.2 (M-Η).
Example 411
5-Bromo- 1 -methyl-2- (2-methyl-imidazol- 1 -ylmethyl) - IH-imidazole
(5-Bromo-l-methyl-lH-imidazol-2-yl)-methanol (1.0 g, 5.24 mmol) and tetrabromomethane (2.48 g, 7.33 mmol) were dissolved in TΗF (10.0 ml) and cooled to 0 °C. Triphenylphosphine (1.98 g, 7.33 mmol) was added portionwise over a period of 30 min. The reaction mixture was stirred at 0 °C for 1 h to provide a white suspension. In a second flask, NaΗ (1.05 g, 26.18 mmol, 60% in mineral ofl) was suspended in DMF (20 ml) and cooled to 0 °C. 2-Methylimidazole (2.15 g, 26.2 mmol) was added portionwise. The reaction mixture was stirred at 60 °C for 30 min, cooled to 0 °C and treated with the above suspension. After 2 h stirring at room temperature, the reaction mixture was quenched with aqueous saturated NaΗCθ3 solution (50 ml). The aqueous layer was extracted 3 times with AcOEt. The combined extracts were dried over Na2SO4, filtered and the solvent was removed in vacuo. The residue was chromatographed (sUica, elution with CH2C12 / MeOH = 95 : 5) to provide the title compound (0.7 g, 52%) as a brown solid. MS: m/e = 255.0 (M+). Example 412
(5-Bromo-l-methyl-lH-imidazol-2-yl)-methanol
l-Methylimidazole-2-methanol (3.15 g, 28 mmol) (R. J. Sundberg; P. V. Nguyen; Me Chem. Res. 7, 2, 1997, 123-136) was suspensed in THF (75 ml) at -20 °C and treated slowly (within 30 min) with N-bromosuccinimide (4.9 g, 27 mmol). The reaction mixture was allowed to warm up slowly to room temperature and quenched with saturated aqueous NaHCO3 solution (50 ml). The aqueous layer was extracted 3 times with AcOEt. The combined extracts were washed with saturated aqueous NaHCO3 solution, dried over Na2SO4, filtered and the solvent was removed in vacuo. The residue was chromatographed (silica, elution first with AcOEt / hexane = 1:1, then with CH2C12 / MeOH = 95 : 05) to provide the title compound (2.11 g, 67 %) as a white solid. MS: m/e = 191.2 (M+).
Example A
Tablet Formulation (Wet Granulation)
Item Ingredients mg/tablet
5 g 25 mg lOOmg 500mg
1. Compound of formula 1 5 25 100 500
2. Lactose Anhydrous DTG 125 105 30 150
Sta-Rx 1500 6 6 6 30
4. Microcrystalline Cellulose 30 30 30 150
5. Magnesium Stearate 1 1 1 1
Total 167 167 167 831
Manufacturing Procedure
1 Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granulation at 50 °C.
3. Pass the granulation through suitable milling equipment.
4. Add item 5 and mix for three minutes; compress on a suitable press. Example B
Capsule Formulation
Item Ingredients mg/capsule
5 mg 25mg lOOmg 500mg
αd of formula 1 5 25 100 500
2. Hydrous Lactose 159 123 148
3. Corn Starch 25 35 40 70
4. Talc 10 15 10 25
5. Magnesium Stearate 5
Total 200 200 300 600
Manufacturing Procedure
1 Mix items 1, 2, and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. FiU into a suitable capsule. 4. Add item 5 and mix for three minutes; compress on a suitable press.

Claims

Claims
Figure imgf000128_0001
wherein
A is phenyl, pyridin-2-yl, pyridin-3-yl, or piperidin-1-yl;
R R2 are independently from each other hydrogen, halogen, lower alkyl, cycloalkyl, lower alkenyl, trifluoromethyl, -O- trifluoromethyl, -S-trifluoromethyl, S-lower alkyl, lower alkoxy, -CHF2, -C(lower alkyl)F2, -OCHF2, phenyl, nitro, benzyloxy, hydroxy or amino or are together with the carbon atoms to which they are attached in any adjacent positions -CH=CH-CH=CH-, -CH=CH-CH=N-, -(CH2)3-, -O-CH2-O-, -O-CF2-O-, -CH2-O-CH2- or -CH2CH2-O-; R3 is hydrogen, lower alkyl, cycloalkyl, phenyl, S-lower alkyl, amino, lower alkyl-amino, -NHC(O)-lower alkyl or hydroxy-lower alkyl;
R4/R5 are independentiy from each other hydrogen or lower alkyl or are together with the carbon atom to which they are attached -(CH2)4-; R6/R6 are independently from each other hydrogen or lower alkyl;
X is -N< or c ;
Y is =N-, -NH-, -N=CH- or -CH=; z is -CR7=, -N=, -NR7-, -N=CR7-, =CH-N=C(R7)- or
=N-CH=CH-;
R7 is hydrogen, -CH2OH or lower alkyl; n is 0, 1 or 2; m is 0 or 1; and the dotted line may be a bond; and pharmaceutically acceptable acid addition salts thereof.
2. Compounds according to claim 1 having the formula
Figure imgf000129_0001
wherein
P R2 are independently from each other hydrogen, halogen, lower alkyl, trifluoromethyl, S-lower alkyl, lower alkoxy, -OCHF2, phenyl, nitro, benzyloxy, hydroxy or amino or are together with the carbon atoms to which they are attached -(CH2)3-, -O-CH2-O-, -CH2-O-CH2- or -CH2CH2-O-;
R3 is hydrogen, lower alkyl, phenyl, S-lower alkyl, amino, lower alkyl-amino, -NHC(O)-lower alkyl or hydroxy-lower alkyl; R /R5 are independently from each other hydrogen or lower alkyl or are together with the carbon atom to which they are attached
-(CH2)4-;
R6/R6' are independently from each other hydrogen or lowi
X is -N< or c == ;
Y is =N-, -NH-, -N=CH- or -CH=; z is -CR7=, -N=, -NH-, -N=CR7-, =CH-N=C(R7)- or
=N-CH=CH-;
R7 is hydrogen or lower alkyl; n is 0, 1 or 2; m is 0 or 1; and the dotted line may be a bond; and pharmaceutically acceptable acid addition salts thereof.
3. Compounds according to claims 1 or 2 having the formula
Figure imgf000130_0001
wherein A and R1 to R7 are defined in claim 1, or A is phenyl and R1 to R7 are defined as in claim 2.
4. Compounds of formula la in accordance with claim 3, wherein A is phenyl, R1 and R2 are independently from each other lower alkyl, -CHF2, -C(lower alkyl)F2, CF3 or halogen, or are together with the corresponding carbon atoms -(CH2)3-, R3 is lower alkyl or amino and R4, R5 and R6, R6 are hydrogen.
5. Compounds of formula la in accordance with claim 4, which are IH-imidazole, l-[[l-(4-chloro-3-methylphenyl)-lH-imidazol-4-yl]methyl]-2-ethyl-, lΗ-imidazole, l-[[l-(4-chloro-3-methylphenyl)-lH-imidazol-4-yl]methyl] -2-methyl-, lΗ-imidazole, 1- [ [ l-(2,3-dihydro-lH-inden-5-yl)-lH-imidazol-4-yl]methyl] -2-methyl-, lΗ-imidazole, 1- [ [ 1- [4-fluoro-3-(trifluoromethyl)phenyl] -lH-imidazol-4-yl] methyl] -2- methyl,
1 - [ 1 - (4-chloro-3-methyl-phenyl)- lH-imidazol-4-yl-methyl] - lH-imidazol-2-yl-amine, lΗ-imidazole, l-[[l-[3-(l,l-difluoroethyl)phenyl]-lH-imidazol-4-yl]methyl]-2-methyl-, lΗ-imidazole, 1- [ [ l-(3-difluoromethyl-4-fluorophenyl)-lH-imidazol-4-yl]methyl] -2- methyl- or lΗ-imidazole, l-[[l-[3-(l,l-difluoroethyl)-4-fluorophenyI]-lH-imidazol-4-yl]methyl]-2- methyl-.
6. Compounds according to claims 1 or 2 having the formula
Figure imgf000130_0002
wherein A and R1 to R6 are defined in claim 1, or A is phenyl and R1 to R6 are defined as in claim 2.
7. Compounds of formula lb in accordance with claim 6, wherein A is phenyl, R1 and R2 are halogen, R3 is lower alkyl or hydrogen and R4, R5 and R6, R6 are hydrogen.
8. Compounds of formula lb in accordance with claim 7, which is l-(3,4-dichloro-phenyl)-3-(2-methyl-imidazol-l-yl-methyl)-lH-pyrazole.
9. Compounds according to claims 1 or 2 having the formula
Figure imgf000131_0001
wherein A and Rl to R6 are defined in claim 1, or A is phenyl and R1 to R6 are defined as in claim 2.
10. Compounds of formula Ic in accordance with claim 9, wherein A is phenyl, R1 and R2 are halogen, R3 is lower alkyl or hydrogen and R4, R5 and R6, R6 are hydrogen.
11. Compounds of formula Ic in accordance with claim 10, which are l-(3,4-dichloro-phenyl)-4-imidazol-l-yl-methyl-lH-pyrazole or 1 -( 3,4-dichloro-phenyl) -4- ( 2-methyl-imidazol- 1 -yl-methyl) - 1 H-pyrazole.
12. Compounds according to claims 1 or 2 having the formula
Figure imgf000131_0002
wherein A and R1 to R7 are defined in claim 1, or A is phenyl and R1 to R7 are defined as in claim 2.
13. Compounds of formula Id in accordance with claim 12, wherein A is phenyl, R1 and R2 are halogen, hydrogen, CF3 or lower alkyl, R3 is lower alkyl or hydrogen and R4, R5 and R6, R6 are hydrogen.
14. Compounds of formula Id in accordance with claim 13, which are IH-imidazole, 2-methyl- 1 - [ [4- [3- (trifluoromethyl)phenyl] - lH-imidazol-2-yl] methyl] -, IH-imidazole, 1 - [ [4- (4-fluoro-3-methylphenyl) - lH-imidazol-2-yl] methyl] -2- methyl-, lH-imidazole, 1- [ [4- (3,4-difluorophenyl) - lH-imidazol-2-yl] methyl] -2-methyl- or IH-imidazole, 4-(4-fluoro-3-methylphenyl)-2-(lH-imidazol-l-yl-methyl)-.
15. Compounds according to claims 1 or 2 having the formula
Figure imgf000132_0001
wherein A and R1 to R7 are defined in claim 1 or A is phenyl and R1 to R7are defined as in claim 2.
16. Compounds of formula le in accordance with claim 15, wherein A is phenyl, R1 and R2 are lower alkyl, halogen or CF3, R3 is lower alkyl or hydrogen and R4, R5 and R6, R5 are hydrogen.
17. Compounds of formula le in accordance with claim 16, which are
3 -( 3 ,4-dimethyl-phenyl) -5-(2-methyl-imidazol- 1 -yl-methyl) -pyridine, 3-(4-fluoro-3-methyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine, 3-(4-chloro-3-methyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine, 3-(3-chloro-4-fluoro-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyridine or 3-(4-chloro-3-trifluoromethyl-phenyl)-5-(2-methyl-imidazol-l-yl-methyl)-pyτidine.
18. Compounds according to claims 1 or 2 having the formula
Figure imgf000132_0002
wherein A and R1 to R6 are defined in claim 1, or A is phenyl and R1 to R6 are defined as in claim 2.
19. Compounds of formula If in accordance with claim 18, wherein A is phenyl and
R1 and R2 are halogen, R3 is lower alkyl and R4, R5 and R6, R6 are hydrogen.
20. Compounds of formula If in accordance with claim 19, which is 4-(3,4-dichloro-phenyl)-2-(2-methyl-imidazol-l-yl-methyl)-pyridine.
21. Compounds according to claims 1 or 2 having the formula
Figure imgf000133_0001
wherein A and R1 to R6 are defined in claim 1, or A is phenyl and R1 to R6 are defined as in claim 2.
22. Compounds of formula Ig in accordance with claim 21, wherein A is phenyl, R1 and R2 are halogen, R3 is lower alkyl and R4, R5 and R6, R6 are hydrogen.
23. Compounds of formula Ig in accordance with claim 22, which is 2-(3,4-dichloro-phenyl)-4-(2-methyl-imidazol-l-yl-methyl)-pyridine.
24. A medicament containing one or more compounds of formula I of any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof and an inert carrier for the treatment of diseases.
25. A medicament according to claim 24 for the treatment of diseases based on therapeutic indications for NMDA receptor subtype specific blockers, which include acute forms of neurodegeneration caused, e.g., by stroke and brain trauma, and chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis) and neurodegeneration associated with bacterial or viral infections, and, in addition, depression and chronic or acute pain.
26. A process for preparing a compound of formula I as defined in claim 1, which process comprises
a) reacting a compound of formula
Figure imgf000133_0002
Figure imgf000134_0001
with a compound of formula
Figure imgf000134_0002
to give a compound of formula
Figure imgf000134_0003
or
Figure imgf000134_0004
wherein A is phenyl or pyridin-2 or 3-yl, R1 - R7 have the significances given above and hal is Br or Cl, or
b) cleaving off a N-protecting group from a compound of formula
Figure imgf000135_0001
to obtain a compound of formula
Figure imgf000135_0002
Id
wherein A and R1 - R6 have the significances given above and P is a N-protecting group, such as a 2-(trimethylsilyl)-ethoxymethyl group, or
c) reacting a compound of formula
Figure imgf000135_0003
with a compound of formula
Figure imgf000135_0004
to give a compound of formula
Figure imgf000136_0001
or
Figure imgf000136_0002
or
Figure imgf000136_0003
wherein A is phenyl or pyridin-2 or 3-yl and R1 - R6 have the significances given above and hal is Cl or Br, and
if desired, converting the compound of formula I obtained into a pharmaceuticaUy acceptable salt.
27. A compound of formula I according to any one of claims 1-23 whenever prepared by a process as claimed in claim 26 or by an equivalent method.
28. The use of a compound of formula I in accordance with any one of claims 1 - 23 for the treatment of diseases.
29. The use of a compound of formula I in accordance with any one of claims
1 - 23 for the manufacture of a medicament for the treatment of diseases, based on therapeutic indications for NMDA receptor subtype specific blockers, which include acute forms of neurodegeneration caused e.g, by stroke and brain trauma, and chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis) and neurodegeneration associated with bacterial or viral infections, and, in addition, depression and chronic or acute pain.
30. The invention as hereinbefore described.
PCT/EP2002/000552 2001-01-29 2002-01-21 Imidazole derivatives WO2002060877A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MXPA03006773A MXPA03006773A (en) 2001-01-29 2002-01-21 Imidazole derivatives.
JP2002561027A JP4094956B2 (en) 2001-01-29 2002-01-21 Imidazole derivatives
CN028042557A CN1489580B (en) 2001-01-29 2002-01-21 Imidazole derivatives
KR1020037009992A KR100619106B1 (en) 2001-01-29 2002-01-21 Imidazole derivatives
BR0206758-7A BR0206758A (en) 2001-01-29 2002-01-21 Imidazole Derivatives
CA002434813A CA2434813C (en) 2001-01-29 2002-01-21 Imidazole derivatives
DK02714095T DK1358165T3 (en) 2001-01-29 2002-01-21 imidazole
DE60231477T DE60231477D1 (en) 2001-01-29 2002-01-21 Imidazolderivate
EP02714095A EP1358165B1 (en) 2001-01-29 2002-01-21 Imidazole derivatives
HK04106638.1A HK1063794A1 (en) 2001-01-29 2004-09-03 Imidazole derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101947 2001-01-29
EP01101947.8 2001-01-29

Publications (1)

Publication Number Publication Date
WO2002060877A1 true WO2002060877A1 (en) 2002-08-08

Family

ID=8176317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000552 WO2002060877A1 (en) 2001-01-29 2002-01-21 Imidazole derivatives

Country Status (24)

Country Link
US (3) US6610723B2 (en)
EP (1) EP1358165B1 (en)
JP (1) JP4094956B2 (en)
KR (1) KR100619106B1 (en)
CN (2) CN101798298B (en)
AR (1) AR035422A1 (en)
AT (1) ATE425147T1 (en)
BR (1) BR0206758A (en)
CA (1) CA2434813C (en)
CY (1) CY1110265T1 (en)
DE (1) DE60231477D1 (en)
DK (1) DK1358165T3 (en)
ES (1) ES2319967T3 (en)
GC (1) GC0000318A (en)
GT (1) GT200200013A (en)
HK (2) HK1063794A1 (en)
JO (1) JO2292B1 (en)
MX (1) MXPA03006773A (en)
MY (1) MY138334A (en)
PA (1) PA8537801A1 (en)
PE (1) PE20020917A1 (en)
PT (1) PT1358165E (en)
WO (1) WO2002060877A1 (en)
ZA (1) ZA200305626B (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093263A1 (en) * 2002-05-02 2003-11-13 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
WO2007042545A1 (en) * 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
WO2008147786A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. ((bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists
JP4836280B2 (en) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド N- (1- (1-benzyl-4-phenyl-1H-imidazol-2-yl) -2,2-dimethylpropyl) benzamide derivatives and related as kinesin spindle protein (KSP) inhibitors for the treatment of cancer Compound
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
US8536186B2 (en) 2008-08-04 2013-09-17 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8883785B2 (en) 2010-01-25 2014-11-11 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8993743B2 (en) 2010-02-18 2015-03-31 B.R.A.I.N. Biotechnology Research And Information Network Ag Chimeric surface active proteins
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9981918B2 (en) 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
US10617676B2 (en) 2016-10-06 2020-04-14 Janssen Pharmaceutica Nv Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators
US10766880B2 (en) 2016-02-10 2020-09-08 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11161846B2 (en) 2019-06-14 2021-11-02 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
US11214563B2 (en) 2019-06-14 2022-01-04 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
US11530210B2 (en) 2019-06-14 2022-12-20 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
US11618750B2 (en) 2019-06-14 2023-04-04 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
US11993587B2 (en) 2020-06-12 2024-05-28 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050094A1 (en) * 2005-03-04 2006-09-05 Univ Siena DERIVATIVES OF 1- (1,5-DI (4-CHLOROPHENYL) -2-METHYL-1H-3-PYRROLS) METHYL -4-METHYLPYZINE (BM 212), PROCEDURE FOR THEIR PRODUCTION AND USE OF THEM AS ANTI-TUBULAR.
KR100694181B1 (en) * 2005-11-25 2007-03-12 연세대학교 산학협력단 Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compound useful for inducing neuron differentiation
WO2010009327A1 (en) 2008-07-17 2010-01-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds for the treatment of pathologies associated with aging and degenerative disorders
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
WO2013049565A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Imidazole derivatives as cyp17 inhibitors for the treatment of cancer
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
PL3180329T3 (en) * 2014-08-15 2020-08-24 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
TW201822637A (en) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 Substituted sulfonamides for controlling animal pests

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054314A1 (en) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments
EP1070708A1 (en) * 1999-07-21 2001-01-24 F. Hoffmann-La Roche Ag Triazole and imidazole derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3627155A1 (en) 1986-08-11 1988-02-18 Schering Ag IMIDAZOLE DERIVATIVES
CN1040107C (en) * 1993-01-02 1998-10-07 山道士有限公司 Imidazolylmethyl-pyridines
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054314A1 (en) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments
EP1070708A1 (en) * 1999-07-21 2001-01-24 F. Hoffmann-La Roche Ag Triazole and imidazole derivatives

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030144B2 (en) 2002-05-02 2006-04-18 Neurogen Corporation Substituted imidazole derivatives: GABAA receptor ligands
WO2003093263A1 (en) * 2002-05-02 2003-11-13 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
US8318791B2 (en) 2004-06-18 2012-11-27 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
JP4836280B2 (en) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド N- (1- (1-benzyl-4-phenyl-1H-imidazol-2-yl) -2,2-dimethylpropyl) benzamide derivatives and related as kinesin spindle protein (KSP) inhibitors for the treatment of cancer Compound
WO2007042545A1 (en) * 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
US7939556B2 (en) 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
WO2008147786A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. ((bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists
AU2008256926B2 (en) * 2007-05-23 2013-09-19 Allergan, Inc. ((Bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists
US8536186B2 (en) 2008-08-04 2013-09-17 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9145373B2 (en) 2008-08-04 2015-09-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8883785B2 (en) 2010-01-25 2014-11-11 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8993743B2 (en) 2010-02-18 2015-03-31 B.R.A.I.N. Biotechnology Research And Information Network Ag Chimeric surface active proteins
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
JP2013540145A (en) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス Selective CYP11B1 inhibitor for the treatment of cortisol-dependent diseases
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9981918B2 (en) 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
US10766880B2 (en) 2016-02-10 2020-09-08 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
US10617676B2 (en) 2016-10-06 2020-04-14 Janssen Pharmaceutica Nv Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators
US11207298B2 (en) 2016-10-06 2021-12-28 Janssen Pharmaceutica Nv Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
US11759455B2 (en) 2016-10-06 2023-09-19 Janssen Pharmaceutica Nv Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11214563B2 (en) 2019-06-14 2022-01-04 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
US11530210B2 (en) 2019-06-14 2022-12-20 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
US11618750B2 (en) 2019-06-14 2023-04-04 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
US11161846B2 (en) 2019-06-14 2021-11-02 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
US11993587B2 (en) 2020-06-12 2024-05-28 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators

Also Published As

Publication number Publication date
AR035422A1 (en) 2004-05-26
ES2319967T3 (en) 2009-05-18
GC0000318A (en) 2006-11-01
CA2434813C (en) 2009-12-22
ATE425147T1 (en) 2009-03-15
CA2434813A1 (en) 2002-08-08
US20030191311A1 (en) 2003-10-09
KR20030070615A (en) 2003-08-30
DE60231477D1 (en) 2009-04-23
MXPA03006773A (en) 2003-10-24
BR0206758A (en) 2004-02-17
CN1489580A (en) 2004-04-14
PA8537801A1 (en) 2002-09-17
US6667335B2 (en) 2003-12-23
PE20020917A1 (en) 2002-10-19
CN101798298B (en) 2013-01-09
US20030187268A1 (en) 2003-10-02
US6683097B2 (en) 2004-01-27
ZA200305626B (en) 2004-10-21
CN1489580B (en) 2010-05-26
MY138334A (en) 2009-05-29
DK1358165T3 (en) 2009-05-11
US20020151715A1 (en) 2002-10-17
JO2292B1 (en) 2005-09-12
CN101798298A (en) 2010-08-11
HK1063794A1 (en) 2005-01-14
US6610723B2 (en) 2003-08-26
JP4094956B2 (en) 2008-06-04
CY1110265T1 (en) 2015-01-14
KR100619106B1 (en) 2006-09-01
EP1358165A1 (en) 2003-11-05
GT200200013A (en) 2002-09-02
HK1146646A1 (en) 2011-06-24
EP1358165B1 (en) 2009-03-11
JP2004523535A (en) 2004-08-05
PT1358165E (en) 2009-04-22

Similar Documents

Publication Publication Date Title
US6610723B2 (en) Imidazole derivatives
DK175218B1 (en) (1H-Azol-1-ylmethyl) substituted benzotriazole derivatives, process for their preparation and pharmaceutical composition containing a benzotriazole derivative according to the invention
TWI452035B (en) 5-membered heterocycle-based p38 kinase inhibitors
EP1194144B1 (en) Antibacterial compounds
US5998437A (en) Benzimidazole derivatives
US5332831A (en) Benzofuran derivatives
SK278998B6 (en) Imidazole, triazole and tetrazole derivatives, method of producing same, their use and pharmaceutical compositons on their base
CA2129146A1 (en) Imidazole, triazole and tetrazole derivatives
IE60514B1 (en) (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives
SK283542B6 (en) Imidazole derivatives, pharmaceutical composition containing them and use
EA001730B1 (en) Quinoxalinediones
US6015825A (en) Triazole antifungal agents
NO169894B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TETRAHYDRONE AGREEMENTS
US4943574A (en) (1H-azol-1-ylmethyl) substituted benzotriazole derivatives and pharmaceutical compositions containing them
AU2002246043B2 (en) Imidazole derivatives
US6248768B1 (en) Benzimidazole derivatives and pharmacologically acceptable salts thereof
AU2002246043A1 (en) Imidazole derivatives
HU206343B (en) Process for producing 1,2-benzizoxazol- and 1,2-benzizothiazol derivatives and pharmaceutical compositions containing them
TWI328584B (en) Imidazole derivatives
PH26050A (en) (1H-azol-1=ylmethyl)substituted benzotriazole derivatives
LT3594B (en) Imidazole,triazole and tetrazole derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2434813

Country of ref document: CA

Ref document number: 2002246043

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/05626

Country of ref document: ZA

Ref document number: 200305626

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002714095

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006773

Country of ref document: MX

Ref document number: 2002561027

Country of ref document: JP

Ref document number: 1020037009992

Country of ref document: KR

Ref document number: 028042557

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037009992

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2002714095

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1020037009992

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2002246043

Country of ref document: AU